<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Medical Oncology - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Medicine
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">158</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 19793,
    "choices": [
      {
        "id": 79133,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung </span></span></span></p>"
      },
      {
        "id": 79134,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate </span></span></span></p>"
      },
      {
        "id": 79135,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal </span></span></span></p>"
      },
      {
        "id": 79136,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pancreas</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which cancer site had the highest incidence rate among males in 2021?</span></span></span></p>",
    "unique_key": "Q7644128",
    "question_audio": null,
    "question_video": null,
    "map_id": 19704,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Prostate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table shows that prostate cancer had the highest percentage of new cases (26%) among males. While lung cancer is the leading cause of cancer deaths, it does not have the highest incidence rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lung:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While lung cancer is the leading cause of cancer deaths, it does not have the highest number of new cases (incidence) among males (12%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Colorectal:</span></strong><span style=\"font-size:12.0pt\"> Colorectal cancer is the third most common (8%) cancer in men, but its incidence rate is lower than that of prostate cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pancreas:</span></strong><span style=\"font-size:12.0pt\"> Pancreatic cancer is less common than prostate cancer, with a lower incidence rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate cancer screening and early detection are crucial for men&#39;s health.</span></span></span></p>",
    "correct_choice_id": 79134,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19799,
    "choices": [
      {
        "id": 79157,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Small cell lung cancer </span></span></span></p>"
      },
      {
        "id": 79158,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesothelioma </span></span></span></p>"
      },
      {
        "id": 79159,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Squamous cell carcinoma of the lung </span></span></span></p>"
      },
      {
        "id": 79160,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenocarcinoma of the lung</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old man, with a history of silicosis presents with progressive dyspnea and pleural plaques on imaging. Which of the following malignancies is he most likely at risk for developing in future?</span></span></span></p>",
    "unique_key": "Q2139793",
    "question_audio": null,
    "question_video": null,
    "map_id": 19710,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Mesothelioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Silicosis&nbsp;</span></strong><span style=\"font-size:12.0pt\">is a lung disease caused by inhaling silica dust. It&#39;s often found in occupations like mining, quarrying, and sandblasting.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pleural plaques&nbsp;</span></strong><span style=\"font-size:12.0pt\">are thickening of the lining of the lungs (pleura) and are a hallmark of asbestos exposure.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Asbestos exposure&nbsp;</span></strong><span style=\"font-size:12.0pt\">is the primary risk factor for mesothelioma, a rare but aggressive cancer of the pleura.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the patient has both silicosis and pleural plaques, it strongly suggests a history of asbestos exposure, making mesothelioma the most likely future malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Small cell lung cancer:</span></strong><span style=\"font-size:12.0pt\"> While smoking is the primary risk factor, it&#39;s not directly associated with silicosis or pleural plaques.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Squamous cell carcinoma of the lung:</span></strong><span style=\"font-size:12.0pt\"> Also primarily linked to smoking, not specifically to silicosis or asbestos.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adenocarcinoma of the lung:</span></strong><span style=\"font-size:12.0pt\"> The most common type of lung cancer but not directly associated with silicosis or asbestos.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of silicosis and pleural plaques is a strong indicator of asbestos exposure and significantly increases the risk of developing mesothelioma. Early detection and monitoring are crucial for individuals with this history.</span></span></p>",
    "correct_choice_id": 79158,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19800,
    "choices": [
      {
        "id": 79161,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asbestos </span></span></span></p>"
      },
      {
        "id": 79162,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aflatoxin </span></span></span></p>"
      },
      {
        "id": 79163,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arsenic </span></span></span></p>"
      },
      {
        "id": 79164,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzene</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A farmer from a developing country presents with jaundice, abdominal distention, and elevated alpha-fetoprotein (AFP) levels. Which of the following dietary contaminants is MOST likely associated with his suspected malignancy?</span></span></span></p>",
    "unique_key": "Q7424757",
    "question_audio": null,
    "question_video": null,
    "map_id": 19711,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Aflatoxin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aflatoxins are potent carcinogens produced by certain molds that can contaminate crops, particularly corn and peanuts. They are a significant risk factor for hepatocellular carcinoma (HCC) in developing countries where food storage practices may be inadequate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Asbestos:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While asbestos is a known carcinogen, it primarily affects the lungs and pleura, causing mesothelioma and lung cancer. It is not typically associated with hepatocellular carcinoma (HCC) or the symptoms presented by the farmer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Arsenic:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Arsenic exposure is linked to various cancers, including skin, bladder, and lung cancer. However, it is not the primary risk factor for HCC in the scenario described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Benzene:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Benzene is an industrial solvent and a known carcinogen, primarily associated with leukemia and other blood cancers. It is not a major risk factor for HCC in the context of this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aflatoxin contamination of food is a major global health concern and a significant risk factor for HCC.</span></span></p>",
    "correct_choice_id": 79162,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19801,
    "choices": [
      {
        "id": 79165,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CEA </span></span></span></p>"
      },
      {
        "id": 79166,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">AFP </span></span></span></p>"
      },
      {
        "id": 79167,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">NSE </span></span></span></p>"
      },
      {
        "id": 79168,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old man with a history of smoking presents with cough, hemoptysis, and a lung mass on chest X-ray. Which of the following tumor markers is MOST likely to be elevated?</span></span></span></p>",
    "unique_key": "Q5904508",
    "question_audio": null,
    "question_video": null,
    "map_id": 19712,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) NSE</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NSE is a marker for neuroendocrine tumors, including small cell lung cancer (SCLC). Its elevation in this scenario, along with the clinical presentation and imaging findings, supports the diagnosis of SCLC. The other markers are not typically associated with SCLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation</span></strong><span style=\"font-size:12.0pt\">: &nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CEA (Carcinoembryonic Antigen):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While CEA can be elevated in some lung cancers, it&#39;s more commonly associated with colorectal, breast, and other gastrointestinal cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. AFP (Alpha-fetoprotein):</span></strong><span style=\"font-size:12.0pt\"> AFP is primarily used as a marker for liver cancer (hepatocellular carcinoma) and certain germ cell tumors. It&#39;s not typically elevated in lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CA 19-9 (Carbohydrate Antigen 19-9):&nbsp;</span></strong><span style=\"font-size:12.0pt\">CA 19-9 is most commonly used as a marker for pancreatic cancer and some other gastrointestinal malignancies. It&#39;s not a primary marker for lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NSE is a useful marker for the diagnosis and monitoring of neuroendocrine tumors, particularly SCLC.</span></span></p>",
    "correct_choice_id": 79167,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19802,
    "choices": [
      {
        "id": 79169,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9 </span></span></span></p>"
      },
      {
        "id": 79170,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA-125 </span></span></span></p>"
      },
      {
        "id": 79171,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">PSA </span></span></span></p>"
      },
      {
        "id": 79172,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD30</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old man with chronic pancreatitis presents with jaundice and weight loss. Which tumor marker would be the MOST helpful in evaluating for a possible malignancy?</span></span></span></p>",
    "unique_key": "Q3422053",
    "question_audio": null,
    "question_video": null,
    "map_id": 19713,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CA 19-9</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 19-9 is elevated in pancreatic cancer and can also be elevated in other conditions like pancreatitis. However, in the context of a patient with chronic pancreatitis presenting with concerning symptoms, elevated CA 19-9 would raise suspicion for pancreatic cancer and warrant further investigation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: &nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CA-125:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is primarily used for ovarian cancer and is not typically elevated in pancreatic cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PSA:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is specific for prostate cancer and would not be helpful in evaluating for a pancreatic malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD30:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is used in lymphoma diagnosis and is not relevant for pancreatic cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CA 19-9 can be a useful marker in evaluating for pancreatic cancer, especially in patients with risk factors like chronic pancreatitis.</span></span></p>",
    "correct_choice_id": 79169,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19794,
    "choices": [
      {
        "id": 79137,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung cancer</span></span></span></p>"
      },
      {
        "id": 79138,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate cancer</span></span></span></p>"
      },
      {
        "id": 79139,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal cancer</span></span></span></p>"
      },
      {
        "id": 79140,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver cancer</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the leading cause of cancer-related deaths in males worldwide?</span></span></p>",
    "unique_key": "Q1299333",
    "question_audio": null,
    "question_video": null,
    "map_id": 19705,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Lung cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung cancer is the leading cause of cancer-related deaths in males worldwide. It accounts for a significant proportion of cancer mortality due to its high incidence and poor prognosis. Lung cancer is often diagnosed at an advanced stage, which contributes to its high mortality rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B</strong>. Prostate cancer is a common cancer in males, but it generally has a better prognosis than lung cancer, and thus it is not the leading cause of cancer-related deaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.&nbsp;</strong>Colorectal cancer is also a common cancer in males, but it is not the leading cause of cancer-related deaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. Liver cancer is a significant cause of cancer-related deaths, but it is not the leading cause globally in males.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer is the leading cause of cancer-related deaths in males worldwide, due to its high incidence and poor prognosis.</span></span></p>",
    "correct_choice_id": 79137,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19795,
    "choices": [
      {
        "id": 79141,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They are a safe alternative to smoking. </span></span></span></p>"
      },
      {
        "id": 79142,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They are proven to cause lung cancer. </span></span></span></p>"
      },
      {
        "id": 79143,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-term cancer risks are unknown. </span></span></span></p>"
      },
      {
        "id": 79144,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They only cause oral cancers.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about e-cigarettes (vaping) is MOST accurate?</span></span></p>",
    "unique_key": "Q9328119",
    "question_audio": null,
    "question_video": null,
    "map_id": 19706,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Long-term cancer risks are unknown.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While e-cigarettes may be less harmful than traditional cigarettes, their long-term health effects, including cancer risk, are still under investigation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. They are a safe alternative to smoking.</span></strong><span style=\"font-size:12.0pt\"> E-cigarettes are not harmless. While they may expose users to fewer toxins than traditional cigarettes, they still contain potentially harmful chemicals like nicotine and heavy metals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. They are proven to cause lung cancer.</span></strong><span style=\"font-size:12.0pt\"> While some studies have shown e-cigarettes contain carcinogenic substances, definitive long-term studies directly linking them to lung cancer are lacking. More research is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. They only cause oral cancers.</span></strong><span style=\"font-size:12.0pt\"> While e-cigarettes expose the oral cavity to potentially harmful substances, their impact is not limited to this area. There are concerns about potential damage to the lungs and cardiovascular system as well.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E-cigarettes are not harmless, and more research is needed to determine their long-term cancer risks.</span></span></p>",
    "correct_choice_id": 79143,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19796,
    "choices": [
      {
        "id": 79145,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50% </span></span></span></p>"
      },
      {
        "id": 79146,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">80% </span></span></span></p>"
      },
      {
        "id": 79147,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30%</span></span></span></p>"
      },
      {
        "id": 79148,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10%</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is a major risk factor for various types of cancer. What percentage of cancer-related deaths are attributed to smoking?</span></span></span></p>",
    "unique_key": "Q3763422",
    "question_audio": null,
    "question_video": null,
    "map_id": 19707,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) 30%</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is estimated to be responsible for approximately 30% of all cancer deaths worldwide. It&#39;s a leading cause of preventable death and significantly increases the risk of developing various types of cancer, including lung, throat, esophagus, bladder, pancreas, and more.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking cessation is crucial in reducing cancer-related deaths. It&#39;s never too late to quit, and the benefits of quitting can be seen relatively quickly after stopping smoking. </span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tobacco &ndash; single most important preventable cause of death in India .</span></strong></span></span></p>",
    "correct_choice_id": 79147,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19797,
    "choices": [
      {
        "id": 79149,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human herpesvirus 8 (HHV-8) </span></span></span></p>"
      },
      {
        "id": 79150,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epstein-Barr virus (EBV) </span></span></span></p>"
      },
      {
        "id": 79151,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human papillomavirus (HPV) </span></span></span></p>"
      },
      {
        "id": 79152,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human T-lymphotropic virus 1 (HTLV-1)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old man with HIV presents with multiple violet-colored skin lesions and lymphadenopathy. The lesion is shown below. Which of the following is the most common etiological agent for his skin condition?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-162222.jpg\" style=\"height:199px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7163034",
    "question_audio": null,
    "question_video": null,
    "map_id": 19708,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Human herpesvirus 8 (HHV-8)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation is consistent with Kaposi sarcoma (KS), a malignancy strongly associated with HHV-8 infection, particularly in immunocompromised individuals like those with HIV. While EBV can cause lymphoma, it doesn&#39;t typically present with skin lesions. HPV is linked to various cancers but not KS. HTLV-1 causes adult T-cell leukemia/lymphoma, which has a different presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Epstein-Barr virus (EBV):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While EBV is associated with several malignancies (lymphoma, nasopharyngeal carcinoma), it doesn&#39;t typically cause the characteristic skin lesions seen in Kaposi sarcoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Human papillomavirus (HPV):&nbsp;</span></strong><span style=\"font-size:12.0pt\">HPV is primarily associated with cervical cancer and other anogenital cancers. It doesn&#39;t cause the type of lesions seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Human T-lymphotropic virus 1 (HTLV-1):&nbsp;</span></strong><span style=\"font-size:12.0pt\">HTLV-1 is associated with adult T-cell leukemia/lymphoma, a type of blood cancer. It doesn&#39;t usually cause the distinctive skin lesions of Kaposi sarcoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HHV-8 is the causative agent of Kaposi sarcoma, a malignancy often seen in HIV-infected individuals.</span></span></span></p>",
    "correct_choice_id": 79149,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 19798,
    "choices": [
      {
        "id": 79153,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">gamma rays </span></span></span></p>"
      },
      {
        "id": 79154,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB </span></span></span></p>"
      },
      {
        "id": 79155,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">x-rays </span></span></span></p>"
      },
      {
        "id": 79156,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">alpha - rays</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following types of UV radiation is MOST strongly linked to the development of skin cancer?</span></span></span></p>",
    "unique_key": "Q8953046",
    "question_audio": null,
    "question_video": null,
    "map_id": 19709,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) UVB</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB radiation is a type of ultraviolet radiation that has a shorter wavelength than UVA but a longer wavelength than UVC. It is the most damaging type of UV radiation that reaches the Earth&#39;s surface. UVB radiation is absorbed by the DNA in skin cells, causing damage that can lead to mutations and the development of skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. gamma rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Gamma rays are a type of ionizing radiation with very short wavelengths and high energy. While they are carcinogenic, they are not the primary type of radiation associated with skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. x-rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">X-rays are also a type of ionizing radiation with shorter wavelengths than UV radiation. They are used in medical imaging and can also be carcinogenic, but their primary association is not with skin cancer. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. alpha-rays:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Alpha rays are a type of particle radiation consisting of two protons and two neutrons. They have low penetrating power and are not associated with skin cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB radiation is the most significant contributor to skin cancer development.</span></span></span></p>",
    "correct_choice_id": 79154,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 53411,
    "choices": [
      {
        "id": 213125,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 19-9 </span></span></span></p>"
      },
      {
        "id": 213126,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA 15-3 </span></span></span></p>"
      },
      {
        "id": 213127,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CA-125 </span></span></span></p>"
      },
      {
        "id": 213128,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">CEA</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a palpable breast mass and nipple discharge. Which tumor marker would be MOST appropriate to order in this scenario?</span></span></span></p>",
    "unique_key": "Q2796124",
    "question_audio": null,
    "question_video": null,
    "map_id": 25215,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CA 15-3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 15-3 is a tumor marker used to monitor breast cancer response to treatment and detect recurrence. While the other options are tumor markers, they are not typically used in the initial evaluation of a breast mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CA 19-9:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This marker is primarily associated with pancreatic cancer and some gastrointestinal malignancies. It&#39;s not routinely used in the initial evaluation of breast masses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CA-125:</span></strong><span style=\"font-size:12.0pt\"> This marker is primarily associated with ovarian cancer and is not routinely used in the evaluation of breast masses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CEA:</span></strong><span style=\"font-size:12.0pt\"> This marker can be elevated in various cancers, including breast cancer. However, it is not specific for breast cancer and is typically used to monitor response to treatment or detect recurrence rather than in the initial diagnosis of a breast mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CA 15-3 is a useful marker for monitoring breast cancer progression and treatment response.</span></span></span></p>",
    "correct_choice_id": 213126,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 53412,
    "choices": [
      {
        "id": 213129,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 10-20% lifetime risk of developing breast cancer. </span></span></span></p>"
      },
      {
        "id": 213130,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 30-40% lifetime risk of developing breast cancer. </span></span></span></p>"
      },
      {
        "id": 213131,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 60-80% lifetime risk of developing breast cancer. </span></span></span></p>"
      },
      {
        "id": 213132,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a 90-100% lifetime risk of developing breast cancer.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old woman with a strong family history of breast and ovarian cancer undergoes genetic testing and is found to have a BRCA1 mutation. Which of the following statements is MOST accurate regarding her risk of developing breast cancer?</span></span></span></p>",
    "unique_key": "Q3928344",
    "question_audio": null,
    "question_video": null,
    "map_id": 25216,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) She has a 60-80% lifetime risk of developing breast cancer.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The passage states that women with BRCA1 mutations have a 60-80% lifetime risk of developing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women who inherit mutated alleles of these genes from either parent have at least a 60&ndash;80% lifetime chance of developing breast cancer and about a 33% chance of developing ovarian cancer. </span></span></p>",
    "correct_choice_id": 213131,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53413,
    "choices": [
      {
        "id": 213133,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual mammogram </span></span></span></p>"
      },
      {
        "id": 213134,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual MRI </span></span></span></p>"
      },
      {
        "id": 213135,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Biennial mammogram </span></span></span></p>"
      },
      {
        "id": 213136,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clinical breast exam only</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 38-year-old woman with a BRCA1 mutation wants to know the best breast cancer screening approach for her. Which of the following is MOST appropriate?</span></span></span></p>",
    "unique_key": "Q9670362",
    "question_audio": null,
    "question_video": null,
    "map_id": 25217,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Annual MRI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Women with BRCA1 or BRCA2 mutations have a significantly higher risk of breast cancer and should consider annual breast MRI in addition to mammograms. MRI is more sensitive for detecting breast cancer in high-risk women, especially those with dense breast tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Annual mammogram:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While mammograms are an important part of breast cancer screening, they are less sensitive than MRI in detecting cancer in women with BRCA mutations, especially those with dense breast tissue. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Biennial mammogram:&nbsp;</span></strong><span style=\"font-size:12.0pt\">The frequency is not sufficient for women with BRCA mutations, who are at higher risk and require more frequent screening. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Clinical breast exam only:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Clinical breast exams are important, but they are not enough for screening high-risk women. Imaging modalities like MRI are more effective for early detection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual MRI (superior to MMG in high risk young female) is recommended for women with BRCA mutations due to their increased breast cancer risk.</span></span></span></p>",
    "correct_choice_id": 213134,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 53414,
    "choices": [
      {
        "id": 213137,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin annual mammograms at age 40 </span></span></span></p>"
      },
      {
        "id": 213138,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin biennial mammograms at age 40 </span></span></span></p>"
      },
      {
        "id": 213139,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin annual mammograms at age 45 </span></span></span></p>"
      },
      {
        "id": 213140,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin biennial mammograms at age 50</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman with a strong family history of breast cancer wants to know the recommended age to start breast cancer screening. According to the American Cancer Society (ACS), what is the MOST appropriate recommendation?</span></span></span></p>",
    "unique_key": "Q7914262",
    "question_audio": null,
    "question_video": null,
    "map_id": 25218,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Begin annual mammograms at age 45</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ACS recommends that women at average risk start yearly mammograms at age 45. Women with a higher risk, such as a strong family history, may need to start screening earlier or have additional screening tests like MRI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Begin annual mammograms at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While some organizations recommend starting at age 40, the ACS specifically suggests starting annual screening at 45 for average-risk women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Begin biennial mammograms at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This option is less frequent than the ACS recommendation for average-risk women, and biennial screening might miss some early-stage cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Begin biennial mammograms at age 50:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is the recommended starting age for biennial mammograms according to the U.S. Preventive Services Task Force (USPSTF), but the ACS recommends starting earlier for average-risk women and even earlier for women with increased risk due to family history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ACS recommends starting annual mammograms at age 45 for average-risk women.</span></span></p>",
    "correct_choice_id": 213139,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 53415,
    "choices": [
      {
        "id": 213141,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bilateral salpingo-oophorectomy (rrBSO) </span></span></span></p>"
      },
      {
        "id": 213142,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Risk-reducing bilateral mastectomy (rrBLM) </span></span></span></p>"
      },
      {
        "id": 213143,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual mammogram starting at age 40 </span></span></span></p>"
      },
      {
        "id": 213144,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tamoxifen chemoprevention</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 32-year-old woman with a known BRCA1 mutation desires the most effective risk reduction strategy for breast cancer. Which of the following options would you recommend?</span></span></span></p>",
    "unique_key": "Q6957628",
    "question_audio": null,
    "question_video": null,
    "map_id": 25219,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Risk-reducing bilateral mastectomy (rrBLM)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image indicates that rrBLM can reduce the risk of breast cancer by &ge; 90% in BRCA1/2 mutation carriers. While rrBSO reduces ovarian cancer risk, it doesn&#39;t directly address breast cancer risk. Mammography and chemoprevention are screening and risk reduction strategies, respectively, but not as effective as rrBLM in preventing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bilateral salpingo-oophorectomy (rrBSO):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While rrBSO is a risk-reducing surgery, it primarily targets ovarian cancer risk. Although it can somewhat decrease breast cancer risk in premenopausal women, it is not as effective as rrBLM in directly addressing breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Annual mammogram starting at age 40:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Mammography is a screening tool for early detection, not a preventive measure. In women with BRCA1 mutations, who often develop breast cancer at a younger age, mammography alone may not be sufficient for early detection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tamoxifen chemoprevention:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While tamoxifen can reduce the risk of breast cancer in women with BRCA2 mutations, its effectiveness is not as high as rrBLM in BRCA1 carriers. Additionally, it comes with potential side effects and is not suitable for all women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">rrBLM is the most effective risk reduction strategy for breast cancer in BRCA1/2 mutation carriers.</span></span></span></p>",
    "correct_choice_id": 213142,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53416,
    "choices": [
      {
        "id": 213145,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 and 11 </span></span></span></p>"
      },
      {
        "id": 213146,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">16 and 18 </span></span></span></p>"
      },
      {
        "id": 213147,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6, 11, and 16 </span></span></span></p>"
      },
      {
        "id": 213148,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">11, 16, and 18</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following HPV types are covered by BOTH Gardasil and Cervarix vaccines?</span></span></span></p>",
    "unique_key": "Q3387637",
    "question_audio": null,
    "question_video": null,
    "map_id": 25220,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 16 and 18</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gardasil covers HPV types 6, 11, 16, and 18, while Cervarix covers types 16 and 18. Therefore, both vaccines cover types 16 and 18.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HPV types 16 and 18 are high-risk types associated with a majority of cervical cancers, making their inclusion in both vaccines crucial.</span></span></span></p>",
    "correct_choice_id": 213146,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53417,
    "choices": [
      {
        "id": 213149,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should continue with annual Pap smears. </span></span></span></p>"
      },
      {
        "id": 213150,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should have a Pap smear every 3 years. </span></span></span></p>"
      },
      {
        "id": 213151,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years. </span></span></span></p>"
      },
      {
        "id": 213152,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No, she does not require further screening.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 67-year-old woman has a history of negative Pap smears for the past 10 years and underwent a total hysterectomy for benign reasons. Does she require further cervical cancer screening?</span></span></span></p>",
    "unique_key": "Q7291140",
    "question_audio": null,
    "question_video": null,
    "map_id": 25221,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) No, she does not require further screening.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image indicates that women over 65 with a history of negative screening in the last 10 years and a total hysterectomy for benign causes (no residual cervix) can stop screening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Yes, she should continue with annual Pap smears:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is incorrect because the patient has a history of negative Pap smears for 10 years and had a total hysterectomy for benign reasons, which means her cervix was removed. There is no remaining cervical tissue to test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Yes, she should have a Pap smear every 3 years:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is also incorrect for the same reasons as option A. There&#39;s no need for Pap smears if there&#39;s no cervix.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is incorrect because co-testing is typically recommended for women aged 30-65. Since the patient is 67 and has a history of negative results, further testing is not necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women with a history of adequate negative screening and no cervix do not require further cervical cancer screening.</span></span></p>",
    "correct_choice_id": 213152,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 53418,
    "choices": [
      {
        "id": 213153,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediately </span></span></span></p>"
      },
      {
        "id": 213154,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">At age 45 </span></span></span></p>"
      },
      {
        "id": 213155,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">At age 50 </span></span></span></p>"
      },
      {
        "id": 213156,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10 years before her father&#39;s age of diagnosis (i.e., at age 45)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old woman has a father who was diagnosed with colorectal cancer at age 55. When should she initiate screening for colorectal cancer, according to the image?</span></span></span></p>",
    "unique_key": "Q9496118",
    "question_audio": null,
    "question_video": null,
    "map_id": 25222,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 10 years before her father&#39;s age of diagnosis (i.e., at age 45)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Individuals with a first-degree relative (FDR) diagnosed with CRC should begin screening 10 years before the earliest diagnosis in the FDR or </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Age &ge; 40-45</span><span style=\"font-size:12.0pt\">. In this case, screening should start at age 45. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immediately:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While having a family history of colorectal cancer (CRC) does increase risk, immediate screening is not recommended unless there are other concerning symptoms or risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. At age 45:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is the general recommended age to begin screening for those with average risk, but with a family history of CRC, earlier screening is appropriate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. At age 50:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is too late for someone with a first-degree relative diagnosed with CRC at age 55. Earlier screening is necessary to detect potential problems early.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Individuals with a family history of colorectal cancer should start screening 10 years younger than the age at which their first-degree relative was diagnosed. This allows for early detection and intervention of precancerous polyps or early-stage cancer, ultimately improving outcomes.</span></span></span></p>",
    "correct_choice_id": 213156,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 53419,
    "choices": [
      {
        "id": 213157,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0 </span></span></span></p>"
      },
      {
        "id": 213158,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 </span></span></span></p>"
      },
      {
        "id": 213159,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 </span></span></span></p>"
      },
      {
        "id": 213160,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with metastatic lung cancer reports fatigue but is still able to perform most of their daily activities, including light housework and grocery shopping. Which ECOG performance status is MOST appropriate for this patient?</span></span></span></p>",
    "unique_key": "Q4549585",
    "question_audio": null,
    "question_video": null,
    "map_id": 25223,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient can perform normal activities but with some effort due to fatigue. This aligns with ECOG PS 1, where strenuous activity is restricted, but the patient remains fully ambulatory.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-172340.jpg\" style=\"height:470px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECOG PS 1 indicates a patient can carry out normal activity with effort, though strenuous activity is limited.</span></span></span></p>",
    "correct_choice_id": 213158,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 19803,
    "choices": [
      {
        "id": 79173,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-sense mutation</span></span></span></p>"
      },
      {
        "id": 79174,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Conservative missense mutation</span></span></span></p>"
      },
      {
        "id": 79175,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-conservative missense mutation</span></span></span></p>"
      },
      {
        "id": 79176,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Frameshift mutation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old boy presents to the emergency department with severe pain in his lower back and legs. He reports that he has experienced similar pain episodes in the past, usually during times of stress or dehydration. He also mentions that he had a recent upper respiratory infection. On examination, he appears to be in distress due to pain, his temperature is 37.8&deg;C (100&deg;F), and his sclerae are icteric. Laboratory tests reveal a hemoglobin level of 8 g/dL, reticulocyte count of 12%, and elevated bilirubin. Peripheral blood smear shows sickle-shaped red blood cells. Which of the following is the most likely mutation responsible for the condition?</span></span></p>",
    "unique_key": "Q7861876",
    "question_audio": null,
    "question_video": null,
    "map_id": 19806,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>C) Non-conservative missense mutation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with sickle cell disease, a genetic disorder characterized by the presence of sickle-shaped red blood cells, hemolytic anemia, and vaso-occlusive crises. Sickle cell disease is caused by a non-conservative missense mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin. Specifically, a single nucleotide substitution (A to T) results in the replacement of glutamic acid with valine at the sixth position of the beta-globin chain (Glu6Val). This amino acid change alters the properties of hemoglobin, leading to the formation of sickle-shaped cells under low oxygen conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-sense mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation introduces a premature stop codon, leading to truncated proteins. It is not the cause of sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Conservative missense mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation changes an amino acid to another with similar properties, which usually does not significantly affect protein function. Sickle cell disease is caused by a non-conservative missense mutation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Frameshift mutation</span></strong><span style=\"font-size:12.0pt\">: This type of mutation is caused by insertions or deletions that shift the reading frame of the genetic code, resulting in a completely different amino acid sequence downstream. It is not the cause of sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell disease is caused by a non-conservative missense mutation in the HBB gene, leading to the substitution of glutamic acid with valine at the sixth position of the beta-globin chain. This mutation alters the properties of hemoglobin, causing red blood cells to assume a sickle shape under low oxygen conditions.</span></span></p>",
    "correct_choice_id": 79175,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19804,
    "choices": [
      {
        "id": 79177,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HER2/ERBB2 amplification </span></span></span></p>"
      },
      {
        "id": 79178,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCR-ABL1 fusion gene </span></span></span></p>"
      },
      {
        "id": 79179,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CBFB-MYH11 fusion gene </span></span></span></p>"
      },
      {
        "id": 79180,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polyploidy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old male presents with fatigue, weight loss, and splenomegaly. Blood tests reveal an elevated white blood cell count with a predominance of immature myeloid cells. Cytogenetic analysis of the patient&#39;s bone marrow cells is most likely to reveal which of the following abnormalities?</span></span></span></p>",
    "unique_key": "Q1744292",
    "question_audio": null,
    "question_video": null,
    "map_id": 19807,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>B) BCR-ABL1 fusion gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation is suggestive of <strong>chronic myeloid leukemia (CML)</strong>, a myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells in the bone marrow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>BCR-ABL1 fusion gene</strong> is the hallmark of CML, resulting from a reciprocal translocation between chromosomes 9 and 22 (t(9;22)). This fusion gene encodes a constitutively active tyrosine kinase that drives the uncontrolled cell growth. &nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HER2/ERBB2 amplification</span></strong><span style=\"font-size:12.0pt\"> is associated with breast and other solid tumors. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CBFB-MYH11 and FIP1L1-PDGFRA</span></strong><span style=\"font-size:12.0pt\"> are fusion genes associated with other hematological malignancies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polyploidy</span></strong><span style=\"font-size:12.0pt\"> refers to an increased number of chromosome sets and is not typically seen in CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BCR-ABL1 fusion gene is a specific genetic abnormality that is highly diagnostic for CML and serves as a target for tyrosine kinase inhibitor therapy</span></span></span></p>",
    "correct_choice_id": 79178,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19805,
    "choices": [
      {
        "id": 79181,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It promotes cell growth and division </span></span></span></p>"
      },
      {
        "id": 79182,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It controls proto-oncogene activity </span></span></span></p>"
      },
      {
        "id": 79183,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It induces angiogenesis </span></span></span></p>"
      },
      {
        "id": 79184,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It evades apoptosis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with a family history of breast and ovarian cancer. Genetic testing reveals a germline mutation in a gene that normally functions to inhibit cell cycle progression and repair DNA damage. Which of the following best describes the role of the affected gene in this patient&#39;s cancer predisposition?</span></span></span></p>",
    "unique_key": "Q3996333",
    "question_audio": null,
    "question_video": null,
    "map_id": 19808,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) It controls proto-oncogene activity</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical vignette describes a patient with a likely germline mutation in a tumor suppressor gene, such as BRCA1 or BRCA2. Tumor suppressor genes normally function to regulate cell growth and division, often by inhibiting proto-oncogene activity or promoting DNA repair. Loss of function of these genes, due to inherited or acquired mutations, removes the critical checks on cell growth and can lead to cancer development. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Promote cell growth and division:</span></strong><span style=\"font-size:12.0pt\"> This is the opposite of what tumor suppressor genes do. They actually inhibit cell growth and division, acting as a brake on the cell cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Induce angiogenesis:</span></strong><span style=\"font-size:12.0pt\"> Angiogenesis (the formation of new blood vessels) is often promoted by cancer cells, not suppressed. Tumor suppressor genes may indirectly inhibit angiogenesis by preventing uncontrolled cell growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Evade apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis (programmed cell death) is a crucial process for eliminating damaged or abnormal cells. Tumor suppressor genes often promote apoptosis, not evade it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary function of tumor suppressor genes is to control proto-oncogene activity, thereby preventing uncontrolled cell growth and maintaining genomic stability. Inherited mutations in tumor suppressor genes can significantly increase an individual&#39;s risk of developing certain types of cancer. </span></span></span></p>",
    "correct_choice_id": 79182,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19806,
    "choices": [
      {
        "id": 79185,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib</span></span></span></p>"
      },
      {
        "id": 79186,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Romidepsin</span></span></span></p>"
      },
      {
        "id": 79187,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Panobinostat</span></span></span></p>"
      },
      {
        "id": 79188,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Belinostat</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents to his primary care physician with a 3-month history of worsening fatigue and unintentional weight loss. His past medical history is significant for hypertension and type 2 diabetes, both well-controlled with medications. He has a 30-pack-year smoking history but quit 10 years ago. Physical examination reveals pallor and generalized lymphadenopathy. Laboratory studies show anemia and thrombocytopenia. A peripheral blood smear demonstrates blast cells. A bone marrow biopsy is performed, and the pathology report indicates acute myeloid leukemia (AML) with a specific chromosomal translocation. Further molecular studies reveal a mutation leading to increased activity of histone deacetylases (HDACs), which is known to be associated with a poor prognosis in this type of leukemia. The oncologist discusses treatment options with the patient, focusing on the potential use of HDAC inhibitors as part of his chemotherapy regimen. Which of the following is not a HDAC inhibitor?</span></span></span></p>",
    "unique_key": "Q9940626",
    "question_audio": null,
    "question_video": null,
    "map_id": 19809,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Ivosidenib</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivosidenib is not a histone deacetylase (HDAC) inhibitor. It is actually an inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is a different target used in the treatment of certain types of leukemia, particularly those with IDH1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B) Romidepsin, C)&nbsp; panobinostat, and D) belinostat</span></strong><span style=\"font-size:12.0pt\"> are all examples of HDAC inhibitors. These drugs work by inhibiting histone deacetylases, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these enzymes, HDAC inhibitors can induce cell cycle arrest, differentiation, and apoptosis of cancer cells, making them useful in the treatment of certain hematologic malignancies and solid tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDAC inhibitors, such as romidepsin, panobinostat, and belinostat, are used in cancer therapy to inhibit histone deacetylases, leading to epigenetic modulation of gene expression and inducing apoptosis in cancer cells. Ivosidenib, on the other hand, is an IDH1 inhibitor used in the treatment of cancers with IDH1 mutations.</span></span></span></p>",
    "correct_choice_id": 79185,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19807,
    "choices": [
      {
        "id": 79189,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Substitution </span></span></span></p>"
      },
      {
        "id": 79190,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deletion </span></span></span></p>"
      },
      {
        "id": 79191,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insertion </span></span></span></p>"
      },
      {
        "id": 79192,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Translocation </span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old patient presents with a darkly pigmented skin lesion that has been growing rapidly. A biopsy is performed and the pathology report reveals a malignant melanoma. Further molecular analysis identifies a BRAFV600E Mutation. This specific alteration is best classified as:</span></span></span></p>",
    "unique_key": "Q8098770",
    "question_audio": null,
    "question_video": null,
    "map_id": 19810,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Substitution</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BRAFV600E mutation, as described in the vignette, is a classic example of a <strong>missense substitution</strong>. It involves the replacement of a single nucleotide in the DNA sequence, leading to a change in the corresponding amino acid in the protein.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> Deletions involve the removal of one or more nucleotides from the DNA sequence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> Insertions involve the addition of one or more nucleotides to the DNA sequence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Translocations involve the rearrangement of genetic material between non-homologous chromosomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The BRAFV600E mutation is a common driver mutation in melanoma and is a target for targeted therapy with BRAF inhibitors. Recognizing this type of mutation has important implications for treatment decisions and prognosis in patients with melanoma.</span></span></span></p>",
    "correct_choice_id": 79189,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19749,
    "choices": [
      {
        "id": 78957,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></span></p>"
      },
      {
        "id": 78958,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are typically inactivated in cancer, while tumor suppressor genes are overactivated.</span></span></p>"
      },
      {
        "id": 78959,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are exclusively found in malignant tumors, while tumor suppressor genes are found in benign tumors.</span></span></p>"
      },
      {
        "id": 78960,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes encode for growth factors, while tumor suppressor genes encode for growth factor receptors.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of cancer development, which of the following statements best differentiates proto-oncogenes from tumor suppressor genes?</span></span></p>",
    "unique_key": "Q1570683",
    "question_audio": null,
    "question_video": null,
    "map_id": 19582,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Proto-oncogenes cause cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proto-oncogenes are normal genes that, when mutated or overexpressed, become oncogenes that can contribute to cancer development. These mutations often result in a gain of function, leading to increased cell growth and proliferation. Examples include the RAS and MYC genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor suppressor genes, on the other hand, normally act to regulate cell growth and prevent uncontrolled cell division. When these genes are inactivated or mutated, their protective functions are lost, leading to the development of cancer. This is typically due to loss of function mutations. Examples include the TP53 and RB1 genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. Proto-oncogenes are not typically inactivated in cancer; they are activated or overexpressed. Tumor suppressor genes are often inactivated or under expressed in cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Both proto-oncogenes and tumor suppressor genes can be involved in both malignant and benign tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Proto-oncogenes and tumor suppressor genes can encode a variety of proteins, not limited to growth factors and growth factor receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes and tumor suppressor genes are two key classes of genes involved in cancer development. Proto-oncogenes promote cell growth and proliferation and can lead to cancer when mutated to gain function. Tumor suppressor genes normally inhibit cell growth, and their inactivation or loss of function can contribute to cancer development.</span></span></p>",
    "correct_choice_id": 78957,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19750,
    "choices": [
      {
        "id": 78961,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">JAK2 V617F </span></span></p>"
      },
      {
        "id": 78962,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EGFR exon 20 insertion </span></span></p>"
      },
      {
        "id": 78963,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRAF V600E </span></span></p>"
      },
      {
        "id": 78964,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5q deletion</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following mutations is MOST likely to be associated with a myeloproliferative neoplasm?</span></span></p>",
    "unique_key": "Q7312271",
    "question_audio": null,
    "question_video": null,
    "map_id": 19583,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) JAK2 V617F</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK2 V617F is a gain-of-function mutation in the JAK2 gene, a tyrosine kinase, frequently found in myeloproliferative neoplasms like polycythemia vera and essential thrombocythemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. EGFR exon 20 insertion:</span></strong><span style=\"font-size:12.0pt\"> This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with resistance to certain targeted therapies. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BRAF V600E:</span></strong><span style=\"font-size:12.0pt\"> This mutation is commonly found in melanoma and some other solid tumors. It is not typically associated with myeloproliferative neoplasms. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5q deletion:</span></strong><span style=\"font-size:12.0pt\"> This is a chromosomal deletion frequently found in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), but not as commonly in myeloproliferative neoplasms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">JAK2 V617F is a key driver mutation in several myeloproliferative neoplasms and a target for therapies like ruxolitinib.</span></span></p>",
    "correct_choice_id": 78961,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19751,
    "choices": [
      {
        "id": 78965,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trinucleotide repeat expansion in the HTT gene </span></span></p>"
      },
      {
        "id": 78966,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deletion of phenylalanine at position 508 of the CFTR gene</span></span></p>"
      },
      {
        "id": 78967,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Point mutation resulting in a glutamate to valine substitution in the &beta;-globin gene</span></span></p>"
      },
      {
        "id": 78968,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Translocation between chromosomes 9 and 22 (t(9;22))</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old African American boy presents with acute onset of severe bone pain in his lower extremities. His history includes similar episodes, often precipitated by dehydration or stress. Lab results reveal anemia, elevated reticulocyte count, and indirect hyperbilirubinemia. A peripheral blood smear demonstrates sickled erythrocytes. Which genetic alteration is MOST likely responsible for this patient&#39;s condition?</span></span></p>",
    "unique_key": "Q6564258",
    "question_audio": null,
    "question_video": null,
    "map_id": 19584,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Point mutation resulting in a glutamate to valine substitution in the &beta;-globin gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings are classic for a sickle cell crisis in a patient with sickle cell disease (SCD). SCD arises from a single point mutation in the &beta;-globin gene (HBB), specifically a substitution of glutamic acid (a negatively charged amino acid) with valine (a hydrophobic amino acid) at position 6. This alteration changes the hemoglobin&#39;s structure, causing it to polymerize under low oxygen conditions, leading to sickled red blood cells and subsequent vaso-occlusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Trinucleotide repeat expansion in the HTT gene:</span></strong><span style=\"font-size:12.0pt\"> This mutation is associated with Huntington&#39;s disease, a neurodegenerative disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Deletion of phenylalanine at position 508 of the CFTR gene:</span></strong><span style=\"font-size:12.0pt\"> This is the most common mutation in cystic fibrosis, causing defective chloride ion transport.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Translocation between chromosomes 9 and 22 (t(9;22)):</span></strong><span style=\"font-size:12.0pt\"> This is the Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell disease is a monogenic disorder caused by a specific point mutation in the &beta;-globin gene. Understanding the molecular basis of SCD is crucial for diagnosis, management, and potential future gene therapies.</span></span></p>",
    "correct_choice_id": 78967,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19752,
    "choices": [
      {
        "id": 78969,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Point mutation in the p53 gene </span></span></p>"
      },
      {
        "id": 78970,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deletion of the RB1 gene </span></span></p>"
      },
      {
        "id": 78971,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypermethylation of the promoter region of a tumor suppressor gene </span></span></p>"
      },
      {
        "id": 78972,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Translocation between chromosomes 9 and 22</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is an example of an epigenetic change that can contribute to cancer development?</span></span></span></p>",
    "unique_key": "Q3588472",
    "question_audio": null,
    "question_video": null,
    "map_id": 19585,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Hypermethylation of the promoter region of a tumor suppressor gene</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epigenetic changes, such as DNA methylation, can alter gene expression without changing the DNA sequence itself. Hypermethylation of tumor suppressor gene promoters can silence their expression, leading to cancer development. The other options represent genetic mutations, not epigenetic changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Point mutation in the p53 gene:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic alteration where a single nucleotide in the DNA sequence of the p53 gene is changed. This can lead to the production of a dysfunctional p53 protein, which is a tumor suppressor. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Deletion of the RB1 gene:</span></strong><span style=\"font-size:12.0pt\"> This is also a genetic alteration where a portion of the RB1 gene, another tumor suppressor, is removed. The absence of the RB1 protein can contribute to uncontrolled cell growth. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Translocation between chromosomes 9 and 22:</span></strong><span style=\"font-size:12.0pt\"> This is a chromosomal rearrangement where a piece of chromosome 9 is transferred to chromosome 22, and vice versa. This translocation creates a new fusion gene, often the BCR-ABL gene, which drives the development of chronic myeloid leukemia (CML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epigenetic modifications, like DNA methylation, play a significant role in carcinogenesis.</span></span></p>",
    "correct_choice_id": 78971,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19753,
    "choices": [
      {
        "id": 78973,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E2 </span></span></p>"
      },
      {
        "id": 78974,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E4 </span></span></p>"
      },
      {
        "id": 78975,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E6</span></span></p>"
      },
      {
        "id": 78976,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">E8</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following HPV genes is MOST directly implicated in the development of cervical cancer?</span></span></p>",
    "unique_key": "Q4310856",
    "question_audio": null,
    "question_video": null,
    "map_id": 19586,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><strong>C) E6</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">E6 and E7 are the primary oncogenes of HPV. E6 inactivates p53, a tumor suppressor protein, while E7 inhibits the retinoblastoma (Rb) protein, both of which are critical for cell cycle regulation. &nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. E2:</span></strong><span style=\"font-size:12.0pt\"> E2 is involved in viral replication and gene expression regulation. While important for the HPV lifecycle, it&#39;s not directly implicated in cellular transformation and cancer development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. E4:</span></strong><span style=\"font-size:12.0pt\"> E4 plays a role in viral release and assembly. It&#39;s not considered a major oncogenic protein in the context of cervical cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. E8:</span></strong><span style=\"font-size:12.0pt\"> There is no E8 gene in the HPV genome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The E6 and E7 proteins are the primary oncoproteins of HPV that drive the development of cervical cancer by interfering with critical cellular pathways that regulate cell growth and survival.</span></span></p>",
    "correct_choice_id": 78975,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19754,
    "choices": [
      {
        "id": 78977,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of BCR-ABL tyrosine kinase</span></span></p>"
      },
      {
        "id": 78978,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of mutant IDH2 enzyme</span></span></p>"
      },
      {
        "id": 78979,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulation of the immune system to attack leukemia cells</span></span></p>"
      },
      {
        "id": 78980,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Induction of differentiation of leukemia cells</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old man with a history of refractory acute myeloid leukemia (AML) presents to the oncology clinic for a follow-up visit. He was recently started on enasidenib after genetic testing revealed a specific mutation in his leukemia cells. The patient has noticed a decrease in fatigue and an improvement in his overall well-being since starting the treatment. The oncologist explains the mechanism of action of the medication, which targets the leukemia cells. Which of the following best describes the mechanism of action of enasidenib?</span></span></p>",
    "unique_key": "Q7228696",
    "question_audio": null,
    "question_video": null,
    "map_id": 19587,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Inhibition of mutant IDH2 enzyme</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Enasidenib is a targeted therapy that inhibits the mutant isocitrate dehydrogenase 2 (IDH2) enzyme, which is found in some patients with acute myeloid leukemia (AML). The IDH2 mutation leads to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to the development and progression of AML by altering the epigenetic regulation of gene expression and blocking the differentiation of myeloid cells. By inhibiting the mutant IDH2 enzyme, enasidenib reduces the levels of 2-HG, thereby promoting the differentiation of myeloid cells and leading to clinical improvement in patients with IDH2-mutant AML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Inhibition of BCR-ABL tyrosine kinase</span></strong><span style=\"font-size:12.0pt\">: This is the mechanism of action of drugs like imatinib, which are used to treat chronic myeloid leukemia (CML), not AML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stimulation of the immune system to attack leukemia cells</span></strong><span style=\"font-size:12.0pt\">: This describes the mechanism of action of immunotherapies, such as CAR T-cell therapy, rather than enasidenib.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Induction of differentiation of leukemia cells</span></strong><span style=\"font-size:12.0pt\">: While enasidenib does lead to differentiation of leukemia cells, it is more specific to say that it inhibits the mutant IDH2 enzyme, which is the direct target of the drug.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enasidenib is a targeted therapy used to treat patients with acute myeloid leukemia (AML) who have a specific mutation in the IDH2 enzyme. It works by inhibiting the mutant enzyme, leading to a reduction in the oncometabolite 2-HG and promoting the differentiation of myeloid cells.</span></span></p>",
    "correct_choice_id": 78978,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19757,
    "choices": [
      {
        "id": 78989,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A (p16INK4A) mutation </span></span></p>"
      },
      {
        "id": 78990,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN1B (p27) mutation</span></span></p>"
      },
      {
        "id": 78991,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification</span></span></p>"
      },
      {
        "id": 78992,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TP53 mutation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with mantle cell lymphoma (MCL). Which of the following genetic alterations is MOST likely associated with this malignancy?</span></span></p>",
    "unique_key": "Q4299528",
    "question_audio": null,
    "question_video": null,
    "map_id": 19590,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CCND1 amplification</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows that CCND1 amplification is associated with MCL. CCND1 encodes Cyclin D1, a protein that promotes the G1/S phase transition in the cell cycle. Amplification of this gene leads to overexpression of Cyclin D1 and uncontrolled cell proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CDKN2A (p16INK4A) mutation:</span></strong><span style=\"font-size:12.0pt\"> While CDKN2A mutations can be seen in various cancers, they are more commonly associated with melanoma and other solid tumors. In mantle cell lymphoma, CDKN2A deletions are associated with poor prognosis but are not the primary driver of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN1B (p27) mutation:</span></strong><span style=\"font-size:12.0pt\"> Mutations in CDKN1B are associated with MEN4 syndrome (multiple endocrine neoplasia type 4) and can be seen in other cancers, but not typically in mantle cell lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TP53 mutation:</span></strong><span style=\"font-size:12.0pt\"> TP53 is a tumor suppressor gene, and mutations are found in various cancers. While TP53 mutations can occur in MCL and are associated with a worse prognosis, they are not the primary genetic alteration driving the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification is a hallmark of mantle cell lymphoma.</span></span></p>",
    "correct_choice_id": 78991,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19758,
    "choices": [
      {
        "id": 78993,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</span></span></p>"
      },
      {
        "id": 78994,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of topoisomerase II in the S phase</span></span></p>"
      },
      {
        "id": 78995,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of microtubule formation in the M phase</span></span></p>"
      },
      {
        "id": 78996,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of DNA repair enzymes in the G2 phase</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is diagnosed with breast cancer and is referred to an oncologist for treatment. The tumor is found to be estrogen receptor-positive and HER2-negative. The oncologist discusses the use of a targeted therapy that specifically interferes with the cell cycle of cancer cells, thereby inhibiting their proliferation. The medication targets a specific phase of the cell cycle, leading to cell cycle arrest and eventual apoptosis of the cancer cells. Which of the following best describes the mechanism of action of the medication likely prescribed to this patient?</span></span></p>",
    "unique_key": "Q7255748",
    "question_audio": null,
    "question_video": null,
    "map_id": 19591,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>A) Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In estrogen receptor-positive, HER2-negative breast cancer, a common targeted therapy is the use of CDK4/6 inhibitors, such as palbociclib, ribociclib, or abemaciclib. These medications work by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for the progression of the cell cycle from the G1 phase to the S phase. By inhibiting these kinases, the medication induces cell cycle arrest at the G1/S transition, preventing cancer cells from replicating their DNA and dividing. This leads to a reduction in tumor growth and can enhance the effectiveness of other therapies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Activation of topoisomerase II in the S phase</span></strong><span style=\"font-size:12.0pt\">: Topoisomerase II inhibitors, such as etoposide, work by interfering with the action of topoisomerase II, an enzyme involved in DNA replication and cell division during the S phase. This mechanism is not specific to CDK inhibitors used in breast cancer treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of microtubule formation in the M phase</span></strong><span style=\"font-size:12.0pt\">: Microtubule inhibitors, such as taxanes (e.g., paclitaxel), target the M phase of the cell cycle by preventing the formation of microtubules, which are essential for chromosome separation during cell division. This mechanism is different from that of CDK inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of DNA repair enzymes in the G2 phase</span></strong><span style=\"font-size:12.0pt\">: This option is not a common mechanism for targeted therapy in breast cancer. Drugs that target DNA repair pathways typically work by inhibiting, not activating, DNA repair enzymes to prevent cancer cells from repairing DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in the treatment of estrogen receptor-positive, HER2-negative breast cancer. They work by inhibiting CDK4/6, leading to cell cycle arrest at the G1/S transition and preventing cancer cell proliferation.</span></span></p>",
    "correct_choice_id": 78993,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19759,
    "choices": [
      {
        "id": 78997,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin A</span></span></p>"
      },
      {
        "id": 78998,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase 2 (CDK2)</span></span></p>"
      },
      {
        "id": 78999,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">p21</span></span></p>"
      },
      {
        "id": 79000,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin E</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a negative regulator that prevents the progression of cells from the G1 phase to the S phase in the cell cycle?</span></span></p>",
    "unique_key": "Q4953150",
    "question_audio": null,
    "question_video": null,
    "map_id": 19592,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>C) p21</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">p21 is a negative regulator of the cell cycle that prevents the progression of cells from the G1 phase to the S phase. It is a cyclin-dependent kinase (CDK) inhibitor that binds to and inhibits the activity of cyclin-CDK complexes, such as cyclin E-CDK2 and cyclin A-CDK2, which are required for the transition from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cyclin A:</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator of the cell cycle that activates CDK2, promoting progression through the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cyclin-dependent kinase 2 (CDK2):</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator that, when activated by cyclins such as cyclin E and cyclin A, helps drive the cell cycle from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclin E:</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator of the cell cycle that activates CDK2, promoting the transition from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">p21 is a negative regulator of the cell cycle that inhibits the activity of cyclin-CDK complexes, preventing the progression of cells from the G1 phase to the S phase. </span></span></p>",
    "correct_choice_id": 78999,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19760,
    "choices": [
      {
        "id": 79001,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 mutation </span></span></p>"
      },
      {
        "id": 79002,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MUTYH mutation </span></span></p>"
      },
      {
        "id": 79003,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MSH2 mutation </span></span></p>"
      },
      {
        "id": 79004,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATM mutation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with a family history of early-onset colon cancer and multiple family members affected by various types of cancer. Which of the following genetic mutations is MOST likely responsible for her increased cancer risk?</span></span></p>",
    "unique_key": "Q5691803",
    "question_audio": null,
    "question_video": null,
    "map_id": 19593,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) MSH2 mutation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation suggests Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer or HNPCC), which is caused by germline mutations in mismatch repair (MMR) genes, including MSH2. BRCA1 is associated with breast and ovarian cancer, MUTYH with a specific type of colorectal cancer, and ATM with ataxia-telangiectasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BRCA1 mutation:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 mutations are primarily associated with increased risks of breast and ovarian cancers. While they can increase the risk of other cancers, the patient&#39;s family history of colon cancer makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MUTYH mutation:</span></strong><span style=\"font-size:12.0pt\"> MUTYH mutations are associated with MUTYH-associated polyposis (MAP), a hereditary condition that increases the risk of colorectal cancer. However, MAP usually presents with multiple polyps, and the patient&#39;s family history doesn&#39;t necessarily fit this pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ATM mutation:</span></strong><span style=\"font-size:12.0pt\"> ATM mutations are associated with ataxia-telangiectasia, a rare neurodegenerative disorder characterized by ataxia, telangiectasias (small dilated blood vessels), and immune deficiencies. While individuals with ataxia-telangiectasia have an increased risk of certain cancers, the presentation in this question doesn&#39;t match the typical features of this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MSH2 mutations are associated with Lynch syndrome, a hereditary cancer syndrome that significantly increases the risk of various cancers, including colorectal, endometrial, and ovarian cancer.</span></span></span></p>",
    "correct_choice_id": 79003,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19761,
    "choices": [
      {
        "id": 79005,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
      },
      {
        "id": 79006,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER)</span></span></p>"
      },
      {
        "id": 79007,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
      },
      {
        "id": 79008,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single-strand break repair</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman presents to your clinic with a newly discovered breast mass. Her family history is significant for multiple cases of breast and ovarian cancer, including her mother and sister. Genetic testing reveals a germline BRCA1 mutation. Which of the following DNA repair pathways is MOST likely deficient in this patient, contributing to her increased cancer risk?</span></span></p>",
    "unique_key": "Q7115506",
    "question_audio": null,
    "question_video": null,
    "map_id": 19594,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Homologous recombination (HR)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 is a tumor suppressor gene that plays a crucial role in homologous recombination (HR), a DNA repair mechanism responsible for repairing double-stranded DNA breaks. A germline mutation in BRCA1 disrupts the HR pathway, leading to genomic instability and increasing the risk of developing breast and ovarian cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> While important for DNA repair, NHEJ is not the primary pathway affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER is primarily responsible for repairing single-base DNA damage and is not directly affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Single-strand break repair:</span></strong><span style=\"font-size:12.0pt\"> This is a broader term encompassing several pathways, including BER and PARP. While PARP inhibitors are used in BRCA-mutant cancers, the primary defect lies in HR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 mutations lead to a deficiency in homologous recombination (HR), a critical DNA repair mechanism. This defect contributes to genomic instability and significantly increases the risk of breast and ovarian cancers in affected individuals.</span></span></span></p>",
    "correct_choice_id": 79007,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19762,
    "choices": [
      {
        "id": 79009,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER) </span></span></p>"
      },
      {
        "id": 79010,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nucleotide excision repair (NER)</span></span></p>"
      },
      {
        "id": 79011,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
      },
      {
        "id": 79012,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child is brought to your clinic by their parents, who are concerned about their child&#39;s extreme sensitivity to sunlight. The child easily sunburns and has developed multiple freckles and skin lesions after minimal sun exposure. On examination, you notice dry skin and patches of hypopigmentation. You suspect an underlying genetic disorder affecting DNA repair mechanisms. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></p>",
    "unique_key": "Q6481675",
    "question_audio": null,
    "question_video": null,
    "map_id": 19595,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Nucleotide excision repair (NER)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation of photosensitivity, skin lesions, and pigmentary changes is highly suggestive of xeroderma pigmentosum (XP). XP is a rare autosomal recessive disorder characterized by defective nucleotide excision repair (NER). NER is the primary mechanism for repairing DNA damage caused by ultraviolet (UV) radiation from the sun.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER primarily repairs damage to single bases in DNA, often caused by oxidation or alkylation. While important, it&#39;s not the primary pathway for repairing the type of damage caused by UV radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Homologous recombination (HR):</span></strong><span style=\"font-size:12.0pt\"> HR is a complex process used to repair double-stranded DNA breaks. While critical for genome stability, it&#39;s not the main mechanism for repairing UV-induced DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> Similar to HR, NHEJ repairs double-stranded breaks but does not play a major role in repairing UV-induced damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inability to repair UV-induced DNA damage in XP leads to a significantly increased risk of skin cancer at a young age, as well as other complications like ocular problems and neurological abnormalities. Early diagnosis and strict sun protection measures are crucial for managing XP.</span></span></span></p>",
    "correct_choice_id": 79010,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53460,
    "choices": [
      {
        "id": 213321,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apoptosis </span></span></p>"
      },
      {
        "id": 213322,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necroptosis </span></span></p>"
      },
      {
        "id": 213323,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pyroptosis </span></span></p>"
      },
      {
        "id": 213324,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necrosis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A researcher is investigating a new drug that inhibits the formation of the inflammasome complex. Which of the following types of cell death would be MOST directly affected by this drug?</span></span></p>",
    "unique_key": "Q1372805",
    "question_audio": null,
    "question_video": null,
    "map_id": 25264,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Pyroptosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a key component of the pyroptosis pathway, responsible for activating caspase-1 and ultimately leading to inflammatory cell death. Inhibiting the inflammasome would therefore block pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis is a programmed cell death pathway, but it is not directly dependent on the inflammasome. It involves a different set of caspases (caspase-3, -6, -7) and is not typically associated with the same inflammatory response as pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necroptosis:</span></strong><span style=\"font-size:12.0pt\"> Necroptosis is another form of programmed cell death, but it is regulated by the RIPK1-RIPK3-MLKL pathway, not the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Necrosis:</span></strong><span style=\"font-size:12.0pt\"> Necrosis is an unregulated form of cell death that is typically caused by injury or trauma. It is not a programmed process and is not mediated by the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a multiprotein complex that plays a central role in pyroptosis. It senses danger signals and activates caspase-1, leading to the production of pro-inflammatory cytokines and ultimately cell death with membrane rupture. By inhibiting the inflammasome, the drug would directly block the pyroptotic pathway.</span></span></span></p>",
    "correct_choice_id": 213323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53461,
    "choices": [
      {
        "id": 213325,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apoptosis </span></span></p>"
      },
      {
        "id": 213326,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necroptosis </span></span></p>"
      },
      {
        "id": 213327,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pyroptosis </span></span></p>"
      },
      {
        "id": 213328,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necrosis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A biopsy of a patient&#39;s liver reveals hepatocytes with extensive swelling, loss of plasma membrane integrity, and leakage of cellular contents into the surrounding tissue. Which of the following types of cell death is MOST likely occurring in these cells?</span></span></p>",
    "unique_key": "Q2549676",
    "question_audio": null,
    "question_video": null,
    "map_id": 25265,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Necrosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The described morphological changes are characteristic of necrosis, an uncontrolled form of cell death that results from cellular injury. Apoptosis, necroptosis, and pyroptosis are forms of programmed cell death with distinct features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis is a programmed cell death that involves cell shrinkage, nuclear condensation, and fragmentation into apoptotic bodies, without leakage of cellular contents.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necroptosis:</span></strong><span style=\"font-size:12.0pt\"> Necroptosis is a regulated form of cell death that shares some features with necrosis, such as cell swelling and membrane rupture. However, it is initiated by specific signaling pathways and does not typically occur in the liver in response to injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pyroptosis:</span></strong><span style=\"font-size:12.0pt\"> Pyroptosis is an inflammatory form of programmed cell death that involves the formation of pores in the cell membrane, but it is primarily associated with immune responses to infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Necrosis is an unregulated cell death process characterized by cell swelling, membrane rupture, and leakage of cellular contents.</span></span></span></p>",
    "correct_choice_id": 213328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53462,
    "choices": [
      {
        "id": 213329,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Overexpression of BCL-2 </span></span></p>"
      },
      {
        "id": 213330,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loss of p53 function </span></span></p>"
      },
      {
        "id": 213331,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of RAS </span></span></p>"
      },
      {
        "id": 213332,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amplification of MYC</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with follicular lymphoma (FL) is found to have a t(14;18) translocation. Which of the following is the MOST likely consequence of this translocation?</span></span></p>",
    "unique_key": "Q3814609",
    "question_audio": null,
    "question_video": null,
    "map_id": 25266,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Overexpression of BCL-2</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;18) translocation juxtaposes the BCL-2 gene with the immunoglobulin heavy chain (IgH) locus, leading to overexpression of BCL-2, an anti-apoptotic protein.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Loss of p53 function:</span></strong><span style=\"font-size:12.0pt\"> While TP53 mutations (leading to loss of p53 function) are common in many cancers, they are not the primary driver of follicular lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Activation of RAS:</span></strong><span style=\"font-size:12.0pt\"> RAS mutations are associated with various cancers, but they are not the hallmark of follicular lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Amplification of MYC:</span></strong><span style=\"font-size:12.0pt\"> MYC amplification is more commonly associated with Burkitt lymphoma and other aggressive lymphomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;18) translocation is a hallmark of follicular lymphoma and contributes to its pathogenesis by inhibiting apoptosis.</span></span></span></p>",
    "correct_choice_id": 213329,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19763,
    "choices": [
      {
        "id": 79013,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutation in BRCA1 </span></span></span></p>"
      },
      {
        "id": 79014,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amplification of HER2 </span></span></span></p>"
      },
      {
        "id": 79015,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of function mutation in VHL </span></span></span></p>"
      },
      {
        "id": 79016,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activation of KRAS</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient presents with painless hematuria and flank pain. Imaging reveals a renal mass with characteristic features of clear cell renal cell carcinoma (RCC). Which of the following genetic alterations is MOST likely involved in the pathogenesis of this tumor?</span></span></p>",
    "unique_key": "Q1660386",
    "question_audio": null,
    "question_video": null,
    "map_id": 19596,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Loss of function mutation in VHL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clear cell RCC is strongly associated with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. This leads to stabilization of hypoxia-inducible factor (HIF), promoting angiogenesis and tumor growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mutation in BRCA1:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 is a tumor suppressor gene primarily associated with breast and ovarian cancers. While it can be involved in other cancers, it&#39;s not the primary driver of clear cell renal cell carcinoma (RCC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Amplification of HER2:</span></strong><span style=\"font-size:12.0pt\"> HER2 amplification is a key feature of certain breast cancers and some other malignancies, but not clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of KRAS:</span></strong><span style=\"font-size:12.0pt\"> KRAS is an oncogene involved in various cancers, including some types of lung and colon cancer. It is not the hallmark of clear cell RCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The VHL gene plays a crucial role in oxygen sensing and regulation of blood vessel growth. When VHL is inactivated, it leads to the stabilization and activation of hypoxia-inducible factor (HIF), which promotes angiogenesis (new blood vessel formation) and tumor growth. This is why VHL loss-of-function mutations are so strongly linked to clear cell RCC.</span></span></p>",
    "correct_choice_id": 79015,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19764,
    "choices": [
      {
        "id": 79017,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Bevacizumab </span></span></span></p>"
      },
      {
        "id": 79018,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cetuximab </span></span></span></p>"
      },
      {
        "id": 79019,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Trastuzumab </span></span></span></p>"
      },
      {
        "id": 79020,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is a monoclonal antibody targeting VEGF and is used in the treatment of various cancers, including renal cell carcinoma?</span></span></p>",
    "unique_key": "Q9244754",
    "question_audio": null,
    "question_video": null,
    "map_id": 19597,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Bevacizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bevacizumab (Avastin) is a monoclonal antibody that binds to and inhibits VEGF, thereby suppressing angiogenesis and tumor growth. It is approved for use in several cancers, including renal cell carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cetuximab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets the epidermal growth factor receptor (EGFR), which is involved in cell growth and proliferation. It is not typically used to treat renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Trastuzumab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast and stomach cancers. It is not indicated for renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Rituximab:</span></strong><span style=\"font-size:12.0pt\"> This monoclonal antibody targets CD20, a protein found on the surface of B cells. It is used to treat certain types of lymphomas and leukemias but not renal cell carcinoma. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Bevacizumab stands out as the correct answer because it specifically targets VEGF, a key player in angiogenesis, which is a crucial process for tumor growth and survival. The other options are monoclonal antibodies targeting different receptors or proteins involved in other cancer types.</span></span></span></p>",
    "correct_choice_id": 79017,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 19765,
    "choices": [
      {
        "id": 79021,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-1</span></span></p>"
      },
      {
        "id": 79022,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-L1</span></span></p>"
      },
      {
        "id": 79023,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CTLA-4</span></span></p>"
      },
      {
        "id": 79024,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CD80/86</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man with metastatic melanoma has progressed on previous therapy. You are considering starting him on an immune checkpoint inhibitor along with nivolumab after which you are planning to keep him on nibolumab. Which of the following immune checkpoint molecules is the DIRECT target for the drug which you have planned to give for this patient along with nivolumab?</span></span></p>",
    "unique_key": "Q6417400",
    "question_audio": null,
    "question_video": null,
    "map_id": 19598,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CTLA-4</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ipilimumab is a monoclonal antibody that specifically targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). CTLA-4 is an inhibitory receptor on T cells that, when bound to its ligands (CD80/CD86) on antigen-presenting cells, downregulates T-cell activation. By blocking CTLA-4, ipilimumab releases this inhibition, allowing T cells to more effectively recognize and attack cancer cells. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. PD-1:</span></strong><span style=\"font-size:12.0pt\"> PD-1 is another inhibitory checkpoint on T cells, but it&#39;s targeted by different drugs like nivolumab and pembrolizumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PD-L1:</span></strong><span style=\"font-size:12.0pt\"> PD-L1 is the ligand for PD-1, and it&#39;s also targeted by different drugs like atezolizumab and durvalumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CD80/86:</span></strong><span style=\"font-size:12.0pt\"> These are the ligands for CTLA-4, but ipilimumab doesn&#39;t directly bind to them; it binds to CTLA-4 itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the specific targets of immune checkpoint inhibitors is crucial for selecting the right therapy for different types of cancer and managing potential immune-related side effects.</span></span></p>",
    "correct_choice_id": 79023,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19766,
    "choices": [
      {
        "id": 79025,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CTLA-4</span></span></p>"
      },
      {
        "id": 79026,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-1</span></span></p>"
      },
      {
        "id": 79027,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PD-L1</span></span></p>"
      },
      {
        "id": 79028,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LAG-3</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman with metastatic Merkel cell carcinoma has progressed on chemotherapy and is now being considered for immunotherapy. You plan to start him on an a monoclonal antibody designed to enhance the anti-tumor immune response. Which of the following immune checkpoint molecules is the DIRECT target of that drug?</span></span></p>",
    "unique_key": "Q1134409",
    "question_audio": null,
    "question_video": null,
    "map_id": 19599,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) PD-L1</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avelumab is a monoclonal antibody that specifically targets PD-L1 (Programmed Death-Ligand 1) on the surface of tumor cells. By binding to PD-L1, avelumab prevents it from interacting with PD-1 on T cells. This interaction normally acts as a &quot;brake&quot; on the immune system, preventing T cells from attacking the tumor. Blocking this interaction allows T cells to recognize and destroy the cancer cells more effectively.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CTLA-4:</span></strong><span style=\"font-size:12.0pt\"> CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) is another immune checkpoint molecule, but it is targeted by different drugs like ipilimumab. Avelumab does not directly bind to or inhibit CTLA-4.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PD-1:</span></strong><span style=\"font-size:12.0pt\"> PD-1 (Programmed Cell Death Protein 1) is the receptor on T cells that PD-L1 binds to. While avelumab indirectly affects PD-1 signaling by blocking its interaction with PD-L1, it doesn&#39;t directly bind to PD-1. Other drugs like nivolumab and pembrolizumab are designed to directly target PD-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. LAG-3:</span></strong><span style=\"font-size:12.0pt\"> LAG-3 (Lymphocyte Activation Gene-3) is another inhibitory receptor on T cells that is being investigated as a target for immunotherapy. However, avelumab does not target LAG-3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> &nbsp;</u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avelumab is a PD-L1 inhibitor used in the treatment of metastatic Merkel cell carcinoma and other cancers to unleash the body&#39;s immune system against tumors.</span></span></p>",
    "correct_choice_id": 79027,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19767,
    "choices": [
      {
        "id": 79029,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxidative phosphorylation</span></span></p>"
      },
      {
        "id": 79030,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Cori cycle </span></span></p>"
      },
      {
        "id": 79031,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Warburg effect</span></span></p>"
      },
      {
        "id": 79032,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gluconeogenesis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A researcher is studying the metabolic profile of cancer cells and notices that they primarily produce energy through glycolysis, even in the presence of oxygen. This phenomenon is BEST described as:</span></span></span></p>",
    "unique_key": "Q7911880",
    "question_audio": null,
    "question_video": null,
    "map_id": 19600,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) The Warburg effect</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is the observation that cancer cells preferentially utilize aerobic glycolysis for energy production. This is in contrast to normal cells, which typically rely on oxidative phosphorylation in the presence of oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oxidative phosphorylation:</span></strong><span style=\"font-size:12.0pt\"> This is the normal process of energy production in cells with sufficient oxygen. It occurs in the mitochondria and is much more efficient at generating ATP than glycolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The Cori cycle:</span></strong><span style=\"font-size:12.0pt\"> This is a metabolic pathway that involves the interconversion of lactate and glucose between the liver and muscles. While lactate is a byproduct of glycolysis, the Cori cycle itself isn&#39;t the primary energy production method in cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gluconeogenesis:</span></strong><span style=\"font-size:12.0pt\"> This is the process of synthesizing glucose from non-carbohydrate sources (like amino acids or lactate). While cancer cells may engage in gluconeogenesis, it&#39;s not the main energy-producing pathway they rely on.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Warburg effect is a hallmark of cancer metabolism and has implications for both cancer diagnosis and potential therapeutic targets.</span></span></span></p>",
    "correct_choice_id": 79031,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19768,
    "choices": [
      {
        "id": 79033,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase inhibitors</span></span></p>"
      },
      {
        "id": 79034,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BH3 mimetics</span></span></p>"
      },
      {
        "id": 79035,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VEGF signaling inhibitors</span></span></p>"
      },
      {
        "id": 79036,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PARP inhibitors</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman with metastatic renal cell carcinoma has recently shown disease progression despite initial chemotherapy. Her oncologist is considering a treatment strategy to target the tumor&#39;s ability to create its own blood supply. Which of the following classes of drugs would be MOST appropriate for this purpose?</span></span></p>",
    "unique_key": "Q2162705",
    "question_audio": null,
    "question_video": null,
    "map_id": 19601,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) VEGF signaling inhibitors</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VEGF (vascular endothelial growth factor) is a key signaling molecule that promotes angiogenesis, the formation of new blood vessels. By inhibiting VEGF signaling, these drugs can starve tumors of their blood supply, thereby slowing or stopping their growth and spread. This approach is often used in the treatment of metastatic renal cell carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cyclin-dependent kinase inhibitors:</span></strong><span style=\"font-size:12.0pt\"> These drugs target cell cycle progression and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. BH3 mimetics:</span></strong><span style=\"font-size:12.0pt\"> These drugs target the apoptotic pathway to induce cell death and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PARP inhibitors:</span></strong><span style=\"font-size:12.0pt\"> These drugs exploit DNA repair defects in cancer cells and are not directly involved in angiogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">VEGF signaling inhibitors are a class of drugs that target angiogenesis, a crucial process for tumor growth and survival. They are used in the treatment of various cancers, including renal cell carcinoma.</span></span></span></p>",
    "correct_choice_id": 79035,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53463,
    "choices": [
      {
        "id": 213333,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurofibromatosis type 2</span></span></p>"
      },
      {
        "id": 213334,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberous sclerosis complex</span></span></p>"
      },
      {
        "id": 213335,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Hippel-Lindau disease</span></span></p>"
      },
      {
        "id": 213336,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li-Fraumeni syndrome</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old male presents with progressive headaches, gait instability, and visual disturbances. MRI was taken and shown below. Patient also has, multiple retinal angiomas. His family history is notable for his father died of uncontrolled hypertension during his 50s and his paternal side uncle was diagnosed with a brain tumor and uncontrolled hypertension along with frequent anger outbursts seeking psychiatric counselling. Which of the following is the MOST likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-172814.jpg\" style=\"height:387px; width:400px\" /></span></span></p>",
    "unique_key": "Q1065130",
    "question_audio": null,
    "question_video": null,
    "map_id": 25267,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Von Hippel-Lindau disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of a cerebellar hemangioblastoma, retinal angiomas, and a strong family history of similar tumors (brain tumor in the paternal uncle) and possible pheochromocytoma (uncontrolled hypertension, anger outbursts suggesting catecholamine excess) strongly suggests Von Hippel-Lindau (VHL) disease. VHL disease is an autosomal dominant inherited disorder that predisposes individuals to a variety of tumors, including, Hemangioblastomas, Renal cell carcinoma, Pheochromocytoma. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Neurofibromatosis type 2:</span></strong><span style=\"font-size:12.0pt\"> This condition is associated with bilateral vestibular schwannomas (tumors of the nerve responsible for hearing and balance) and other nerve tumors, not the specific findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tuberous sclerosis complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. The characteristic brain tumors are cortical tubers and subependymal giant cell astrocytomas, not hemangioblastomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Li-Fraumeni syndrome:</span></strong><span style=\"font-size:12.0pt\"> This syndrome predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. It is not typically associated with the specific combination of findings in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of a cerebellar hemangioblastoma and retinal angiomas, especially in conjunction with a suggestive family history, should raise strong suspicion for Von Hippel-Lindau disease. Early diagnosis and surveillance are crucial for managing this condition and preventing complications.</span></span></span></p>",
    "correct_choice_id": 213335,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53464,
    "choices": [
      {
        "id": 213337,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li-Fraumeni syndrome</span></span></p>"
      },
      {
        "id": 213338,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von Hippel-Lindau disease</span></span></p>"
      },
      {
        "id": 213339,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hereditary diffuse gastric cancer</span></span></p>"
      },
      {
        "id": 213340,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lynch syndrome (HNPCC)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a family history of early-onset colon and endometrial cancer. Which of the following hereditary cancer syndromes is MOST likely in this patient?</span></span></p>",
    "unique_key": "Q5580758",
    "question_audio": null,
    "question_video": null,
    "map_id": 25268,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Lynch syndrome (HNPCC)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lynch syndrome is associated with an increased risk of colorectal and endometrial cancers, often at an early age. The patient&#39;s family history aligns with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Li-Fraumeni syndrome:</span></strong><span style=\"font-size:12.0pt\"> Li-Fraumeni syndrome is associated with a broader range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. While colon cancer can occur in Li-Fraumeni syndrome, the prominence of endometrial cancer in the family history makes Lynch syndrome more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Von Hippel-Lindau disease:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is primarily characterized by the development of hemangioblastomas, renal cell carcinomas, and pheochromocytomas. It&#39;s not typically associated with a strong family history of colon or endometrial cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hereditary diffuse gastric cancer:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is mainly linked to an increased risk of diffuse gastric cancer and lobular breast cancer. While other cancers can occur, the family history in this case points more towards Lynch syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> &nbsp;</u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lynch syndrome is an inherited cancer syndrome characterized by an increased risk of colorectal, endometrial, and other cancers.</span></span></span></p>",
    "correct_choice_id": 213340,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53465,
    "choices": [
      {
        "id": 213341,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKAR1A </span></span></p>"
      },
      {
        "id": 213342,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A </span></span></p>"
      },
      {
        "id": 213343,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SDH </span></span></p>"
      },
      {
        "id": 213344,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MET</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old man presents with multiple pigmented skin lesions and cardiac myxomas. He also reports a family history of sudden cardiac death. Which gene is MOST likely to be mutated in this patient?</span></span></p>",
    "unique_key": "Q9113611",
    "question_audio": null,
    "question_video": null,
    "map_id": 25269,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) PRKAR1A</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death suggests Carney complex, which is caused by mutations in the PRKAR1A gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN2A</span></strong><span style=\"font-size:12.0pt\">: This gene is associated with melanoma and pancreatic cancer in the context of familial atypical multiple mole melanoma (FAMMM) syndrome. While pigmented skin lesions can be present in FAMMM, cardiac myxomas and a family history of sudden cardiac death are not characteristic features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. SDH</span></strong><span style=\"font-size:12.0pt\">: Mutations in SDH genes are linked to hereditary paraganglioma-pheochromocytoma syndrome, which primarily manifests with tumors of the adrenal glands and nervous system. Cardiac myxomas and pigmented skin lesions are not associated with this syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. MET</span></strong><span style=\"font-size:12.0pt\">: MET mutations are involved in hereditary papillary renal cell carcinoma. This condition is not typically associated with cardiac myxomas or pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u>&nbsp; </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The specific constellation of findings in this patient, including pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death, is strongly suggestive of Carney complex, a rare autosomal dominant disorder caused by mutations in the PRKAR1A gene.</span></span></p>",
    "correct_choice_id": 213341,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53466,
    "choices": [
      {
        "id": 213345,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrinoma</span></span></p>"
      },
      {
        "id": 213346,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolactinoma </span></span></p>"
      },
      {
        "id": 213347,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma</span></span></p>"
      },
      {
        "id": 213348,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulinoma</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a history of recurrent kidney stones and hypercalcemia. Her family history is significant for her mother having a pituitary tumor and her brother having undergone surgery for a parathyroid adenoma. Given the patient&#39;s clinical presentation and family history, which of the following tumors is LEAST likely to be associated with her suspected diagnosis?</span></span></p>",
    "unique_key": "Q6885261",
    "question_audio": null,
    "question_video": null,
    "map_id": 25270,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Medullary thyroid carcinoma</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation of recurrent kidney stones and hypercalcemia, along with a family history of pituitary and parathyroid tumors, strongly suggests Multiple Endocrine Neoplasia type 1 (MEN1). MEN1 is characterized by tumors of the parathyroid glands (leading to hypercalcemia), pituitary gland, and pancreas (often gastrinomas or insulinomas).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Medullary thyroid carcinoma</span></strong><span style=\"font-size:12.0pt\"> is associated with Multiple Endocrine Neoplasia type 2 (MEN2), not MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gastrinoma:</span></strong><span style=\"font-size:12.0pt\"> Gastrinomas are tumors of the pancreas that secrete gastrin, leading to excessive stomach acid production and peptic ulcers. They are a common feature of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prolactinoma:</span></strong><span style=\"font-size:12.0pt\"> Prolactinomas are pituitary tumors that secrete prolactin, causing symptoms like irregular periods, infertility, and milk production in women. Pituitary tumors are a key component of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulinoma:</span></strong><span style=\"font-size:12.0pt\"> Insulinomas are pancreatic tumors that secrete insulin, leading to hypoglycemia. They are another common manifestation of MEN1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:&nbsp; </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The constellation of findings in this patient points strongly towards MEN1. While MEN1 can have a variety of manifestations, medullary thyroid carcinoma is a hallmark of MEN2 and is not typically associated with MEN1.</span></span></span></p>",
    "correct_choice_id": 213347,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53467,
    "choices": [
      {
        "id": 213349,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
      },
      {
        "id": 213350,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DNA crosslink repair</span></span></p>"
      },
      {
        "id": 213351,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
      },
      {
        "id": 213352,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mismatch repair (MMR)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 7-year-old boy is brought to the pediatrician due to concerns about his small stature and sun sensitivity. He has also had recurrent respiratory infections. On physical examination, he is noted to have a photosensitive rash on his face, microcephaly, and low body weight for his age. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></span></p>",
    "unique_key": "Q3163636",
    "question_audio": null,
    "question_video": null,
    "map_id": 25271,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Homologous recombination (HR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation, including short stature, photosensitive rash, microcephaly, immunodeficiency, and predisposition to leukemia and lymphoma, is highly suggestive of Bloom syndrome. Bloom syndrome is caused by mutations in the BLM gene, which encodes a protein essential for homologous recombination (HR). HR is a critical DNA repair mechanism that repairs double-strand DNA breaks. Defects in HR lead to genomic instability and increased susceptibility to cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. DNA crosslink repair:</span></strong><span style=\"font-size:12.0pt\"> Defects in DNA crosslink repair are seen in Fanconi anemia, which presents with bone marrow failure, developmental abnormalities, and increased risk of leukemia, but not the other features seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> NHEJ is another DNA repair pathway that repairs double-strand breaks. While important for maintaining genomic stability, it&#39;s not the primary pathway affected in Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mismatch repair (MMR):</span></strong><span style=\"font-size:12.0pt\"> MMR corrects errors that occur during DNA replication. Defects in MMR are seen in Lynch syndrome, which is associated with an increased risk of colorectal and other cancers, but not the characteristic features of Bloom syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bloom syndrome is a rare genetic disorder characterized by growth retardation, sun sensitivity, immunodeficiency, and predisposition to various cancers. It is caused by mutations in the BLM gene, which leads to defective homologous recombination and genomic instability.</span></span></span></p>",
    "correct_choice_id": 213349,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53468,
    "choices": [
      {
        "id": 213353,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ataxia-telangiectasia (AT)</span></span></p>"
      },
      {
        "id": 213354,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bloom syndrome (BLMS)</span></span></p>"
      },
      {
        "id": 213355,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fanconi anemia (FA)</span></span></p>"
      },
      {
        "id": 213356,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Werner syndrome (WRN)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents with premature aging, bilateral cataracts, and diabetes mellitus. She also has a family history of early-onset cancer. On examination, you observe that she has a bird-like peculiar facial feature. Which of the following genetic disorders is MOST likely?</span></span></p>",
    "unique_key": "Q3293565",
    "question_audio": null,
    "question_video": null,
    "map_id": 25272,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Werner syndrome (WRN)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of premature aging, cataracts, diabetes, and a family history of cancer strongly suggests Werner syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ataxia-telangiectasia (AT):</span></strong><span style=\"font-size:12.0pt\"> This condition presents in childhood with ataxia (uncoordinated movements), telangiectasias (dilated blood vessels), and immune deficiency. While it also predisposes to cancer, the premature aging features and cataracts are not characteristic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bloom syndrome (BLMS):</span></strong><span style=\"font-size:12.0pt\"> Bloom syndrome is also associated with an increased cancer risk and sun sensitivity, but the hallmark feature is short stature, not premature aging or cataracts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fanconi anemia (FA):</span></strong><span style=\"font-size:12.0pt\"> This condition is primarily characterized by bone marrow failure and an increased risk of leukemia and other cancers. Premature aging and cataracts are not typical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of premature aging, cataracts, diabetes, a family history of early-onset cancer, and a &quot;bird-like&quot; facial appearance strongly supports the diagnosis of Werner syndrome.</span></span></span></p>",
    "correct_choice_id": 213356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19769,
    "choices": [
      {
        "id": 79037,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fludarabine </span></span></span></p>"
      },
      {
        "id": 79038,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6-Mercaptopurine </span></span></span></p>"
      },
      {
        "id": 79039,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine </span></span></span></p>"
      },
      {
        "id": 79040,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5-Fluorouracil (5-FU)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old woman with metastatic pancreatic cancer is undergoing chemotherapy. Her oncologist is considering adding an antimetabolite that not only disrupts DNA synthesis but also has an inhibitory effect on RNA reductase to further hinder cancer cell growth. Which of the following medications would BEST fit this description?</span></span></p>",
    "unique_key": "Q2443005",
    "question_audio": null,
    "question_video": null,
    "map_id": 19602,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Gemcitabine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine&#39;s unique mechanism of action involves both DNA and RNA synthesis inhibition. Its active metabolite (FdCTP) incorporates into DNA, halting DNA polymerase, and also inhibits ribonucleotide reductase, an enzyme crucial for providing the building blocks for RNA synthesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Fludarabine</span></strong><span style=\"font-size:12.0pt\">: Fludarabine primarily acts by incorporating into DNA and inhibiting DNA polymerase and other enzymes involved in DNA synthesis and repair. It does not have a known mechanism of action involving RNA reductase inhibition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 6-Mercaptopurine</span></strong><span style=\"font-size:12.0pt\">: This purine analog inhibits purine synthesis, indirectly affecting both DNA and RNA synthesis. However, its primary target is not RNA reductase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5-Fluorouracil (5-FU)</span></strong><span style=\"font-size:12.0pt\">: 5-FU acts by inhibiting thymidylate synthase, an enzyme crucial for DNA synthesis. It does not directly inhibit RNA reductase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gemcitabine&#39;s dual mechanism of action, targeting both DNA and RNA synthesis, makes it a valuable chemotherapeutic option for various cancers, including pancreatic cancer.</span></span></p>",
    "correct_choice_id": 79039,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19770,
    "choices": [
      {
        "id": 79041,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vincristine </span></span></p>"
      },
      {
        "id": 79042,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paclitaxel </span></span></p>"
      },
      {
        "id": 79043,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eribulin </span></span></p>"
      },
      {
        "id": 79044,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-Fluorouracil</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with breast cancer is being treated with a drug that stabilizes microtubules, preventing their depolymerization. Which of the following drugs is MOST likely being used?</span></span></p>",
    "unique_key": "Q4179585",
    "question_audio": null,
    "question_video": null,
    "map_id": 19603,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Paclitaxel</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image clearly states that taxanes like paclitaxel stabilize microtubules. Vinca alkaloids and eribulin inhibit microtubule formation, while 5-FU is an antimetabolite, not an anti-microtubule agent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a vinca alkaloid that destabilizes microtubules by binding to tubulin and preventing its polymerization. This leads to disruption of the mitotic spindle and cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Eribulin:</span></strong><span style=\"font-size:12.0pt\"> Eribulin is also a microtubule-destabilizing agent, though its mechanism of action is slightly different from vinca alkaloids. It binds to the plus end of microtubules, preventing their growth and leading to mitotic arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5-Fluorouracil (5-FU):</span></strong><span style=\"font-size:12.0pt\"> 5-FU is an antimetabolite that interferes with DNA synthesis. It has no direct effect on microtubules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key difference lies in the mechanism of action. Paclitaxel stabilizes microtubules, preventing their normal breakdown, which is essential for cell division. In contrast, vinca alkaloids and eribulin destabilize microtubules, also disrupting cell division but through a different process.</span></span></span></p>",
    "correct_choice_id": 79042,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19771,
    "choices": [
      {
        "id": 79045,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitoxantrone </span></span></p>"
      },
      {
        "id": 79046,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dactinomycin </span></span></p>"
      },
      {
        "id": 79047,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bleomycin </span></span></p>"
      },
      {
        "id": 79048,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitomycin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old male with Hodgkin&#39;s lymphoma is undergoing combination chemotherapy. During a follow-up visit, he reports a new onset of dry cough and shortness of breath. Chest X-ray reveals diffuse interstitial infiltrates. Which of the following drugs included in his chemotherapy regimen is MOST likely responsible for these findings?</span></span></p>",
    "unique_key": "Q2479621",
    "question_audio": null,
    "question_video": null,
    "map_id": 19604,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Bleomycin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms and imaging findings are consistent with pulmonary toxicity, a well-known side effect of bleomycin. Bleomycin can cause pneumonitis and pulmonary fibrosis, leading to progressive lung damage and respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mitoxantrone:</span></strong><span style=\"font-size:12.0pt\"> While mitoxantrone can cause some pulmonary toxicity, it is less common and less severe than that associated with bleomycin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dactinomycin:</span></strong><span style=\"font-size:12.0pt\"> Dactinomycin is not typically associated with significant pulmonary toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mitomycin:</span></strong><span style=\"font-size:12.0pt\"> Mitomycin is more commonly associated with hemorrhagic cystitis (inflammation of the bladder with bleeding) and myelosuppression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bleomycin is an important antitumor antibiotic with a significant risk of pulmonary toxicity, which can manifest as pneumonitis and fibrosis. Careful monitoring of lung function is essential during and after treatment with bleomycin.</span></span></p>",
    "correct_choice_id": 79047,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19772,
    "choices": [
      {
        "id": 79049,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G1 phase </span></span></p>"
      },
      {
        "id": 79050,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S phase</span></span></p>"
      },
      {
        "id": 79051,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G2 phase</span></span></p>"
      },
      {
        "id": 79052,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M phase</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a 40 pack-year smoking history presents with a persistent cough and hemoptysis. Imaging reveals a central lung mass, and biopsy confirms small cell lung cancer (SCLC). He is started on a chemotherapy regimen including etoposide. Etoposide exerts its anti-cancer effects by targeting a specific phase of the cell cycle. During which phase is etoposide MOST effective?</span></span></p>",
    "unique_key": "Q5605819",
    "question_audio": null,
    "question_video": null,
    "map_id": 19605,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) M phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Etoposide is a topoisomerase II inhibitor. Topoisomerase II is an enzyme that helps unwind DNA during replication. Etoposide traps the topoisomerase II enzyme on the DNA, leading to the accumulation of double-stranded DNA breaks. These breaks are most detrimental during mitosis (M phase) when the cell is actively dividing and trying to separate its chromosomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase where the cell grows and prepares for DNA replication. Etoposide&#39;s mechanism doesn&#39;t directly target processes in this phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of DNA replication. While DNA damage can occur here, etoposide&#39;s primary action is on the M phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. G2 phase:</span></strong><span style=\"font-size:12.0pt\"> This phase involves further cell growth and preparation for mitosis. Again, etoposide&#39;s primary target is the M phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Etoposide is a topoisomerase II inhibitor that is most effective during the M phase of the cell cycle, where it disrupts chromosome segregation and leads to cell death. Understanding the cell cycle specificity of chemotherapy drugs is crucial for optimizing treatment regimens.</span></span></p>",
    "correct_choice_id": 79052,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19773,
    "choices": [
      {
        "id": 79053,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Directly blocking DNA synthesis </span></span></p>"
      },
      {
        "id": 79054,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preventing cell division by disrupting microtubules</span></span></p>"
      },
      {
        "id": 79055,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trapping an enzyme involved in DNA unwinding, leading to DNA breaks</span></span></p>"
      },
      {
        "id": 79056,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inserting itself into DNA, causing structural damage</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with platinum-resistant ovarian cancer is started on topotecan. You counsel her that this medication works by:</span></span></span></p>",
    "unique_key": "Q9131830",
    "question_audio": null,
    "question_video": null,
    "map_id": 19626,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Trapping an enzyme involved in DNA unwinding, leading to DNA breaks </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan is a topoisomerase I inhibitor.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topoisomerase I is essential for relieving torsional stress during DNA replication by creating transient single-stranded breaks.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan prevents the topoisomerase I enzyme from resealing these breaks, leading to DNA damage and ultimately cell death. &nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Directly blocking DNA synthesis:</span></strong><span style=\"font-size:12.0pt\"> While topotecan ultimately disrupts DNA replication, it doesn&#39;t directly block DNA synthesis in the same way that antimetabolites do. Antimetabolites, like 5-FU, are structurally similar to DNA building blocks and get incorporated into the DNA strand, thus halting its growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Preventing cell division by disrupting microtubules:</span></strong><span style=\"font-size:12.0pt\"> This is the mechanism of action of drugs like taxanes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). They interfere with the formation of the mitotic spindle, which is essential for cell division.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inserting itself into DNA, causing structural damage:</span></strong><span style=\"font-size:12.0pt\"> This describes the mechanism of action of anthracyclines (doxorubicin, daunorubicin). These drugs intercalate between DNA base pairs, leading to distortion of the DNA structure and interfering with replication and transcription.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topotecan targets topoisomerase I, disrupting DNA replication and causing lethal DNA damage in cancer cells. &nbsp; </span></span></p>",
    "correct_choice_id": 79055,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19774,
    "choices": [
      {
        "id": 79057,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Busulfan </span></span></p>"
      },
      {
        "id": 79058,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisplatin </span></span></p>"
      },
      {
        "id": 79059,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Temozolomide </span></span></p>"
      },
      {
        "id": 79060,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procarbazine</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with chronic myeloid leukemia (CML) is started on a drug that alkylates DNA and forms cross-links. Which of the following drugs is MOST likely being used?</span></span></p>",
    "unique_key": "Q6404813",
    "question_audio": null,
    "question_video": null,
    "map_id": 19627,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Busulfan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Busulfan belongs to the alkylsulfonate class, which, as per the image, causes DNA alkylation and cross-linking. Cisplatin also causes cross-linking but through DNA platination. Temozolomide and Procarbazine are monofunctional and don&#39;t cause cross-linking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> Cisplatin is a platinum compound, not an alkylsulfonate. While it also forms DNA cross-links, it does so through a different mechanism involving platinum adducts. It&#39;s not the primary choice for CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Temozolomide:</span></strong><span style=\"font-size:12.0pt\"> Temozolomide is a triazene, a type of alkylating agent that primarily causes methylation of DNA. While effective in certain brain tumors and melanomas, it&#39;s not the first-line treatment for CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Procarbazine:</span></strong><span style=\"font-size:12.0pt\"> Procarbazine is a miscellaneous alkylating agent with a complex mechanism of action involving free radical generation. It&#39;s less commonly used in CML and doesn&#39;t primarily cause DNA cross-linking.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alkylsulfonates are bifunctional alkylating agents that cause DNA cross-linking, which is particularly effective against rapidly dividing cells like those in CML.</span></span></p>",
    "correct_choice_id": 79057,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19775,
    "choices": [
      {
        "id": 79061,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrogen mustards</span></span></p>"
      },
      {
        "id": 79062,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrosoureas</span></span></p>"
      },
      {
        "id": 79063,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platinum compounds</span></span></p>"
      },
      {
        "id": 79064,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triazenes</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with non-Hodgkin lymphoma is undergoing chemotherapy. He presents to the emergency room with complaints of burning urination and blood in his urine. Which of the following classes of chemotherapeutic agents is MOST likely responsible for his symptoms?</span></span></p>",
    "unique_key": "Q5179268",
    "question_audio": null,
    "question_video": null,
    "map_id": 19628,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Nitrogen mustards</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms of burning urination (dysuria) and blood in the urine (hematuria) are highly suggestive of hemorrhagic cystitis, a common side effect of certain nitrogen mustards like cyclophosphamide. The toxic metabolite acrolein, produced during the breakdown of cyclophosphamide, irritates and damages the bladder lining, leading to bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nitrosoureas:</span></strong><span style=\"font-size:12.0pt\"> While nitrosoureas can cause some bladder toxicity, they are more commonly associated with delayed myelosuppression and neurotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Platinum compounds:</span></strong><span style=\"font-size:12.0pt\"> Platinum-based drugs like cisplatin and carboplatin can cause renal toxicity, but hemorrhagic cystitis is not a typical side effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Triazenes:</span></strong><span style=\"font-size:12.0pt\"> Triazenes are alkylating agents, but they are not specifically known to cause hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemorrhagic cystitis is a significant side effect of certain nitrogen mustards like cyclophosphamide. Preventive measures, including adequate hydration and the use of mesna (a drug that binds to acrolein), are crucial in managing this complication. </span></span></p>",
    "correct_choice_id": 79061,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19776,
    "choices": [
      {
        "id": 79065,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nausea and vomiting</span></span></p>"
      },
      {
        "id": 79066,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alopecia (hair loss)</span></span></p>"
      },
      {
        "id": 79067,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiotoxicity</span></span></p>"
      },
      {
        "id": 79068,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myelosuppression (bone marrow suppression)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman with breast cancer has completed her primary treatment, which included several cycles of doxorubicin-containing chemotherapy. She is now in remission and attending a follow-up visit with her oncologist. Which of the following long-term complications is the oncologist MOST concerned about?</span></span></p>",
    "unique_key": "Q2007383",
    "question_audio": null,
    "question_video": null,
    "map_id": 19629,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cardiotoxicity</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin, an anthracycline antibiotic used in chemotherapy, is known for its cumulative dose-dependent cardiotoxicity. This can manifest as heart failure, often years after treatment completion. Therefore, long-term cardiac monitoring is essential for patients who have received doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nausea and vomiting:</span></strong><span style=\"font-size:12.0pt\"> While common during active chemotherapy treatment, nausea and vomiting are usually acute side effects and not a significant long-term concern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alopecia (hair loss):</span></strong><span style=\"font-size:12.0pt\"> Hair loss is another common acute side effect of chemotherapy, but hair usually regrows after treatment is completed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Myelosuppression:</span></strong><span style=\"font-size:12.0pt\"> Myelosuppression (suppression of bone marrow function, leading to decreased blood cell counts) is a significant side effect during active chemotherapy. However, it typically resolves once treatment is stopped and is not a major long-term concern in the same way as cardiotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines, like doxorubicin, can cause delayed cardiotoxicity. Patients who have received these drugs need long-term cardiac follow-up, even years after completing treatment.</span></span></span></p>",
    "correct_choice_id": 79067,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19777,
    "choices": [
      {
        "id": 79069,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G1 phase</span></span></p>"
      },
      {
        "id": 79070,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S phase</span></span></p>"
      },
      {
        "id": 79071,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">G2 phase </span></span></p>"
      },
      {
        "id": 79072,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M phase</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with testicular cancer is scheduled to receive bleomycin- containing chemotherapy regimen. Bleomycin is MOST effective during which phase of the cell cycle?</span></span></p>",
    "unique_key": "Q5188109",
    "question_audio": null,
    "question_video": null,
    "map_id": 19630,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) G2 phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin&#39;s mechanism of action involves the generation of free radicals that cause DNA strand breaks. These breaks are most detrimental to the cell during the G2 phase, when the cell is checking for errors in its replicated DNA before proceeding to mitosis (cell division).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;<u>Explanation:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase where the cell grows and prepares for DNA replication. Bleomycin&#39;s DNA-damaging effects are not specifically targeted to this phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of DNA replication. While DNA damage can occur here, bleomycin&#39;s peak activity is in the G2 phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. M phase:</span></strong><span style=\"font-size:12.0pt\"> This is the phase of actual cell division (mitosis). While bleomycin-induced DNA damage can also affect mitosis, it&#39;s most potent during the G2 phase when the cell is actively preparing for division.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin is a cell cycle-specific antitumor antibiotic that primarily targets the G2 phase of the cell cycle.</span></span></span></p>",
    "correct_choice_id": 79071,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19778,
    "choices": [
      {
        "id": 79073,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></p>"
      },
      {
        "id": 79074,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Doxorubicin</span></span></p>"
      },
      {
        "id": 79075,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paclitaxel</span></span></p>"
      },
      {
        "id": 79076,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-Fluorouracil</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with rapidly dividing tumor cells is being treated with a chemotherapy regimen that includes a drug that targets the M phase of the cell cycle. Which of the following drugs is MOST likely included in this regimen?</span></span></span></p>",
    "unique_key": "Q1047200",
    "question_audio": null,
    "question_video": null,
    "map_id": 19631,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paclitaxel</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image indicates that antimicrotubular agents target the M phase of the cell cycle. Paclitaxel is a well-known antimicrotubular agent that disrupts the formation of the mitotic spindle, thereby preventing cell division.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methotrexate:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Methotrexate is an antimetabolite that targets the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Doxorubicin:</span></strong><span style=\"font-size:12.0pt\"> Doxorubicin is an antitumor antibiotic that is cell cycle non-specific.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5-Fluorouracil:</span></strong><span style=\"font-size:12.0pt\"> 5-Fluorouracil is an antimetabolite that also targets the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Antimicrotubular agents like paclitaxel are effective in treating rapidly dividing tumors because they disrupt the M phase of the cell cycle, leading to cell death.</span></span></p>",
    "correct_choice_id": 79075,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53469,
    "choices": [
      {
        "id": 213357,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bleomycin </span></span></p>"
      },
      {
        "id": 213358,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cytarabine </span></span></p>"
      },
      {
        "id": 213359,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vincristine </span></span></p>"
      },
      {
        "id": 213360,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisplatin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with acute myeloid leukemia (AML) is being treated with a drug that interferes with DNA synthesis. This drug is most likely:</span></span></span></p>",
    "unique_key": "Q4314838",
    "question_audio": null,
    "question_video": null,
    "map_id": 25273,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Cytarabine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antimetabolites, such as cytarabine, interfere with DNA synthesis, typically during the S phase of the cell cycle. The image shows that antimetabolites act on the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;</span><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bleomycin:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Bleomycin is an antitumor antibiotic that acts on the G2 phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> Vincristine is an antimicrotubular agent that acts on the M phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> Cisplatin is an alkylating agent that is cell cycle non-specific.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antimetabolites disrupt DNA synthesis, making them effective against rapidly dividing cancer cells.</span></span></span></p>",
    "correct_choice_id": 213358,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53470,
    "choices": [
      {
        "id": 213361,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen </span></span></p>"
      },
      {
        "id": 213362,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anastrozole </span></span></p>"
      },
      {
        "id": 213363,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fulvestrant </span></span></p>"
      },
      {
        "id": 213364,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A postmenopausal woman with breast cancer is found to have a tumor that overexpresses aromatase. Which of the following medications is MOST likely to be effective in treating this patient?</span></span></p>",
    "unique_key": "Q4542617",
    "question_audio": null,
    "question_video": null,
    "map_id": 25274,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Anastrozole </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aromatase inhibitors like anastrozole block the conversion of androgens to estrogens in peripheral tissues, particularly in postmenopausal women. This reduces estrogen levels, which can inhibit the growth of hormone-receptor-positive breast cancers. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors but doesn&#39;t affect estrogen production. Fulvestrant is an estrogen receptor downregulator. Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist used for ovarian suppression in premenopausal women.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tamoxifen:</span></strong><span style=\"font-size:12.0pt\"> Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen antagonist in breast tissue but an agonist in other tissues like the bone and uterus. While it can be effective in some cases of hormone-receptor-positive breast cancer, it doesn&#39;t directly address the issue of increased estrogen production in tumors that overexpress aromatase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fulvestrant:</span></strong><span style=\"font-size:12.0pt\"> Fulvestrant is a Selective Estrogen Receptor Downregulator (SERD) that binds to and degrades estrogen receptors. While effective in hormone-receptor-positive breast cancer, it also doesn&#39;t directly target the increased estrogen production in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Leuprolide:</span></strong><span style=\"font-size:12.0pt\"> Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist that suppresses ovarian function, leading to decreased estrogen production. However, it&#39;s primarily used in premenopausal women. In postmenopausal women, the ovaries are already inactive, and most estrogen production occurs in peripheral tissues through aromatase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors are effective in treating hormone-receptor-positive breast cancer in postmenopausal women by reducing estrogen production.</span></span></p>",
    "correct_choice_id": 213362,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53471,
    "choices": [
      {
        "id": 213365,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-alpha reductase (5-AR)</span></span></p>"
      },
      {
        "id": 213366,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase</span></span></p>"
      },
      {
        "id": 213367,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17-alpha hydroxylase (17&alpha;1)</span></span></p>"
      },
      {
        "id": 213368,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CYP17</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with prostate cancer has been on androgen deprivation therapy (ADT) but recently shows signs of disease progression. His oncologist suspects that his tumor may be utilizing an alternative pathway to maintain androgen signalling. Which enzyme is MOST likely responsible for converting testosterone to a more potent androgen within the prostate, contributing to this resistance?</span></span></p>",
    "unique_key": "Q2533475",
    "question_audio": null,
    "question_video": null,
    "map_id": 25275,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. A) 5-alpha reductase (5-AR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5-alpha reductase converts testosterone to dihydrotestosterone (DHT), a more potent androgen that binds to the androgen receptor with higher affinity. Even in the setting of low testosterone levels due to ADT, some prostate cancers can upregulate 5-AR activity to continue growing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;</span><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aromatase:</span></strong><span style=\"font-size:12.0pt\"> Aromatase converts androgens to estrogens and is relevant in breast cancer, not prostate cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 17-alpha hydroxylase (17&alpha;1):</span></strong><span style=\"font-size:12.0pt\"> This enzyme is involved in the early steps of steroid hormone synthesis in the adrenal glands and gonads. It doesn&#39;t directly convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CYP17:</span></strong><span style=\"font-size:12.0pt\"> CYP17 is another enzyme involved in steroid hormone synthesis, but it doesn&#39;t directly convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the role of 5-alpha reductase in androgen metabolism is important for comprehending mechanisms of resistance to hormone therapy in prostate cancer and for selecting appropriate treatment strategies.</span></span></p>",
    "correct_choice_id": 213365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53472,
    "choices": [
      {
        "id": 213369,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Efflux</span></span></p>"
      },
      {
        "id": 213370,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Inactivation</span></span></p>"
      },
      {
        "id": 213371,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Target Alteration</span></span></p>"
      },
      {
        "id": 213372,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cell Death Inhibition</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with chronic myeloid leukemia (CML) initially responds well to imatinib therapy but later develops resistance. Which of the following mechanisms is MOST likely responsible for this acquired resistance?</span></span></p>",
    "unique_key": "Q5332338",
    "question_audio": null,
    "question_video": null,
    "map_id": 25276,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Drug Target Alteration</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In CML, resistance to imatinib often occurs due to mutations in the BCR-ABL kinase domain, the target of the drug. These mutations alter the drug&#39;s binding site, rendering it ineffective.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Drug Efflux:</span></strong><span style=\"font-size:12.0pt\"> While drug efflux pumps can contribute to resistance in some cancers, it&#39;s not the most common mechanism in CML specifically. Imatinib resistance is primarily driven by mutations in the BCR-ABL target itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Drug Inactivation:</span></strong><span style=\"font-size:12.0pt\"> This mechanism involves the cancer cells metabolizing or breaking down the drug, rendering it ineffective. While this can occur, it&#39;s less common in CML compared to target alteration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cell Death Inhibition:</span></strong><span style=\"font-size:12.0pt\"> While cancer cells can develop mechanisms to evade apoptosis (programmed cell death), this is usually a contributing factor to resistance rather than the primary cause in CML after imatinib therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Drug target alteration is a common mechanism of acquired resistance, particularly in targeted therapies like imatinib.</span></span></span></p>",
    "correct_choice_id": 213371,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 53473,
    "choices": [
      {
        "id": 213373,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Influx </span></span></p>"
      },
      {
        "id": 213374,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug Efflux </span></span></p>"
      },
      {
        "id": 213375,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DNA Damage Repair </span></span></p>"
      },
      {
        "id": 213376,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EMT</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following mechanisms of drug resistance involves increased expression of proteins that pump drugs out of cancer cells?</span></span></p>",
    "unique_key": "Q5077567",
    "question_audio": null,
    "question_video": null,
    "map_id": 25277,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Drug Efflux</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Drug efflux refers to the active transport of drugs out of the cell by membrane proteins, thereby reducing their intracellular concentration and effectiveness.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Drug Influx:</span></strong><span style=\"font-size:12.0pt\"> This is the opposite of the correct answer. Drug influx refers to the movement of drugs into the cell, which would increase their effectiveness, not contribute to resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. DNA Damage Repair:</span></strong><span style=\"font-size:12.0pt\"> DNA damage repair mechanisms help cells fix damage caused by chemotherapy or radiation. While enhanced repair can contribute to resistance, it doesn&#39;t directly involve pumping drugs out of the cell.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. EMT (Epithelial-Mesenchymal Transition):</span></strong><span style=\"font-size:12.0pt\"> EMT is a process where cells lose their epithelial characteristics and gain mesenchymal properties, allowing them to migrate and invade. While EMT can contribute to resistance, it does so through various mechanisms, not specifically increased drug efflux.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug efflux pumps can contribute to multidrug resistance in cancer.</span></span></p>",
    "correct_choice_id": 213374,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19779,
    "choices": [
      {
        "id": 79077,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone alone </span></span></span></p>"
      },
      {
        "id": 79078,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5HT3 antagonist alone </span></span></span></p>"
      },
      {
        "id": 79079,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist </span></span></span></p>"
      },
      {
        "id": 79080,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient is about to start a chemotherapy regimen containing high-dose cyclophosphamide (&gt;1500mg/m&sup2;). Which antiemetic regimen is MOST appropriate for preventing CINV in this patient?</span></span></span></p>",
    "unique_key": "Q7302794",
    "question_audio": null,
    "question_video": null,
    "map_id": 19632,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose cyclophosphamide (&gt;1500mg/m<sup>2</sup>) as a high-risk emetogenic chemotherapy, requiring a combination of dexamethasone, a 5HT3 antagonist, and an NK1 receptor antagonist on days 1, 2, and 3 of the chemotherapy cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dexamethasone alone:</span></strong><span style=\"font-size:12.0pt\"> While dexamethasone has antiemetic properties, it is not sufficient on its own to prevent CINV in high-risk regimens like those involving high-dose cyclophosphamide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 5HT3 antagonist alone:</span></strong><span style=\"font-size:12.0pt\"> 5HT3 antagonists are effective antiemetics, but they are not potent enough to control CINV in high-risk settings when used alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dexamethasone + 5HT3 antagonist:</span></strong><span style=\"font-size:12.0pt\"> This combination provides better control than either drug alone, but it may still be inadequate for high-risk chemotherapy. The addition of an NK1 receptor antagonist further enhances antiemetic efficacy in these cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-risk emetogenic chemotherapy requires a triple-drug antiemetic regimen to effectively prevent CINV.</span></span></span></p>",
    "correct_choice_id": 79080,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19780,
    "choices": [
      {
        "id": 79081,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loperamide </span></span></span></p>"
      },
      {
        "id": 79082,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
      },
      {
        "id": 79083,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ondansetron </span></span></span></p>"
      },
      {
        "id": 79084,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Palifermin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman undergoing chemotherapy for ovarian cancer presents to your clinic with complaints of frequent, loose stools for the past 3 days. She reports having 5-6 bowel movements per day, with no blood or mucus. Her vital signs are stable, and she is otherwise feeling well. Which medication would be the MOST appropriate initial treatment for her chemotherapy-induced diarrhea?</span></span></p>",
    "unique_key": "Q5901195",
    "question_audio": null,
    "question_video": null,
    "map_id": 19633,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Loperamide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loperamide is an opioid receptor agonist that slows down gut motility. It is the first-line treatment for most cases of chemotherapy-induced diarrhea.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Octreotide:</span></strong><span style=\"font-size:12.0pt\"> Octreotide is a somatostatin analog that can be used for refractory cases of chemotherapy-induced diarrhea, particularly if there is a secretory component. It is not the initial drug of choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ondansetron:</span></strong><span style=\"font-size:12.0pt\"> Ondansetron is a 5-HT3 receptor antagonist primarily used for nausea and vomiting. It is not effective for diarrhea.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Racicodotril: </span></strong><span style=\"font-size:12.0pt\">Racicodotril is an antisecretory anti-diarrheal agent that works by inhibiting enkephalinase, an enzyme that breaks down enkephalins. Enkephalins are naturally occurring substances that decrease intestinal secretion. While it can be effective in some cases of diarrhoea, it is not the first-line treatment for chemotherapy-induced diarrhoea. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loperamide is the first-line treatment for chemotherapy-induced diarrhoea. It acts by slowing down gut motility and reducing the frequency of bowel movements.</span></span></p>",
    "correct_choice_id": 79081,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19781,
    "choices": [
      {
        "id": 79085,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia. </span></span></span></p>"
      },
      {
        "id": 79086,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a history of febrile neutropenia from prior chemotherapy. </span></span></span></p>"
      },
      {
        "id": 79087,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment. </span></span></span></p>"
      },
      {
        "id": 79088,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You are seeing a 60-year-old woman with newly diagnosed breast cancer scheduled to start chemotherapy with a regimen known to have a high risk of causing neutropenia. In which of the following scenarios is the use of G-CSF therapy MOST strongly indicated for this patient?</span></span></span></p>",
    "unique_key": "Q9220134",
    "question_audio": null,
    "question_video": null,
    "map_id": 19634,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) She has a history of febrile neutropenia from prior chemotherapy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A history of febrile neutropenia is a strong indication for primary prophylaxis with G-CSF, even if the current chemotherapy regimen is not considered high-risk. G-CSF stimulates the production of neutrophils, reducing the risk of severe neutropenia and subsequent infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.</span></strong><span style=\"font-size:12.0pt\"> While this is a moderate risk, it&#39;s not high enough to warrant primary prophylaxis with G-CSF in the absence of other risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/&micro;L during her current treatment.</span></strong><span style=\"font-size:12.0pt\"> This scenario indicates the patient has already developed febrile neutropenia. G-CSF would be used for secondary prophylaxis in this case, not primary prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</span></strong><span style=\"font-size:12.0pt\"> Radiation therapy to the chest wall can sometimes cause a decrease in blood counts, but it&#39;s not a primary indication for G-CSF prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of febrile neutropenia is a strong indication for G-CSF prophylaxis, even if the current chemotherapy regimen is not considered high-risk. This is because patients who have experienced febrile neutropenia in the past are at a significantly higher risk of developing it again with subsequent chemotherapy. </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Use if FN risk &ge; 20%, H/o Febrile Neutropenia, Neutropenia prior to starting chemo or active infection while starting chemo. </span></span></p>",
    "correct_choice_id": 79086,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19782,
    "choices": [
      {
        "id": 79089,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To provide a site for repeated blood transfusions</span></span></span></p>"
      },
      {
        "id": 79090,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To deliver high-dose chemotherapy directly to the tumor</span></span></span></p>"
      },
      {
        "id": 79091,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To facilitate the continuous and safe administration of chemotherapy</span></span></span></p>"
      },
      {
        "id": 79092,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To monitor the progression of cancer through imaging</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the primary purpose of the instrument shown in the image?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-093031.jpg\" style=\"height:202px; width:350px\" /></span></span></span></p>",
    "unique_key": "Q8563523",
    "question_audio": null,
    "question_video": null,
    "map_id": 19635,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) To facilitate the continuous and safe administration of chemotherapy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a <strong>chemotherapy port</strong> or <strong>port-a-cath</strong>. It&#39;s a small medical device implanted under the skin, typically in the chest area. It has a catheter that leads to a large vein, allowing easy access for administering chemotherapy drugs, drawing blood samples, and giving other intravenous medications or fluids. It reduces the need for repeated needle sticks, which can be painful and damage veins over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. To provide a site for repeated blood transfusions:</span></strong><span style=\"font-size:12.0pt\"> While a port can be used for blood transfusions, its primary function is for chemotherapy administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. To deliver high-dose chemotherapy directly to the tumor:</span></strong><span style=\"font-size:12.0pt\"> Ports deliver chemotherapy systemically, not directly to the tumor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. To monitor the progression of cancer through imaging:</span></strong><span style=\"font-size:12.0pt\"> Ports are not used for imaging or monitoring cancer progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chemotherapy ports are implanted devices that provide convenient and safe access to the bloodstream for patients undergoing long-term chemotherapy or other intravenous treatments.</span></span></span></p>",
    "correct_choice_id": 79091,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InstrumentsBased"
    ]
  },
  {
    "id": 19852,
    "choices": [
      {
        "id": 79369,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rash </span></span></span></p>"
      },
      {
        "id": 79370,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">pneumonitis</span></span></span></p>"
      },
      {
        "id": 79371,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colitis </span></span></span></p>"
      },
      {
        "id": 79372,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the MOST common adverse drug reaction (ADR) associated with immune checkpoint inhibitors, as indicated in the image?</span></span></span></p>",
    "unique_key": "Q9931349",
    "question_audio": null,
    "question_video": null,
    "map_id": 19805,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Rash</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image lists rash as the most common ADR, occurring more frequently than the other listed side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pneumonitis: </span></strong><span style=\"font-size:12.0pt\">While pneumonitis (inflammation of the lungs) is a serious potential side effect of immune checkpoint inhibitors, it&#39;s not as frequent as rash<strong>.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Colitis: </span></strong><span style=\"font-size:12.0pt\">Colitis (inflammation of the colon) is another immune-related adverse event, but it&#39;s also less common than rash.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hepatitis: </span></strong><span style=\"font-size:12.0pt\">Hepatitis (inflammation of the liver) can occur with immune checkpoint inhibitors, but it&#39;s less frequent compared to rash.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key point: </span></strong><span style=\"font-size:12.0pt\">Rash is the most common adverse event associated with immune checkpoint inhibitors, although other serious immune-related adverse events can occur and require vigilant monitoring<strong>.</strong></span></span></span></p>",
    "correct_choice_id": 79369,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 19847,
    "choices": [
      {
        "id": 79349,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary function tests </span></span></span></p>"
      },
      {
        "id": 79350,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram </span></span></span></p>"
      },
      {
        "id": 79351,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal ultrasound </span></span></span></p>"
      },
      {
        "id": 79352,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver function tests</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old woman with breast cancer is scheduled to begin a chemotherapy regimen including doxorubicin. Which of the following pre-treatment evaluations is MOST essential for this patient? </span></span></p>",
    "unique_key": "Q9393193",
    "question_audio": null,
    "question_video": null,
    "map_id": 19800,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Echocardiogram</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines, like doxorubicin, have a risk of dose-dependent cardiomyopathy. An echocardiogram is crucial to assess baseline cardiac function before starting treatment, allowing for early detection of any cardiac abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: &nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pulmonary function tests (PFTs):</span></strong><span style=\"font-size:12.0pt\"> PFTs assess lung function and are not directly relevant to the primary concern of cardiotoxicity associated with doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Renal ultrasound:</span></strong><span style=\"font-size:12.0pt\"> While some chemotherapy drugs can affect kidney function, it&#39;s not the primary concern with doxorubicin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Liver function tests:</span></strong><span style=\"font-size:12.0pt\"> Liver function tests are important for evaluating the liver&#39;s ability to metabolize medications, but doxorubicin&#39;s primary toxicity is cardiac, not hepatic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Baseline cardiac evaluation with an echocardiogram is essential before starting anthracycline-based chemotherapy.</span></span></span></p>",
    "correct_choice_id": 79350,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19848,
    "choices": [
      {
        "id": 79353,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemorrhagic cystitis </span></span></span></p>"
      },
      {
        "id": 79354,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hemorrhage </span></span></span></p>"
      },
      {
        "id": 79355,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiomyopathy </span></span></span></p>"
      },
      {
        "id": 79356,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corneal opacity</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old man with a history of heavy smoking is diagnosed with squamous cell lung cancer. He is started on chemotherapy with carboplatin and paclitaxel, along with bevacizumab, a targeted therapy. During his treatment, which of the following adverse events is his oncologist MOST concerned about monitoring for, given his specific cancer type and treatment regimen?</span></span></span></p>",
    "unique_key": "Q5183462",
    "question_audio": null,
    "question_video": null,
    "map_id": 19801,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Pulmonary hemorrhage</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bevacizumab, an anti-angiogenic agent, is known to increase the risk of pulmonary hemorrhage, especially in patients with squamous cell lung cancer. This is because squamous cell carcinomas tend to be more vascular and fragile, making them prone to bleeding when angiogenesis is disrupted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemorrhagic cystitis:</span></strong><span style=\"font-size:12.0pt\"> This is a potential side effect of certain chemotherapy drugs, like cyclophosphamide, but not typically associated with bevacizumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardiomyopathy:</span></strong><span style=\"font-size:12.0pt\"> While some chemotherapy drugs can cause cardiotoxicity, it&#39;s not a major concern with bevacizumab. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Corneal opacity</span></strong><span style=\"font-size:12.0pt\">: Corneal opacity is not a recognized side effect of bevacizumab or the other drugs in this regimen. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bevacizumab, while effective in treating various cancers, carries a risk of pulmonary hemorrhage, particularly in patients with squamous cell lung cancer. Close monitoring for any signs of respiratory distress or bleeding is essential in these patients.</span></span></p>",
    "correct_choice_id": 79354,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 19849,
    "choices": [
      {
        "id": 79357,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna </span></span></span></p>"
      },
      {
        "id": 79358,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dexamethasone </span></span></span></p>"
      },
      {
        "id": 79359,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ondansetron </span></span></span></p>"
      },
      {
        "id": 79360,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allopurinol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy with cyclophosphamide. During her second cycle, she complains of burning sensation while urinating and notices blood in her urine. You suspect a complication due to chemotherapy. Which of the following medications is MOST likely to prevent this complication?</span></span></span></p>",
    "unique_key": "Q4316952",
    "question_audio": null,
    "question_video": null,
    "map_id": 19802,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Mesna</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Cyclophosphamide is metabolized to acrolein, a toxic compound that can damage the bladder lining, leading to hemorrhagic cystitis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is a uroprotectant agent that specifically binds to acrolein in the bladder, neutralizing its toxic effects and preventing hemorrhagic cystitis.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dexamethasone:</span></strong><span style=\"font-size:12.0pt\"> A corticosteroid used to manage nausea and vomiting associated with chemotherapy; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ondansetron:</span></strong><span style=\"font-size:12.0pt\"> A 5-HT3 receptor antagonist used to manage nausea and vomiting; it&#39;s not effective for preventing hemorrhagic cystitis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Allopurinol:</span></strong><span style=\"font-size:12.0pt\"> A medication used to reduce uric acid levels, often in the context of tumor lysis syndrome; it has no role in preventing hemorrhagic cystitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesna is the standard preventive agent for hemorrhagic cystitis associated with cyclophosphamide. It should be administered concurrently with cyclophosphamide to minimize bladder toxicity.</span></span></span></p>",
    "correct_choice_id": 79357,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19850,
    "choices": [
      {
        "id": 79361,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytarabine </span></span></span></p>"
      },
      {
        "id": 79362,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ifosfamide </span></span></span></p>"
      },
      {
        "id": 79363,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin </span></span></span></p>"
      },
      {
        "id": 79364,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving chemotherapy develops a &quot;glove and stocking&quot; pattern of numbness and tingling in their hands and feet. Which of the following drugs is MOST likely responsible?</span></span></span></p>",
    "unique_key": "Q7378733",
    "question_audio": null,
    "question_video": null,
    "map_id": 19803,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cisplatin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image explicitly states that platinum-based drugs like cisplatin are associated with glove and stocking neuropathy (a type of peripheral neuropathy affecting the hands and feet) and ototoxicity (hearing loss).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cytarabine:</span></strong><span style=\"font-size:12.0pt\"> Cytarabine is primarily associated with cerebellar toxicity and myelosuppression. While it can rarely cause peripheral neuropathy, it is not typically characterized by a glove and stocking distribution.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ifosfamide:</span></strong><span style=\"font-size:12.0pt\"> Ifosfamide can cause hemorrhagic cystitis and neurotoxicity, but the characteristic glove and stocking neuropathy is less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gemcitabine:</span></strong><span style=\"font-size:12.0pt\"> Gemcitabine is associated with myelosuppression, flu-like symptoms, and rash. Peripheral neuropathy is not a typical side effect of this drug.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum-based chemotherapy agents carry the risk of peripheral neuropathy and ototoxicity.</span></span></span></p>",
    "correct_choice_id": 79363,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19851,
    "choices": [
      {
        "id": 79365,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hemorrhage </span></span></span></p>"
      },
      {
        "id": 79366,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colitis </span></span></span></p>"
      },
      {
        "id": 79367,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pneumonitis </span></span></span></p>"
      },
      {
        "id": 79368,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving pembrolizumab develops new-onset cough and shortness of breath. Chest X-ray shows interstitial infiltrates. Which of the following adverse drug reactions (ADRs) is MOST likely?</span></span></span></p>",
    "unique_key": "Q8658265",
    "question_audio": null,
    "question_video": null,
    "map_id": 19804,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pneumonitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image lists pneumonitis as a potential ADR of PD-1 inhibitors like pembrolizumab. The patient&#39;s symptoms and imaging findings are consistent with this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pulmonary hemorrhage: </span></strong><span style=\"font-size:12.0pt\">While possible, pulmonary hemorrhage is less common than pneumonitis as an irAE of pembrolizumab. It would typically present with more dramatic symptoms like coughing up blood (hemoptysis).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colitis:</span></strong><span style=\"font-size:12.0pt\"> Colitis, or inflammation of the colon, can be an immune-related adverse event of checkpoint inhibitors. However, its primary symptoms would be diarrhea, abdominal pain, and possibly blood in the stool, not respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hepatitis:</span></strong><span style=\"font-size:12.0pt\"> Hepatitis, or inflammation of the liver, can also be an immune-related adverse event. Its typical presentation would involve jaundice, elevated liver enzymes, and possibly right upper quadrant pain, rather than respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune checkpoint inhibitors can cause immune-related adverse events, including pneumonitis, which requires prompt recognition and management.</span></span></span></p>",
    "correct_choice_id": 79367,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53420,
    "choices": [
      {
        "id": 213161,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor lysis syndrome </span></span></span></p>"
      },
      {
        "id": 213162,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine release syndrome (CRS) </span></span></span></p>"
      },
      {
        "id": 213163,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Graft-versus-host disease (GVHD) </span></span></span></p>"
      },
      {
        "id": 213164,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient receiving CAR T-cell therapy develops fever, hypotension, and tachycardia two days after infusion. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
    "unique_key": "Q5227100",
    "question_audio": null,
    "question_video": null,
    "map_id": 25224,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Cytokine release syndrome (CRS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The triad of fever, hypotension, and tachycardia shortly after CAR T-cell therapy is highly suggestive of CRS. This is due to the massive release of cytokines from activated T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tumor lysis syndrome:</span></strong><span style=\"font-size:12.0pt\"> While it can cause fever and electrolyte abnormalities, it&#39;s less likely to cause hypotension and tachycardia shortly after T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. GVHD:</span></strong><span style=\"font-size:12.0pt\"> This occurs in allogeneic stem cell transplantation, not CAR T-cell therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sepsis:</span></strong><span style=\"font-size:12.0pt\"> Though sepsis can present similarly, the timing and context point more towards CRS in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CRS is a serious complication of CAR T-cell therapy characterized by a systemic inflammatory response due to cytokine release.</span></span></p>",
    "correct_choice_id": 213162,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53421,
    "choices": [
      {
        "id": 213165,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache </span></span></span></p>"
      },
      {
        "id": 213166,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aphasia </span></span></span></p>"
      },
      {
        "id": 213167,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Delirium </span></span></span></p>"
      },
      {
        "id": 213168,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Optic neuritis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient receiving CAR T-cell therapy for refractory large B-cell lymphoma develops confusion, word-finding difficulty, and a severe headache three days after infusion. Which of the following neurological manifestations is LEAST likely to be associated with this patient&#39;s suspected diagnosis of Immune effector cell-associated neurotoxicity syndrome (ICANS)?</span></span></p>",
    "unique_key": "Q5315095",
    "question_audio": null,
    "question_video": null,
    "map_id": 25225,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Optic neuritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option E.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation is consistent with ICANS, a potential complication of CAR T-cell therapy characterized by a range of neurological symptoms. The most common manifestations include headache, encephalopathy (confusion, delirium), and aphasia (language impairment). Seizures can also occur, though less frequently.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Optic neuritis, or inflammation of the optic nerve, is not a typical feature of ICANS. It&#39;s more commonly associated with demyelinating diseases like multiple sclerosis. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Headache:</span></strong><span style=\"font-size:12.0pt\"> Headache is a very common symptom of ICANS, often presenting early in the course of the syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aphasia:</span></strong><span style=\"font-size:12.0pt\"> Aphasia, or difficulty with language, is another frequent manifestation of ICANS, reflecting the impact of cerebral edema on language centers in the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Delirium:</span></strong><span style=\"font-size:12.0pt\"> Delirium, or acute confusional state, is a hallmark of ICANS and can range from mild confusion to severe agitation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ICANS is a serious complication of CAR T-cell therapy that can present with a variety of neurological symptoms. Recognizing these symptoms early is crucial for prompt management and improved patient outcomes. &nbsp;</span></span></span></p>",
    "correct_choice_id": 213168,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19789,
    "choices": [
      {
        "id": 79117,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of hypotension</span></span></span></p>"
      },
      {
        "id": 79118,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of chronic obstructive pulmonary disease (COPD)</span></span></span></p>"
      },
      {
        "id": 79119,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No dehydration requiring intravenous fluids</span></span></span></p>"
      },
      {
        "id": 79120,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fever of unknown origin without localizing signs or symptoms</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy. Three days after her most recent cycle, she presents to the emergency department with a fever of 38.7&deg;C (101.7&deg;F) and generalized weakness. Her past medical history is significant for hypertension, well-controlled with medication. On examination, she appears fatigued but is otherwise stable. Laboratory tests reveal an absolute neutrophil count (ANC) of 500 cells/&micro;L, confirming neutropenia. Given her presentation with fever and neutropenia, the emergency department team considers her risk of complications using the Multinational Association for Supportive Care in Cancer (MASCC) risk index to guide her management. Based on the MASCC risk index for febrile neutropenia, which of the following factors would categorize this patient as low risk?</span></span></span></p>",
    "unique_key": "Q2862613",
    "question_audio": null,
    "question_video": null,
    "map_id": 19700,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) No dehydration requiring intravenous fluids</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Multinational Association for Supportive Care in Cancer (MASCC) risk index score is a tool used to identify febrile neutropenia patients at low risk of complications, who may be suitable for outpatient management. Factors that contribute to a higher score (indicating lower risk) include stable vital signs, no dehydration, outpatient status at the onset of fever, absence of chronic obstructive pulmonary disease (COPD), solid tumor or hematologic malignancy with no previous fungal infection, and no recent hospitalization. Specifically, &quot;No dehydration requiring intravenous fluids&quot; is a factor that would categorize a patient as low risk according to the MASCC risk index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Presence of hypotension would categorize a patient as high risk, as it indicates hemodynamic instability, which is a serious complication of febrile neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B.</strong> A history of chronic obstructive pulmonary disease (COPD) would also place a patient in a higher risk category, as underlying lung disease can complicate the management of febrile neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> Fever of unknown origin without localizing signs or symptoms could apply to many cases of febrile neutropenia and, by itself, does not necessarily categorize a patient as low risk according to the MASCC risk index. Other factors, such as the patient&#39;s overall clinical stability, presence of comorbidities, and intensity of the chemotherapy regimen, also need to be considered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The MASCC risk index is used to identify febrile neutropenia patients who are at low risk for complications and might be suitable for outpatient management. Factors that indicate lower risk include stable vital signs, no significant comorbidities like COPD, and no dehydration requiring intravenous fluids.</span></span></span></p>",
    "correct_choice_id": 79119,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19790,
    "choices": [
      {
        "id": 79121,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Febrile neutropenia </span></span></span></p>"
      },
      {
        "id": 79122,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor-related fever </span></span></span></p>"
      },
      {
        "id": 79123,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Central line-associated bloodstream infection (CLABSI) </span></span></span></p>"
      },
      {
        "id": 79124,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pneumonia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 67-year-old man with metastatic lung cancer on chemotherapy develops fever, chills, and tenderness with purulent discharge at his PICC line site. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q4736378",
    "question_audio": null,
    "question_video": null,
    "map_id": 19701,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CLABSI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of fever, chills, and local signs of infection at the PICC line site strongly suggests a central line-associated bloodstream infection (CLABSI).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Febrile neutropenia:</span></strong><span style=\"font-size:12.0pt\"> While this patient likely has neutropenia due to chemotherapy, the local signs of infection at the PICC line point more specifically towards CLABSI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tumor-related fever:</span></strong><span style=\"font-size:12.0pt\"> This is less likely in the presence of clear signs of infection at the catheter site.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pneumonia:</span></strong><span style=\"font-size:12.0pt\"> While possible, the absence of respiratory symptoms and the presence of local signs of infection at the catheter site make CLABSI more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong><span style=\"font-size:12.0pt\"> CLABSI is a serious complication of central venous catheters. Prompt recognition and treatment are essential to prevent morbidity and mortality.</span></span></span></p>",
    "correct_choice_id": 79123,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 19791,
    "choices": [
      {
        "id": 79125,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Muscle strain </span></span></span></p>"
      },
      {
        "id": 79126,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osteoarthritis </span></span></span></p>"
      },
      {
        "id": 79127,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metastatic spinal cord compression </span></span></span></p>"
      },
      {
        "id": 79128,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lumbar disc herniation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with a known history of prostate cancer presents to your clinic complaining of severe back pain that has been progressively worsening over the past few weeks. The pain is particularly intense at night, making it difficult for him to sleep, and it does not improve with rest. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
    "unique_key": "Q6344135",
    "question_audio": null,
    "question_video": null,
    "map_id": 19702,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Metastatic spinal cord compression (MSCC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s age, history of prostate cancer, and the characteristic nature of the back pain (worse at night, unrelieved by rest) strongly suggest metastatic spinal cord compression (MSCC). Prostate cancer has a propensity to metastasize to the bone, and spinal metastases can compress the spinal cord or nerve roots, leading to pain and neurological symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Muscle strain:</span></strong><span style=\"font-size:12.0pt\"> Muscle strain typically presents with localized pain that worsens with movement and improves with rest. It&#39;s less likely to be severe at night or associated with a history of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Osteoarthritis:</span></strong><span style=\"font-size:12.0pt\"> Osteoarthritis is a degenerative joint disease that can cause back pain, but it&#39;s usually associated with stiffness and pain that worsens with activity and improves with rest. The patient&#39;s age and cancer history make MSCC more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lumbar disc herniation:</span></strong><span style=\"font-size:12.0pt\"> While a herniated disc can cause severe back pain, it&#39;s often associated with radicular pain (shooting pain down the leg) and neurological deficits. The patient&#39;s presentation and cancer history are more consistent with MSCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Back pain in a patient with a history of cancer, especially if it&#39;s worse at night or unrelieved by rest, warrants prompt evaluation for possible MSCC. Early diagnosis and treatment are critical to prevent neurological complications.</span></span></span></p>",
    "correct_choice_id": 79127,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19792,
    "choices": [
      {
        "id": 79129,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plain X-ray of the spine </span></span></span></p>"
      },
      {
        "id": 79130,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent intravenous dexamethasone </span></span></span></p>"
      },
      {
        "id": 79131,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Whole spine MRI </span></span></span></p>"
      },
      {
        "id": 79132,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical decompression</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old man with a history of lung cancer presents with severe back pain and weakness in his legs. Neurological examination reveals decreased lower extremity strength and hyperreflexia. What is the MOST appropriate initial management step?</span></span></span></p>",
    "unique_key": "Q3105699",
    "question_audio": null,
    "question_video": null,
    "map_id": 19703,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Urgent intravenous dexamethasone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has back pain and abnormal neurological findings, suggesting MSCC. In this scenario, urgent administration of high-dose dexamethasone is crucial to reduce spinal cord edema and prevent further neurological deterioration. MRI is also indicated, but dexamethasone should be given first to avoid delays in treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Plain X-ray of the spine:</span></strong><span style=\"font-size:12.0pt\"> While plain X-rays can sometimes show bony destruction suggestive of metastases, they are not sensitive enough to visualize the spinal cord or nerve roots, which are crucial for assessing the extent of compression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Whole spine MRI:</span></strong><span style=\"font-size:12.0pt\"> MRI is the gold standard for diagnosing MSCC, but it should not delay the administration of dexamethasone, which is crucial to prevent further neurological deterioration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Surgical decompression:</span></strong><span style=\"font-size:12.0pt\"> While surgery may be indicated in some cases of MSCC, it is not the initial management step. High-dose dexamethasone should be given first to reduce spinal cord edema and stabilize the patient before considering surgical intervention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong><span style=\"font-size:12.0pt\"> In patients with suspected MSCC and neurological deficits, urgent high-dose dexamethasone is the priority to reduce spinal cord edema and prevent further neurological damage.</span></span></span></p>",
    "correct_choice_id": 79130,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19788,
    "choices": [
      {
        "id": 79113,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Appendicitis </span></span></span></p>"
      },
      {
        "id": 79114,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diverticulitis </span></span></span></p>"
      },
      {
        "id": 79115,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutropenic enterocolitis (typhlitis)</span></span></span></p>"
      },
      {
        "id": 79116,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic colitis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with acute myeloid leukemia (AML) undergoing chemotherapy presents to the emergency department with a 2-day history of fever, right lower quadrant abdominal pain, and watery diarrhea. His absolute neutrophil count (ANC) is 300/&micro;L. Abdominal CT scan reveals cecal wall thickening. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
    "unique_key": "Q5572605",
    "question_audio": null,
    "question_video": null,
    "map_id": 19699,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Neutropenic enterocolitis (typhlitis)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of neutropenia, fever, right lower quadrant abdominal pain, diarrhea, and cecal wall thickening on imaging is highly suggestive of typhilitis, (aka. neutropenic enterocolitis). This is a serious complication of neutropenia, where the bowel wall becomes inflamed and can potentially perforate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Appendicitis:</span></strong><span style=\"font-size:12.0pt\"> While appendicitis can present with similar symptoms, it is less likely in this patient with neutropenia and cecal wall thickening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diverticulitis:</span></strong><span style=\"font-size:12.0pt\"> Diverticulitis typically affects the left colon and is less common in younger individuals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ischemic colitis:</span></strong><span style=\"font-size:12.0pt\"> Ischemic colitis is more common in older individuals with cardiovascular risk factors. It usually presents with bloody diarrhea and is less likely in the context of neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutropenic enterocolitis is a life-threatening complication that can occur in patients with severe neutropenia. Early recognition and prompt treatment are essential.</span></span></span></p>",
    "correct_choice_id": 79115,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53422,
    "choices": [
      {
        "id": 213169,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperkalemia </span></span></span></p>"
      },
      {
        "id": 213170,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperuricemia </span></span></span></p>"
      },
      {
        "id": 213171,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperphosphatemia </span></span></span></p>"
      },
      {
        "id": 213172,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hypercalcemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old male with Burkitt&#39;s lymphoma is undergoing chemotherapy. Three days after starting treatment, he presents with fatigue, muscle cramps, and nausea. Lab results show:</span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium: 6.2 mEq/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uric acid: 9.0 mg/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phosphate: 5.5 mg/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium: 9.5 mg/dL</span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following electrolyte abnormalities found in this patient is NOT a criterion for the diagnosis of Laboratory Tumor Lysis Syndrome (LTLS)?</span></span></span></p>",
    "unique_key": "Q9102153",
    "question_audio": null,
    "question_video": null,
    "map_id": 25226,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypercalcemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laboratory Tumor Lysis Syndrome (LTLS) is characterized by a specific constellation of electrolyte abnormalities that result from the rapid breakdown of tumor cells. The criteria for LTLS, as reflected in the patient&#39;s case, include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperkalemia (K+ &ge; 6 mEq/L)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperuricemia (uric acid &ge; 8 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphosphatemia (PO4 &ge; 4.5 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypocalcemia (Ca2+ &le; 7 mg/dL) OR a 25% decrease from baseline</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient in this vignette demonstrates hyperkalemia, hyperuricemia, and hyperphosphatemia, fulfilling the criteria for LTLS. His calcium level is within the normal range, so hypercalcemia is NOT a part of the diagnostic criteria for LTLS in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyperkalemia:</span></strong><span style=\"font-size:12.0pt\"> This is a defining feature of LTLS, as the breakdown of tumor cells releases intracellular potassium into the bloodstream.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hyperuricemia:</span></strong><span style=\"font-size:12.0pt\"> Tumor cell lysis releases nucleic acids, which are metabolized to uric acid, leading to hyperuricemia in LTLS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperphosphatemia:</span></strong><span style=\"font-size:12.0pt\"> The breakdown of tumor cells also releases intracellular phosphate, contributing to hyperphosphatemia in LTLS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LTLS is a potentially life-threatening oncologic emergency characterized by specific electrolyte abnormalities: hyperkalemia, hyperuricemia, hyperphosphatemia, and sometimes hypocalcemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">CTLS (&ge; 1) </span></em></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">(Clinical criteria for TLS)<em>: </em></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">AKI, arrhythmias, Sz, symptomatic hypocalcemia</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prompt recognition and management of LTLS are critical to prevent complications like acute kidney injury, cardiac arrhythmias, and seizures.</span></span></li>\r\n</ul>",
    "correct_choice_id": 213172,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 53423,
    "choices": [
      {
        "id": 213173,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low risk </span></span></span></p>"
      },
      {
        "id": 213174,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intermediate risk </span></span></span></p>"
      },
      {
        "id": 213175,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High risk </span></span></span></p>"
      },
      {
        "id": 213176,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cannot be determined</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old male presents to your clinic with a rapidly growing neck mass that has caused him discomfort over the past few weeks. He also reports feeling fatigued and has lost some weight recently. On examination, you palpate a large, firm, non-tender lymph node in his left cervical region. A biopsy of the lymph node reveals Burkitt lymphoma. Further workup shows his lactate dehydrogenase (LDH) level is 3 times the upper limit of normal. Considering his diagnosis and laboratory findings, which Tumor Lysis Syndrome (TLS) risk category does this patient fall into?</span></span></span></p>",
    "unique_key": "Q2049561",
    "question_audio": null,
    "question_video": null,
    "map_id": 25227,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) High risk</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkitt lymphoma is a highly aggressive B-cell lymphoma with a rapid growth rate. The presence of a rapidly enlarging lymph node and a significantly elevated LDH level (3 times the upper limit of normal) places this patient in the high-risk category for TLS. High-risk patients are more likely to experience severe complications from TLS, such as acute kidney injury, cardiac arrhythmias, and even death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low risk:</span></strong><span style=\"font-size:12.0pt\"> Low-risk malignancies generally have a slower growth rate and lower tumor burden, making TLS less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intermediate risk:</span></strong><span style=\"font-size:12.0pt\"> Intermediate-risk malignancies have a moderate risk of TLS, often based on specific tumor characteristics or laboratory findings. In this case, the patient&#39;s elevated LDH level and rapid tumor growth place him in the high-risk category.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cannot be determined:</span></strong><span style=\"font-size:12.0pt\"> The information provided is sufficient to determine the patient&#39;s TLS risk category.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkitt lymphoma is a high-risk malignancy for TLS, especially when associated with elevated LDH levels.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with high-risk TLS require aggressive preventive measures, including intensive hydration and uric acid-lowering therapy, to minimize the risk of complications.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 213175,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 53424,
    "choices": [
      {
        "id": 213177,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute heart failure</span></span></span></p>"
      },
      {
        "id": 213178,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Superior vena cava (SVC) syndrome</span></span></span></p>"
      },
      {
        "id": 213179,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism</span></span></span></p>"
      },
      {
        "id": 213180,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 64-year-old man presents to the emergency department with progressive swelling of his face and neck over the past two weeks. He also reports increasing breathlessness, especially when lying flat, and a feeling of fullness in his head. His medical history is significant for a 40-pack-year smoking history, although he quit smoking 10 years ago. On examination, his face appears plethoric, and there is evident distension of the veins in his neck and chest. Additionally, he exhibits mild cyanosis of the upper body and swelling of the arms. A chest X-ray reveals a mass in the right upper mediastinum. Based on the patient&#39;s presentation and history, which of the following is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q2608490",
    "question_audio": null,
    "question_video": null,
    "map_id": 25228,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Superior vena cava (SVC) syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with progressive swelling of the face and neck, breathlessness, plethoric facial appearance, distended neck and chest veins, and cyanosis of the upper body, along with a mediastinal mass on chest X-ray, is highly suggestive of Superior Vena Cava (SVC) syndrome. SVC syndrome occurs when there is obstruction of the SVC, leading to impaired venous return from the head, neck, and upper extremities to the heart. This can cause the symptoms noted above. The presence of a mediastinal mass in a patient with a significant smoking history raises concern for a malignancy such as lung cancer, which is a common cause of SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A.</strong> Acute heart failure can cause facial and upper extremity swelling due to fluid overload, but it is less likely to present with the pronounced venous distension and plethoric face that are characteristic of SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Pulmonary embolism typically presents with acute shortness of breath, chest pain, and possibly hemoptysis, but not with the venous distension and facial swelling seen in SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> Constrictive pericarditis can cause symptoms of venous congestion due to impaired cardiac filling, but it usually presents with generalized edema, ascites, and elevated jugular venous pressure, rather than the localized swelling of the face and neck and the specific venous distension seen in SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Superior vena cava (SVC) syndrome is characterized by obstruction of the SVC, leading to impaired venous return from the head, neck, and upper extremities. Symptoms include facial and upper extremity swelling, plethoric facial appearance, distended neck and chest veins, and cyanosis of the upper body. A mediastinal mass, especially in patients with a significant smoking history, raises suspicion for an underlying malignancy such as lung cancer as a cause of SVC syndrome.</span></span></span></p>",
    "correct_choice_id": 213178,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53425,
    "choices": [
      {
        "id": 213181,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Small cell lung cancer (SCLC) </span></span></span></p>"
      },
      {
        "id": 213182,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-small cell lung cancer (NSCLC) </span></span></span></p>"
      },
      {
        "id": 213183,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphoma </span></span></span></p>"
      },
      {
        "id": 213184,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metastatic breast cancer</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with a history of smoking presents with facial swelling, distended neck veins, and shortness of breath. Chest X-ray shows a large right lung mass. Which of the following malignancies is the MOST likely cause of this patient&#39;s diagnosis?</span></span></span></p>",
    "unique_key": "Q8592019",
    "question_audio": null,
    "question_video": null,
    "map_id": 25229,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>B) Non-small cell lung cancer (NSCLC)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of the patient&#39;s smoking history, lung mass on chest X-ray, and symptoms of facial swelling, distended neck veins, and shortness of breath strongly suggests superior vena cava (SVC) syndrome.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common cause of SVC syndrome is lung cancer, and among lung cancers, non-small cell lung cancer (NSCLC) is more frequently associated with SVC syndrome than small cell lung cancer (SCLC).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Small cell lung cancer (SCLC):</span></strong><span style=\"font-size:12.0pt\"> While SCLC can also cause SVC syndrome, it is less common than NSCLC as a cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lymphoma:</span></strong><span style=\"font-size:12.0pt\"> Lymphoma can sometimes cause SVC syndrome, but it is less frequent than lung cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metastatic breast cancer:</span></strong><span style=\"font-size:12.0pt\"> While metastatic breast cancer can spread to the mediastinum and cause SVC syndrome, it&#39;s less common than primary lung cancer as a cause in this clinical scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SVC syndrome is a medical emergency caused by obstruction of the superior vena cava, leading to impaired venous return from the head, neck, and upper extremities.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer, particularly NSCLC, is the most common cause of SVC syndrome.</span></span></li>\r\n</ul>",
    "correct_choice_id": 213182,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 53426,
    "choices": [
      {
        "id": 213185,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 positive, CK20 negative, TTF-1 negative </span></span></span></p>"
      },
      {
        "id": 213186,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 negative, CK20 positive, CDX2 positive </span></span></span></p>"
      },
      {
        "id": 213187,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 positive, TTF-1 positive, Napsin A positive </span></span></span></p>"
      },
      {
        "id": 213188,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ER positive, PR positive, HER2 negative</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman presents with weight loss, fatigue, and a left supraclavicular lymph node. Biopsy reveals metastatic adenocarcinoma. Extensive imaging fails to identify a primary tumor site. Immunohistochemistry (IHC) is ordered to help determine the origin of the malignancy. Which IHC staining pattern would MOST STRONGLY suggest a gastrointestinal (GI) primary?</span></span></span></p>",
    "unique_key": "Q5134057",
    "question_audio": null,
    "question_video": null,
    "map_id": 25230,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CK7 negative, CK20 positive, CDX2 positive</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This IHC pattern is highly suggestive of a GI origin, particularly colorectal adenocarcinoma. CK20 is a cytokeratin predominantly expressed in epithelial cells of the GI tract, and CDX2 is a transcription factor involved in intestinal development and differentiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CK7 positive, CK20 negative, TTF-1 negative:</span></strong><span style=\"font-size:12.0pt\"> This pattern is more suggestive of lung or breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CK7 positive, TTF-1 positive, Napsin A positive:</span></strong><span style=\"font-size:12.0pt\"> This pattern is strongly indicative of lung adenocarcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ER positive, PR positive, HER2 negative:</span></strong><span style=\"font-size:12.0pt\"> This pattern is typically seen in breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> IHC staining can aid in identifying the primary site in cancers of unknown primary (CUP), guiding further management and treatment decisions.</span></span></p>",
    "correct_choice_id": 213186,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53427,
    "choices": [
      {
        "id": 213189,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TTF-1 </span></span></span></p>"
      },
      {
        "id": 213190,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CDX2 </span></span></span></p>"
      },
      {
        "id": 213191,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S-100 </span></span></span></p>"
      },
      {
        "id": 213192,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ER</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old woman Non-smoker presents to your clinic with a persistent cough and recent episodes of coughing up blood (hemoptysis). Chest X-ray reveals a suspicious lung mass. A biopsy is performed, and you suspect lung adenocarcinoma based on the initial histopathology. Which of the following immunohistochemical (IHC) markers would be MOST helpful in confirming this diagnosis?</span></span></span></p>",
    "unique_key": "Q9097560",
    "question_audio": null,
    "question_video": null,
    "map_id": 25231,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) TTF-1</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Even though the patient is a non-smoker, TTF-1 (Thyroid Transcription Factor-1) remains the most helpful IHC marker for confirming the diagnosis of lung adenocarcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">TTF-1</span></strong><span style=\"font-size:12.0pt\"> is a nuclear transcription factor highly expressed in lung and thyroid tissues. It is a sensitive and specific marker for lung adenocarcinoma, aiding in its distinction from other lung cancers or metastases, regardless of smoking history.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDX2:</span></strong><span style=\"font-size:12.0pt\"> CDX2 is a marker of intestinal differentiation and is typically used to identify cancers of gastrointestinal origin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. S-100:</span></strong><span style=\"font-size:12.0pt\"> S-100 is a marker for melanomas and neural crest-derived tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ER (Estrogen Receptor):</span></strong><span style=\"font-size:12.0pt\"> ER is a hormone receptor that is primarily used in the context of breast cancer. While some lung adenocarcinomas can be ER-positive, it&#39;s not a specific or sensitive marker for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While smoking is a major risk factor for lung cancer, adenocarcinoma can occur in non-smokers as well.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TTF-1 remains a valuable IHC marker for confirming the diagnosis of lung adenocarcinoma, regardless of smoking history.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IHC staining can aid in differentiating between various types of lung cancer and metastases, which is critical for guiding treatment decisions.</span></span></li>\r\n</ul>",
    "correct_choice_id": 213189,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53428,
    "choices": [
      {
        "id": 213193,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum and 5-FU</span></span></span></p>"
      },
      {
        "id": 213194,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pembrolizumab</span></span></span></p>"
      },
      {
        "id": 213195,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum and etoposide</span></span></span></p>"
      },
      {
        "id": 213196,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Palliative care with a focus on symptom management</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman presents with metastatic adenocarcinoma of unknown primary origin. Imaging and biopsy have failed to identify the primary site. What is the most appropriate initial approach to the treatment of her cancer?</span></span></span></p>",
    "unique_key": "Q4737180",
    "question_audio": null,
    "question_video": null,
    "map_id": 25232,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Platinum and 5-FU</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cases of metastatic adenocarcinoma of unknown primary origin (CUP - Cancer of Unknown Primary), treatment often involves empiric chemotherapy regimens aimed at controlling the disease and alleviating symptoms, given the absence of a known primary site to guide more targeted therapy. A combination of platinum-based chemotherapy (such as cisplatin or carboplatin) and 5-fluorouracil (5-FU) is a common choice for empiric treatment in patients with CUP, particularly for adenocarcinomas. This regimen has demonstrated efficacy in various adenocarcinomas and is often used when the primary site cannot be identified.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B.</strong> Pembrolizumab, a PD-1 inhibitor, has shown promise in certain types of cancers, particularly those with high levels of microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). While it represents an exciting advancement in cancer therapy, pembrolizumab would typically be considered in the context of CUP after specific testing for MSI-H or dMMR, or PD-L1 expression, rather than as an initial empiric treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Platinum and etoposide are often used together in the treatment of small cell lung cancer and other neuroendocrine tumors, but without evidence of a neuroendocrine component, this regimen would not be the first choice for an adenocarcinoma of unknown primary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> While palliative care and symptom management are crucial aspects of cancer treatment, especially in advanced disease, they are not typically the initial approach for a patient who may still benefit from systemic therapy aimed at controlling the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with metastatic adenocarcinoma of unknown primary origin, an empiric chemotherapy regimen that includes a platinum agent (cisplatin or carboplatin) and 5-fluorouracil (5-FU) is often used as the initial treatment approach, aiming to control the disease and alleviate symptoms.</span></span></span></p>",
    "correct_choice_id": 213193,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53429,
    "choices": [
      {
        "id": 213197,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Single, small axillary node involvement</span></span></span></p>"
      },
      {
        "id": 213198,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenocarcinoma</span></span></span></p>"
      },
      {
        "id": 213199,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated serum tumor markers with a single site of metastasis</span></span></span></p>"
      },
      {
        "id": 213200,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of liver metastasis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 54-year-old woman presents to the oncology clinic with a 3-month history of unexplained weight loss, night sweats, and a palpable mass in her left axilla. A comprehensive workup, including mammography, abdominal CT, PET scan, and colonoscopy, fails to identify a primary tumor site. Biopsy of the axillary mass reveals adenocarcinoma. Which of the following features is considered unfavorable in the prognosis of cancer of unknown primary?</span></span></span></p>",
    "unique_key": "Q7100274",
    "question_audio": null,
    "question_video": null,
    "map_id": 25233,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Adenocarcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cancers of unknown primary (CUP), certain histological subtypes and clinical features are associated with the prognosis. Adenocarcinoma, when presenting as CUP, is generally considered to have an unfavorable prognosis compared to certain other subtypes, such as squamous cell carcinoma confined to lymph nodes (especially cervical) or certain well-defined subsets of CUP with favorable prognoses (like women with axillary nodal metastases resembling breast cancer or men with blastic bone metastases resembling prostate cancer). Adenocarcinoma as CUP often indicates widespread disease and may respond less favorably to empirical chemotherapy regimens compared to more well-defined, treatable primary cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A.</strong> Single, small axillary node involvement, especially in women, can sometimes be managed similarly to breast cancer, with a relatively better prognosis than other forms of CUP. This is often considered a subset with a favorable prognosis if it resembles breast cancer histologically and clinically.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Elevated serum tumor markers with a single site of metastasis could influence prognosis, depending on the specific context and markers involved. However, this alone does not universally signify an unfavorable prognosis without considering other clinical and histopathological features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> The absence of liver metastasis is generally a favorable prognostic sign in CUP. Liver involvement is often associated with a more aggressive disease course and a poorer prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the context of cancer of unknown primary (CUP), adenocarcinoma histology is generally considered to have an unfavorable prognosis compared to other subsets of CUP that may have more defined treatment approaches and better outcomes, such as squamous cell carcinoma confined to lymph nodes or women with axillary nodal metastases resembling breast cancer</span></span></span></p>",
    "correct_choice_id": 213198,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19833,
    "choices": [
      {
        "id": 79293,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased bone resorption mediated by parathyroid hormone-related protein (PTHrP) </span></span></span></p>"
      },
      {
        "id": 79294,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ectopic production of 1,25-dihydroxyvitamin D (1,25 DHCC) </span></span></span></p>"
      },
      {
        "id": 79295,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osteolytic bone metastases </span></span></span></p>"
      },
      {
        "id": 79296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with a history of squamous cell lung cancer presents with fatigue, constipation, and confusion. Her laboratory tests reveal a serum calcium level of 13 mg/dL. Which of the following is the MOST Common mechanism underlying her hypercalcemia?</span></span></p>",
    "unique_key": "Q8353660",
    "question_audio": null,
    "question_video": null,
    "map_id": 19744,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Increased bone resorption mediated by parathyroid hormone-related protein (PTHrP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Squamous cell lung cancer&nbsp;</span></strong><span style=\"font-size:12.0pt\">is well-known for its ability to produce <strong>PTHrP</strong>. This protein mimics the action of parathyroid hormone, leading to increased bone resorption and calcium release into the bloodstream.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <strong>osteolytic bone metastases</strong> and <strong>ectopic production of 1,25 DHCC</strong> can also contribute to hypercalcemia in some cases of squamous cell lung cancer, they are <strong>less common</strong> than PTHrP-mediated bone resorption.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ectopic production of 1,25-dihydroxyvitamin D (1,25 DHCC):</span></strong><span style=\"font-size:12.0pt\"> This mechanism is more commonly seen in lymphomas and some other solid tumors, not as frequently in squamous cell lung cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Osteolytic bone metastases:</span></strong><span style=\"font-size:12.0pt\"> While possible, it is less frequent than PTHrP production as the cause of hypercalcemia in squamous cell lung cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. All of the above:</span></strong><span style=\"font-size:12.0pt\"> Although all three mechanisms can contribute to hypercalcemia in SCC, PTHrP-mediated bone resorption is the most prevalent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PTHrP-mediated bone resorption is the predominant mechanism of hypercalcemia in squamous cell lung cancer and certain other malignancies.</span></span></span></p>",
    "correct_choice_id": 79293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19834,
    "choices": [
      {
        "id": 79297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral calcium supplements</span></span></span></p>"
      },
      {
        "id": 79298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous bisphosphonates</span></span></span></p>"
      },
      {
        "id": 79299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thiazide diuretics</span></span></span></p>"
      },
      {
        "id": 79300,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcitonin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with advanced lung cancer presents with confusion, polyuria, and dehydration. Laboratory tests reveal a serum calcium level of 13.5 mg/dL. The most likely diagnosis is humoral hypercalcemia of malignancy. Which of the following is the most appropriate initial treatment?</span></span></p>",
    "unique_key": "Q3789940",
    "question_audio": null,
    "question_video": null,
    "map_id": 19745,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Intravenous bisphosphonates</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation and high serum calcium level suggest a diagnosis of hypercalcemia of malignancy. This condition is most commonly associated with certain types of cancer, including lung cancer, and is often mediated by the secretion of parathyroid hormone-related peptide (PTHrP) by tumor cells, leading to increased bone resorption and calcium release into the bloodstream. The initial treatment of choice for hypercalcemia of malignancy is aggressive hydration with intravenous fluids to restore intravascular volume and promote renal excretion of calcium, followed by the administration of intravenous bisphosphonates. Bisphosphonates such as pamidronate or zoledronic acid inhibit bone resorption and can help lower serum calcium levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Oral calcium supplements</strong>: Would be contraindicated as the patient already has hypercalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Thiazide diuretics</strong>: Would be inappropriate as they tend to increase serum calcium levels by promoting renal reabsorption of calcium.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Calcitonin</strong>: Can be used as an additional therapy for hypercalcemia, but it has a much weaker effect compared to bisphosphonates and is often used in conjunction with bisphosphonates for a quicker response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The appropriate initial management of hypercalcemia of malignancy involves the use of intravenous bisphosphonates, after initial hydration with intravenous fluids. Bisphosphonates inhibit osteoclastic bone resorption and reduce serum calcium levels</span></span></p>",
    "correct_choice_id": 79298,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19836,
    "choices": [
      {
        "id": 79305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary hyperparathyroidism </span></span></span></p>"
      },
      {
        "id": 79306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcoidosis </span></span></span></p>"
      },
      {
        "id": 79307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma </span></span></span></p>"
      },
      {
        "id": 79308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Humoral hypercalcemia of malignancy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman complains of fatigue, constipation, increased thirst and urination, decreased appetite, and unintentional weight loss. Labs reveal hypercalcemia, normal creatinine, suppressed PTH, and elevated PTHrP. A chest X-ray identifies a right upper lung mass. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q3882817",
    "question_audio": null,
    "question_video": null,
    "map_id": 19789,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Humoral hypercalcemia of malignancy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of hypercalcemia with suppressed PTH and elevated PTHrP, along with a lung mass, points strongly towards humoral hypercalcemia of malignancy (HHM). This occurs when a tumor secretes PTHrP, mimicking the action of PTH and causing increased bone resorption and calcium release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Primary hyperparathyroidism:</span></strong><span style=\"font-size:12.0pt\"> This would cause hypercalcemia but with elevated PTH levels, not suppressed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Sarcoidosis can cause hypercalcemia due to increased vitamin D production, but PTHrP would not be elevated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Multiple myeloma:</span></strong><span style=\"font-size:12.0pt\"> While myeloma can cause hypercalcemia through bone destruction, PTHrP is usually not elevated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of hypercalcemia, suppressed PTH, and elevated PTHrP in the setting of a malignancy is indicative of humoral hypercalcemia of malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Question Id-19836 Unique Key-Q3882817</span></span></strong></p>",
    "correct_choice_id": 79308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19837,
    "choices": [
      {
        "id": 79309,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Central diabetes insipidus </span></span></span></p>"
      },
      {
        "id": 79310,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrogenic diabetes insipidus </span></span></span></p>"
      },
      {
        "id": 79311,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH) </span></span></span></p>"
      },
      {
        "id": 79312,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary hyperaldosteronism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of small cell lung cancer (SCLC) presents with confusion, lethargy, and muscle cramps. Laboratory findings reveal hyponatremia with a serum sodium level of 120 mEq/L, high urine sodium, and high urine osmolality. Which of the following is the MOST likely diagnosis?</span></span></p>",
    "unique_key": "Q1077488",
    "question_audio": null,
    "question_video": null,
    "map_id": 19790,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with hyponatremia, high urine sodium, and high urine osmolality, in the context of SCLC, is consistent with SIADH. SCLC is a known cause of SIADH due to ectopic production of vasopressin (ADH). The other options do not fit the clinical and laboratory picture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Central diabetes insipidus:</span></strong><span style=\"font-size:12.0pt\"> This condition is caused by deficient production of ADH, leading to excessive water loss and hypernatremia (high serum sodium), not hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nephrogenic diabetes insipidus:</span></strong><span style=\"font-size:12.0pt\"> In this condition, the kidneys are unable to respond to ADH, also leading to excessive water loss and hypernatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Primary hyperaldosteronism:</span></strong><span style=\"font-size:12.0pt\"> This condition is characterized by excessive aldosterone production, leading to sodium retention, hypertension, and hypokalemia. It does not typically cause hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SIADH is characterized by hyponatremia with inappropriately concentrated urine due to excessive ADH secretion. SCLC is a common cause of SIADH.</span></span></p>",
    "correct_choice_id": 79311,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19838,
    "choices": [
      {
        "id": 79313,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ectopic ACTH production </span></span></span></p>"
      },
      {
        "id": 79314,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary adrenal adenoma </span></span></span></p>"
      },
      {
        "id": 79315,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary ACTH-secreting adenoma (Cushing&#39;s disease) </span></span></span></p>"
      },
      {
        "id": 79316,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exogenous glucocorticoid use</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman smoker with a recent diagnosis of small cell lung cancer (SCLC) presents with rapid weight gain, proximal muscle weakness, and easy bruising. She also reports experiencing mood swings and insomnia. On examination, she has central obesity, facial plethora, and purple striae on her abdomen. Her blood pressure is 150/90 mmHg. Further investigations reveal hypokalemia and hyperglycemia. Which of the following is the MOST likely underlying mechanism for her clinical presentation?</span></span></span></p>",
    "unique_key": "Q9220117",
    "question_audio": null,
    "question_video": null,
    "map_id": 19791,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Ectopic ACTH production </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of Cushingoid features (central obesity, facial plethora, purple striae, hypertension, hypokalemia, hyperglycemia) in a patient with SCLC strongly suggests ectopic ACTH production. SCLC is a common cause of ectopic Cushing&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Primary adrenal adenoma:</span></strong><span style=\"font-size:12.0pt\"> While an adrenal adenoma could cause Cushing&#39;s syndrome, it wouldn&#39;t explain the recent onset of symptoms in the context of SCLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pituitary ACTH-secreting adenoma (Cushing&#39;s disease):</span></strong><span style=\"font-size:12.0pt\"> Cushing&#39;s disease is less likely in this scenario, especially with a known SCLC diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exogenous glucocorticoid use:</span></strong><span style=\"font-size:12.0pt\"> This is less likely given the absence of a history of glucocorticoid use and the presence of SCLC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ectopic Cushing&#39;s syndrome is a paraneoplastic syndrome caused by the ectopic production of ACTH by non-pituitary tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the clinical features of Cushing&#39;s syndrome in patients with cancer is crucial for prompt diagnosis and management.</span></span></span></p>",
    "correct_choice_id": 79313,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19839,
    "choices": [
      {
        "id": 79317,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Serum cortisol </span></span></span></p>"
      },
      {
        "id": 79318,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">24-hour urinary 5-HIAA </span></span></span></p>"
      },
      {
        "id": 79319,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Serum calcitonin </span></span></span></p>"
      },
      {
        "id": 79320,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum gastrin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with recurrent episodes of flushing, accompanied by diarrhea and abdominal cramping. She has also noticed a rash on her face and neck that worsens during these episodes. On physical examination, you note telangiectasias on her cheeks and a palpable liver mass. Which of the following diagnostic tests is MOST likely to be elevated in this patient?</span></span></p>",
    "unique_key": "Q9966236",
    "question_audio": null,
    "question_video": null,
    "map_id": 19792,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 24-hour urinary 5-HIAA</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of flushing, diarrhea, skin changes, and a palpable liver mass raises strong suspicion for carcinoid syndrome. Carcinoid tumors secrete vasoactive substances, primarily serotonin, leading to these characteristic symptoms. 24-hour urinary 5-HIAA (a metabolite of serotonin) is the most sensitive and specific test for diagnosing carcinoid syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Serum cortisol:</span></strong><span style=\"font-size:12.0pt\"> Cortisol is elevated in Cushing&#39;s syndrome, which presents with different clinical features (central obesity, muscle weakness, hypertension).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Serum calcitonin:</span></strong><span style=\"font-size:12.0pt\"> Calcitonin is a marker for medullary thyroid carcinoma (MTC), which can also cause flushing but usually presents with a neck mass or thyroid nodules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum gastrin:</span></strong><span style=\"font-size:12.0pt\"> Gastrin is elevated in gastrinomas (a type of neuroendocrine tumor), which primarily cause peptic ulcers and abdominal pain, not the classic carcinoid syndrome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</span></span></li>\r\n</ul>",
    "correct_choice_id": 79318,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19840,
    "choices": [
      {
        "id": 79321,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulinoma </span></span></span></p>"
      },
      {
        "id": 79322,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adrenal insufficiency </span></span></span></p>"
      },
      {
        "id": 79323,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ectopic production of IGF-2 by the tumor </span></span></span></p>"
      },
      {
        "id": 79324,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary insufficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of weight loss and fatigue presents with recurrent episodes of confusion, sweating, and tremors. These episodes typically occur in the morning or after prolonged fasting. His blood glucose level during one of these episodes is 40 mg/dL. Abdominal imaging reveals a large retroperitoneal mass. Which of the following is the MOST likely cause of this patient&#39;s hypoglycemia?</span></span></p>",
    "unique_key": "Q1912981",
    "question_audio": null,
    "question_video": null,
    "map_id": 19793,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Ectopic production of IGF-2 by the tumor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-islet cell hypoglycemia is a rare paraneoplastic syndrome associated with certain mesenchymal and hepatic tumors, as well as gastrointestinal stromal tumors (GISTs).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with hypoglycemia, weight loss, and a retroperitoneal mass suggests a paraneoplastic syndrome.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common mechanism of non-islet cell hypoglycemia is the ectopic production of IGF-2 (insulin-like growth factor 2) by the tumor. IGF-2 can have insulin-like effects, leading to decreased glucose production and increased glucose uptake by tissues.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Insulinoma:</span></strong><span style=\"font-size:12.0pt\"> Insulinomas are pancreatic neuroendocrine tumors that secrete insulin, leading to hypoglycemia. However, the presence of a retroperitoneal mass makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adrenal insufficiency:</span></strong><span style=\"font-size:12.0pt\"> Adrenal insufficiency can cause hypoglycemia, but it&#39;s usually associated with other symptoms like hypotension, fatigue, and hyperpigmentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pituitary insufficiency:</span></strong><span style=\"font-size:12.0pt\"> Pituitary insufficiency can cause secondary adrenal insufficiency, which can lead to hypoglycemia. However, it&#39;s less likely in this patient with a retroperitoneal mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-islet cell hypoglycemia is a rare but important paraneoplastic syndrome associated with certain tumors.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing this syndrome is crucial for proper management and treatment of the underlying malignancy.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 79323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53430,
    "choices": [
      {
        "id": 213201,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary hyperparathyroidism </span></span></span></p>"
      },
      {
        "id": 213202,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin D deficiency </span></span></span></p>"
      },
      {
        "id": 213203,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mesenchymal tumor producing FGF23 </span></span></span></p>"
      },
      {
        "id": 213204,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple myeloma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man presents with persistent bone pain and muscle weakness for several months. He has a history of recurrent fractures. Laboratory findings show hypophosphatemia, normal serum calcium, and decreased 1,25-dihydroxyvitamin D levels. Imaging studies reveal multiple bone lesions. Which of the following is the MOST likely underlying cause of his condition?</span></span></p>",
    "unique_key": "Q9219581",
    "question_audio": null,
    "question_video": null,
    "map_id": 25234,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Mesenchymal tumor producing FGF23</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of bone pain, muscle weakness, recurrent fractures, hypophosphatemia, normal calcium, and decreased 1,25-dihydroxyvitamin D levels strongly suggests oncogenic osteomalacia. This rare paraneoplastic syndrome is caused by tumors that secrete fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and impaired vitamin D activation. The image lists hemangiopericytomas, fibromas, sarcomas, giant cell tumors, and osteoblastomas as potential culprits, along with prostate and lung cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Primary hyperparathyroidism:</span></strong><span style=\"font-size:12.0pt\"> This would cause hypercalcemia, not hypophosphatemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Vitamin D deficiency:</span></strong><span style=\"font-size:12.0pt\"> This would also cause hypophosphatemia, but 1,25-dihydroxyvitamin D levels would be low or inappropriately normal, not decreased.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Multiple myeloma:</span></strong><span style=\"font-size:12.0pt\"> Myeloma can cause bone pain and fractures, but it typically presents with hypercalcemia and renal insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 213203,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53431,
    "choices": [
      {
        "id": 213205,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Male breast cancer</span></span></span></p>"
      },
      {
        "id": 213206,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gynecomastia</span></span></span></p>"
      },
      {
        "id": 213207,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Male feminization</span></span></span></p>"
      },
      {
        "id": 213208,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non cancerous breast lump</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man presents to his primary care physician with complaints of breast tenderness and enlargement over the past 3 months. He has also noticed a significant decrease in his libido and erectile function during this time. On physical examination, you note bilateral gynecomastia without palpable masses and testicular atrophy. Laboratory findings reveal a normal testosterone level, elevated estradiol level, and a slightly elevated hCG level. A chest CT scan demonstrates a mass in the right lung&#39;s lower lobe, with no evidence of metastasis. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q6327904",
    "question_audio": null,
    "question_video": null,
    "map_id": 25235,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Male feminization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of breast tenderness and enlargement (gynecomastia), decreased libido, and erectile dysfunction in the context of normal testosterone levels, elevated estradiol levels, and slightly elevated human chorionic gonadotropin (hCG) levels, along with the finding of a lung mass, suggests male feminization syndrome. This condition, also known as paraneoplastic hyperestrogenism, occurs when certain tumors, particularly lung tumors like non-small cell lung cancer, produce hormones or hormone-like substances (in this case, hCG, which can stimulate estrogen production) leading to feminization effects in males. The lung mass identified on the chest CT scan, combined with the hormonal findings, supports this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Male breast cancer: </strong>Usually presents as a unilateral, hard, and sometimes painful mass located beneath the nipple, without necessarily being associated with elevated estradiol levels or symptoms of feminization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. </span></strong><span style=\"font-size:12.0pt\"><strong>Gynecomastia:&nbsp;</strong>Refers to the benign enlargement of breast tissue in males and can be a component of male feminization syndrome, but by itself, it does not explain the full clinical picture, including the lung mass and hormonal imbalances.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Non-cancerous breast lumps:</strong> Can cause breast enlargement, but they do not typically lead to hormonal changes like elevated estradiol or the systemic symptoms of feminization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male feminization syndrome, or paraneoplastic hyperestrogenism, can occur when tumors (commonly lung tumors) produce hormones or hormone-like substances leading to elevated estrogen levels, resulting in feminization effects such as gynecomastia, decreased libido, and erectile dysfunction. The diagnosis is supported by the presence of a lung mass, normal testosterone, elevated estradiol, and slightly elevated hCG levels. </span></span></p>",
    "correct_choice_id": 213207,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 53432,
    "choices": [
      {
        "id": 213209,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dermatomyositis</span></span></span></p>"
      },
      {
        "id": 213210,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Paraneoplastic pemphigus</span></span></span></p>"
      },
      {
        "id": 213211,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pyoderma gangrenosum</span></span></span></p>"
      },
      {
        "id": 213212,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sweet syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male with acute myeloid leukemia presents with stomatitis as shown in the image. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162506.jpg\" style=\"height:202px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q5783810",
    "question_audio": null,
    "question_video": null,
    "map_id": 25236,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Paraneoplastic pemphigus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation of severe stomatitis with erosive and ulcerative lesions in the context of acute myeloid leukemia is most suggestive of paraneoplastic pemphigus (PNP). Paraneoplastic pemphigus is an autoimmune blistering disorder that can be associated with underlying malignancies, most commonly hematologic cancers such as leukemia and lymphoma. It is characterized by painful mucosal erosions and polymorphous skin lesions. The severe stomatitis seen in the image is consistent with the mucosal involvement typically seen in PNP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Dermatomyositis: </strong>Generally presents with a heliotrope rash (purple discoloration around the eyes) and Gottron&#39;s papules, not typically with the severe oral involvement shown.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Pyoderma gangrenosum:</strong>&nbsp;Is a neutrophilic dermatosis that usually presents as rapidly progressing painful skin ulcers, primarily on the legs, not in the oral cavity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Sweet syndrome:</strong>&nbsp;or acute febrile neutrophilic dermatosis, presents with painful erythematous plaques on the skin, typically without the severe mucosal involvement depicted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paraneoplastic pemphigus is associated with underlying malignancies and presents with painful mucosal erosions and various skin lesions. It is important to recognize the oral manifestations which can be severe and impact a patient&#39;s ability to eat and maintain oral hygiene.</span></span></span></p>",
    "correct_choice_id": 213210,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 53433,
    "choices": [
      {
        "id": 213213,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocytic leukemia</span></span></span></p>"
      },
      {
        "id": 213214,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myelodysplastic syndrome</span></span></span></p>"
      },
      {
        "id": 213215,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin&#39;s lymphoma</span></span></span></p>"
      },
      {
        "id": 213216,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycythemia vera</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old male patient presents with fever, arthralgia, and painful erythematous plaques on her upper extremities as shown in the image. Laboratory tests reveal leukocytosis with neutrophilia and anemia. A bone marrow biopsy is performed, suspecting an underlying hematological disorder. Which of the following conditions is most likely associated with this patient&#39;s presentation?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-163404.jpg\" style=\"height:266px; width:300px\" /></span></span></p>",
    "unique_key": "Q5464784",
    "question_audio": null,
    "question_video": null,
    "map_id": 25237,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Myelodysplastic syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation of fever, arthralgia, and painful erythematous plaques, along with leukocytosis with neutrophilia and anemia, is suggestive of Sweet&#39;s syndrome, also known as acute febrile neutrophilic dermatosis. This condition is often associated with hematological malignancies and disorders. Sweet&#39;s syndrome is characterized by the abrupt onset of painful, erythematous, and edematous plaques, typically accompanied by systemic symptoms such as fever and arthralgias. It is frequently associated with hematologic disorders, and among them, myelodysplastic syndrome is one of the most common associations. This syndrome can sometimes precede, occur concurrently with, or follow the diagnosis of the associated hematological malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Chronic lymphocytic leukemia (CLL):</strong> May be associated with various skin manifestations, but Sweet&#39;s syndrome is more classically associated with myeloid disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Hodgkin&#39;s lymphoma:</strong> Is not commonly associated with Sweet&#39;s syndrome. Hodgkin&#39;s lymphoma typically presents with lymphadenopathy and sometimes with B symptoms (fever, weight loss, night sweats), but not typically with the cutaneous manifestations seen in Sweet&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Polycythemia vera:&nbsp;</strong>Could present with a plethoric face and splenomegaly and is a myeloproliferative disorder, but it is not the hematologic disorder most typically associated with Sweet&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sweet&#39;s syndrome, characterized by painful erythematous plaques, fever, and arthralgias, is often associated with hematological disorders, particularly myelodysplastic syndrome.</span></span></span></p>",
    "correct_choice_id": 213214,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53434,
    "choices": [
      {
        "id": 213217,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Addison&#39;s disease </span></span></p>"
      },
      {
        "id": 213218,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin resistance </span></span></p>"
      },
      {
        "id": 213219,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastric adenocarcinoma </span></span></p>"
      },
      {
        "id": 213220,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old male, with a known case of GERD presents with a 6-month history of weight loss, decreased appetite along with darkening and thickening of the skin on his neck and axillae. The areas are asymptomatic but have been progressively worsening. He has no other significant past medical history. On examination, you note hyperpigmented, velvety plaques in the affected areas along with the small nodule near the umblicus. Given the patient&#39;s presentation, which of the following is the MOST likely underlying condition?</span></span></p>",
    "unique_key": "Q6233642",
    "question_audio": null,
    "question_video": null,
    "map_id": 25238,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Gastric adenocarcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s rapid-onset acanthosis nigricans, combined with weight loss, decreased appetite, and the presence of a Sister Mary Joseph nodule (a sign of metastatic cancer, often from an abdominal malignancy), points strongly toward an underlying malignancy. Gastric adenocarcinoma is the most frequent malignancy associated with acanthosis nigricans in adults, especially when it has an aggressive presentation like this.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Addison&#39;s disease:</span></strong><span style=\"font-size:12.0pt\"> While Addison&#39;s disease can cause hyperpigmentation, it is typically more diffuse and doesn&#39;t have the velvety texture characteristic of acanthosis nigricans. Additionally, Addison&#39;s disease would present with other symptoms like hypotension, fatigue, and electrolyte imbalances.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Insulin resistance:</span></strong><span style=\"font-size:12.0pt\"> While insulin resistance can cause acanthosis nigricans, it&#39;s usually seen in younger individuals with obesity and metabolic syndrome. The rapid progression, associated symptoms, and the presence of a Sister Mary Joseph nodule in this case point more towards malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Hypothyroidism can cause skin changes like dryness and coarseness, but it doesn&#39;t typically cause the velvety hyperpigmentation seen in acanthosis nigricans.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapidly progressive acanthosis nigricans in an adult, especially with associated symptoms like weight loss, decreased appetite, and the presence of a Sister Mary Joseph nodule, should prompt immediate investigation for an underlying malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gastric adenocarcinoma is the most common malignancy associated with acanthosis nigricans in adults, and the presence of a Sister Mary Joseph nodule further supports this possibility.</span></span></span></p>",
    "correct_choice_id": 213219,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53435,
    "choices": [
      {
        "id": 213221,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic lupus erythematosus (SLE) </span></span></span></p>"
      },
      {
        "id": 213222,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermatomyositis </span></span></span></p>"
      },
      {
        "id": 213223,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleroderma </span></span></span></p>"
      },
      {
        "id": 213224,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polymyositis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman presents with progressive muscle weakness and peculiar rashes present on her knuckles and eyes as shown below. She also reports difficulty swallowing and has noticed a scaly rash over her shoulders and upper back. Which of the following is the MOST likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-163958.jpg\" style=\"height:226px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q2584110",
    "question_audio": null,
    "question_video": null,
    "map_id": 25239,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Dermatomyositis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of the characteristic skin findings (heliotrope rash, Gottron&#39;s papules, shawl sign) and muscle weakness is highly suggestive of dermatomyositis. The difficulty swallowing (dysphagia) further supports the diagnosis, as it can be a manifestation of muscle involvement in the esophagus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Systemic lupus erythematosus (SLE):</span></strong><span style=\"font-size:12.0pt\"> While SLE can cause a malar rash and muscle weakness, it doesn&#39;t typically present with the specific skin findings seen in dermatomyositis (heliotrope rash, Gottron&#39;s papules, shawl sign).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Scleroderma:</span></strong><span style=\"font-size:12.0pt\"> Scleroderma primarily affects the skin and internal organs, causing thickening and tightening of the skin. It doesn&#39;t typically present with the muscle weakness or characteristic rash seen in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polymyositis:</span></strong><span style=\"font-size:12.0pt\"> Polymyositis presents with muscle weakness but lacks the characteristic skin manifestations of dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermatomyositis is an inflammatory myopathy characterized by muscle weakness and distinctive skin manifestations. It is also associated with an increased risk of malignancy, particularly ovarian cancer.</span></span></span></p>",
    "correct_choice_id": 213222,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 19830,
    "choices": [
      {
        "id": 79281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortical encephalitis</span></span></span></p>"
      },
      {
        "id": 79282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Limbic encephalitis</span></span></span></p>"
      },
      {
        "id": 79283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cerebellar encephalitis</span></span></span></p>"
      },
      {
        "id": 79284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brainstem encephalitis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents to the clinic with a 2-month history of progressive memory loss, confusion, and episodes of hallucinations. Her family also reports a change in her behavior, describing her as increasingly irritable and sometimes displaying inappropriate emotional responses. She was recently diagnosed with lung cancer. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q2388852",
    "question_audio": null,
    "question_video": null,
    "map_id": 19741,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Limbic encephalitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Limbic encephalitis is a type of autoimmune encephalitis that affects the limbic system, which includes structures such as the hippocampus, amygdala, and parts of the frontal and temporal lobes. These areas are involved in memory, emotion, and behavior. Limbic encephalitis often presents with subacute (developing over weeks to months) symptoms of memory loss, confusion, seizures, and behavioral changes, including irritability and inappropriate emotional responses. Hallucinations, both visual and auditory, can also be a feature. The association with lung cancer, especially small cell lung cancer, suggests a paraneoplastic etiology, where the body&#39;s immune response against the tumor also targets similar antigens expressed in the nervous system.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cortical encephalitis:</strong> Would involve more widespread cerebral cortex symptoms, including significant changes in cognition, motor, and sensory functions but might not specifically target memory and emotional regulation as in limbic encephalitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cerebellar encephalitis:</strong> Would primarily affect coordination, gait, and balance due to inflammation of the cerebellum, and would be less likely to cause the memory and behavioral symptoms described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Brainstem encephalitis:</strong> Would involve symptoms related to the functions of the brainstem, including vital functions, cranial nerve functions, and coordination, rather than primarily memory and behavior.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Limbic encephalitis presents with progressive memory loss, confusion, behavioral changes, and sometimes hallucinations due to the involvement of the limbic system. It can be associated with lung cancer as a paraneoplastic syndrome, where the immune system&#39;s response to the cancer also affects the nervous system.</span></span></p>",
    "correct_choice_id": 79282,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19831,
    "choices": [
      {
        "id": 79285,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticosteroids and intravenous immunoglobulin (IVIG) or plasma exchange </span></span></span></p>"
      },
      {
        "id": 79286,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antiepileptic drugs only </span></span></span></p>"
      },
      {
        "id": 79287,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chemotherapy for ovarian cancer </span></span></span></p>"
      },
      {
        "id": 79288,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiation therapy to the brain</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a recent diagnosis of ovarian cancer is brought to the emergency department due to altered mental status, memory loss, and involuntary movements. Her family reports that she has also been experiencing seizures. Further evaluation reveals anti-NMDA receptor antibodies in her serum. Which of the following is the most appropriate initial treatment for this patient&#39;s condition?</span></span></p>",
    "unique_key": "Q3929564",
    "question_audio": null,
    "question_video": null,
    "map_id": 19743,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Corticosteroids and intravenous immunoglobulin (IVIG) or plasma exchange</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and the presence of anti-NMDA receptor antibodies strongly suggest anti-NMDA receptor encephalitis, a paraneoplastic syndrome often associated with ovarian teratomas. The most appropriate initial treatment for this condition is immunotherapy, which includes corticosteroids and either IVIG or plasma exchange to remove the pathogenic antibodies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Antiepileptic drugs only:</span></strong><span style=\"font-size:12.0pt\"> While antiepileptic drugs are necessary to manage seizures, they do not address the underlying autoimmune process.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chemotherapy for ovarian cancer:</span></strong><span style=\"font-size:12.0pt\"> While treating the underlying cancer is important, immediate immunotherapy is crucial to control the neurological symptoms and prevent further brain damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Radiation therapy to the brain:</span></strong><span style=\"font-size:12.0pt\"> Radiation therapy is not the primary treatment for anti-NMDA receptor encephalitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-NMDA receptor encephalitis is a potentially reversible autoimmune disorder that requires prompt recognition and treatment with immunotherapy.</span></span></p>",
    "correct_choice_id": 79285,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19841,
    "choices": [
      {
        "id": 79325,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies against intracellular antigens are almost always paraneoplastic. </span></span></span></p>"
      },
      {
        "id": 79326,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies against cell surface antigens can be autoimmune and may not always be associated with cancer. </span></span></span></p>"
      },
      {
        "id": 79327,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies can be detected in both CSF and serum. </span></span></span></p>"
      },
      {
        "id": 79328,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of antibodies in CSF excludes an autoimmune cause.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements regarding antibodies in paraneoplastic neurological syndromes (PNS) is FALSE?</span></span></p>",
    "unique_key": "Q4174462",
    "question_audio": null,
    "question_video": null,
    "map_id": 19794,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) The presence of antibodies in CSF excludes an autoimmune cause.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies can be present in CSF in both paraneoplastic and autoimmune neurological disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antibodies against intracellular antigens are almost always paraneoplastic:</span></strong><span style=\"font-size:12.0pt\"> This is generally true. Antibodies targeting intracellular antigens, such as Hu, Yo, or Ri, are highly suggestive of a paraneoplastic neurological syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Antibodies against cell surface antigens can be autoimmune and may not always be associated with cancer:</span></strong><span style=\"font-size:12.0pt\"> This is also accurate. Some antibodies target cell surface antigens, and these can be associated with autoimmune conditions without an underlying malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Antibodies can be detected in both CSF and serum:</span></strong><span style=\"font-size:12.0pt\"> This is correct. In PNS, the antibodies can often be found in both the cerebrospinal fluid (CSF) and the serum.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of antibodies in CSF does not differentiate between paraneoplastic and autoimmune causes.</span></span></span></p>",
    "correct_choice_id": 79328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19842,
    "choices": [
      {
        "id": 79329,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Hu </span></span></span></p>"
      },
      {
        "id": 79330,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Yo </span></span></span></p>"
      },
      {
        "id": 79331,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ANNA-2</span></span></span></p>"
      },
      {
        "id": 79332,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ma2</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman with a BG of CA Breast on chemotherapy presents with progressive ataxia and opsoclonus (rapid, multidirectional eye movements). Which antibody is MOST likely to be found in her serum?</span></span></p>",
    "unique_key": "Q7379324",
    "question_audio": null,
    "question_video": null,
    "map_id": 19795,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) ANNA - 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of cerebellar ataxia (difficulty with coordination and balance) and opsoclonus (rapid, involuntary eye movements in various directions) is highly characteristic of a paraneoplastic neurological syndrome associated with <strong>anti-Ri antibodies (also known as ANNA-2)</strong>. While paraneoplastic neurological syndromes can occur with various cancers, the presence of these specific symptoms and antibodies in a patient with breast cancer makes anti-Ri the most likely answer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anti-Hu:</span></strong><span style=\"font-size:12.0pt\"> Anti-Hu antibodies are associated with paraneoplastic encephalomyelitis and sensory neuronopathy, which typically present with sensory loss, limb weakness, and autonomic dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-Yo:</span></strong><span style=\"font-size:12.0pt\"> Anti-Yo antibodies are linked to paraneoplastic cerebellar degeneration, causing ataxia, but not typically opsoclonus. They are more commonly associated with gynecological and breast cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anti-Ma2:</span></strong><span style=\"font-size:12.0pt\"> Anti-Ma2 antibodies are associated with limbic encephalitis and brainstem encephalitis, which usually present with psychiatric symptoms, seizures, and sometimes brainstem dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Certain antibodies are highly associated with specific paraneoplastic neurological syndromes.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the presence of ataxia and opsoclonus, particularly in a patient with breast cancer, points strongly toward anti-Ri antibodies.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing these paraneoplastic syndromes is crucial for early diagnosis and appropriate management.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 79331,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 19843,
    "choices": [
      {
        "id": 79333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Hu antibodies </span></span></span></p>"
      },
      {
        "id": 79334,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Yo antibodies </span></span></span></p>"
      },
      {
        "id": 79335,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-recoverin antibodies </span></span></span></p>"
      },
      {
        "id": 79336,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-amphiphysin antibodies</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman with a history of small cell lung cancer (SCLC) presents with unexplained vision loss and abnormal retinal pigmentation. Which of the following antibodies is MOST likely associated with her suspected diagnosis?</span></span></p>",
    "unique_key": "Q4810003",
    "question_audio": null,
    "question_video": null,
    "map_id": 19796,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-recoverin antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of vision loss and retinal changes in a patient with SCLC is highly suggestive of <strong>cancer-associated retinopathy (CAR)</strong>. This is a paraneoplastic syndrome where the body&#39;s immune system mistakenly attacks retinal proteins, leading to vision impairment. <strong>Anti-recoverin antibodies</strong> are the most commonly detected antibodies in patients with CAR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anti-Hu antibodies:</span></strong><span style=\"font-size:12.0pt\"> These antibodies are associated with paraneoplastic encephalomyelitis and sensory neuronopathy, which typically present with neurological symptoms like ataxia, sensory loss, and autonomic dysfunction, not primarily vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-Yo antibodies:</span></strong><span style=\"font-size:12.0pt\"> Anti-Yo antibodies are linked to paraneoplastic cerebellar degeneration, causing ataxia but not typically vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anti-amphiphysin antibodies:</span></strong><span style=\"font-size:12.0pt\"> These antibodies are associated with stiff person syndrome, a rare neurological disorder characterized by muscle rigidity and spasms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cancer-associated retinopathy is a paraneoplastic syndrome that can cause vision loss in patients with underlying malignancies, particularly SCLC.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-recoverin antibodies are highly specific for CAR and their presence can help confirm the diagnosis.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 79335,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19844,
    "choices": [
      {
        "id": 79337,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-mGluR1</span></span></p>"
      },
      {
        "id": 79338,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-mGluR2</span></span></p>"
      },
      {
        "id": 79339,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Tr</span></span></p>"
      },
      {
        "id": 79340,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti LGI1</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with recent diagnosis of Hodgkin&#39;s lymphoma presents to neurology clinic with a 3-month history of progressive unsteadiness and difficulty walking. He reports feeling clumsy and has noticed frequent stumbling, particularly when trying to navigate stairs. Additionally, he mentions episodes of slurred speech and difficulty swallowing. Given the presentation, which of the following antibodies is not involved in the condition?</span></span></p>",
    "unique_key": "Q1869533",
    "question_audio": null,
    "question_video": null,
    "map_id": 19797,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anti LGI1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-LGI1 (Leucine-rich glioma inactivated 1) antibodies are associated with limbic encephalitis, not paraneoplastic cerebellar degeneration. Patients with Anti-LGI1 antibodies typically present with cognitive impairment, seizures, and psychiatric symptoms, which are distinct from the cerebellar symptoms described in this patient&#39;s presentation. Therefore, Anti-LGI1 antibodies are not involved in the condition suggested by this patient&#39;s clinical presentation and recent diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms of progressive unsteadiness, difficulty walking, slurred speech, and difficulty swallowing, in the context of a recent diagnosis of Hodgkin&#39;s lymphoma, suggest a paraneoplastic neurological syndrome. Specifically, the symptoms are indicative of paraneoplastic cerebellar degeneration (PCD), which can be associated with Hodgkin&#39;s lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: &nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> <strong>Anti-mGluR1</strong>: Antibodies are associated with paraneoplastic cerebellar degeneration, especially in cases related to Hodgkin&#39;s lymphoma. These antibodies target the metabotropic glutamate receptor 1, which is involved in neuronal signaling in the cerebellum.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> <strong>Anti-mGluR2</strong>: Antibodies target the metabotropic glutamate receptor 2. While less commonly associated with PCD, they have been implicated in some paraneoplastic neurological syndromes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> <strong>Anti-Tr:</strong> Antibodies are strongly associated with paraneoplastic cerebellar degeneration, particularly in patients with Hodgkin&#39;s lymphoma. They are one of the hallmark antibodies for this association.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paraneoplastic cerebellar degeneration (PCD) associated with Hodgkin&#39;s lymphoma is commonly linked with Anti-mGluR1 and Anti-Tr antibodies, which target neuronal components in the cerebellum. In contrast, Anti-LGI1 antibodies are associated with limbic encephalitis and present with a different clinical picture, including seizures and cognitive changes, rather than the cerebellar dysfunction seen in PCD.</span></span></p>",
    "correct_choice_id": 79340,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19845,
    "choices": [
      {
        "id": 79341,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Renal cell carcinoma (RCC) </span></span></span></p>"
      },
      {
        "id": 79342,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatocellular carcinoma (HCC) </span></span></span></p>"
      },
      {
        "id": 79343,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cerebellar hemangioblastoma </span></span></span></p>"
      },
      {
        "id": 79344,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Small cell lung cancer (SCLC)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male smoker with a 50-pack-year history presents with fatigue and a ruddy complexion. His hemoglobin is elevated at 18 g/dL and hematocrit is 55%. Which of the following malignancies is the MOST likely underlying cause of his erythrocytosis?</span></span></p>",
    "unique_key": "Q8840712",
    "question_audio": null,
    "question_video": null,
    "map_id": 19798,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Renal cell carcinoma (RCC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong> <strong><span style=\"font-size:12.0pt\">A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows that erythrocytosis (increased red blood cell mass) can be a paraneoplastic syndrome associated with several cancers, with RCC being the most common at 3%. The patient&#39;s smoking history increases the risk of lung cancer, but the association with erythrocytosis is less strong.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hepatocellular carcinoma (HCC):</span></strong><span style=\"font-size:12.0pt\"> While HCC can also be associated with erythrocytosis, it&#39;s less common than RCC. Additionally, there&#39;s no mention of risk factors for HCC in this patient&#39;s history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cerebellar hemangioblastoma:</span></strong><span style=\"font-size:12.0pt\"> Although hemangioblastomas can produce erythropoietin and cause erythrocytosis, they are much rarer than RCC and usually present with neurological symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Small cell lung cancer (SCLC):</span></strong><span style=\"font-size:12.0pt\"> SCLC is a possible cause of paraneoplastic erythrocytosis, but it&#39;s less common than RCC. The patient&#39;s smoking history increases the risk of lung cancer, but the absence of other respiratory symptoms makes it less likely in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erythrocytosis can be a paraneoplastic manifestation of RCC, and appropriate evaluation is warranted in patients with unexplained erythrocytosis.</span></span></span></p>",
    "correct_choice_id": 79341,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19846,
    "choices": [
      {
        "id": 79345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erythropoietin</span></span></span></p>"
      },
      {
        "id": 79346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombopoietin</span></span></span></p>"
      },
      {
        "id": 79347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vascular endothelial growth factor (VEGF)</span></span></span></p>"
      },
      {
        "id": 79348,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interleukin-6 (IL-6)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">A 63-year-old woman presents to the emergency department with acute onset of left-sided weakness and slurred speech that began 2 hours ago. She also mentions experiencing a burning sensation in her palms and soles for the past month, which she attributed to her new gardening hobby. On examination, she has noticeable splenomegaly. Laboratory tests reveal a platelet count of 950,000/&mu;L, hemoglobin of 12.2 g/dL, and a white blood cell count of 7,800/&mu;L. A chest X-ray reveals a mass in the right lung hilum. Which protein is most likely responsible for this patient&#39;s thrombocytosis?</span></span></span></span></span></p>",
    "unique_key": "Q3191038",
    "question_audio": null,
    "question_video": null,
    "map_id": 19799,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">Ans. D) Interleukin-6 (IL-6)</span></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">In this scenario, the patient presents with signs suggestive of a paraneoplastic syndrome associated with the underlying lung cancer (indicated by the mass in the right lung hilum). Paraneoplastic thrombocytosis is commonly seen in association with various malignancies, including lung cancer. Interleukin-6 (IL-6) is a cytokine that can be produced by tumor cells and is known to play a significant role in paraneoplastic thrombocytosis. IL-6 stimulates the liver to produce thrombopoietin, which in turn increases platelet production in the bone marrow.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">Explanation: </span></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\"><strong>A.</strong> <strong>Erythropoietin:</strong> Primarily regulates red blood cell production and is more associated with polycythemia than thrombocytosis.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\"><strong>B.</strong> <strong>Thrombopoietin:</strong> Is the primary growth factor for platelet production. While it directly regulates platelet production, in the context of paraneoplastic thrombocytosis, it&#39;s the production of cytokines like IL-6 by the tumor that indirectly leads to increased thrombopoietin levels and subsequent thrombocytosis.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\"><strong>C.</strong> <strong>Vascular endothelial growth factor (VEGF</strong>): Is mainly involved in angiogenesis and not directly in the regulation of platelet production.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">Educational Objective:</span></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">Interleukin-6 (IL-6) can be produced by tumor cells and lead to paraneoplastic thrombocytosis in patients with malignancies such as lung cancer. IL-6 acts indirectly by stimulating the liver to produce more thrombopoietin, which then promotes increased platelet production in the bone marrow. Recognizing the role of IL-6 in paraneoplastic syndromes is important for understanding the systemic effects of certain cancers.</span></span></span></span></span></p>",
    "correct_choice_id": 79348,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53436,
    "choices": [
      {
        "id": 213225,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low ionizing power for deep tissue penetration and targeting distant metastases.</span></span></span></p>"
      },
      {
        "id": 213226,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High ionizing power causing dense ionization with limited penetration, ideal for localized disease.</span></span></span></p>"
      },
      {
        "id": 213227,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Extremely high ionizing power causing widespread damage beyond targeted cells, high toxicity risk.</span></span></span></p>"
      },
      {
        "id": 213228,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Similar ionizing power to beta particles but with longer range, suitable for larger tumors.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 62-year-old woman with a history of cervical cancer is being considered for targeted radionuclide therapy using an alpha-emitting radiopharmaceutical. The discussion focuses on the ionizing power of alpha particles in targeting residual microscopic disease. Which statement best describes the ionizing power of alpha particles in this therapy?</span></span></span></p>",
    "unique_key": "Q2052019",
    "question_audio": null,
    "question_video": null,
    "map_id": 25240,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) High ionizing power causing dense ionization with limited penetration, ideal for localized disease</span></strong><span style=\"font-size:12.0pt\">.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha particles are known for their high ionizing power due to their large mass and charge. This characteristic allows them to cause dense ionization along a very short path, which makes them highly effective at damaging DNA within cancer cells. However, this high ionizing power also means that alpha particles have limited penetration depth in tissue, typically only a few cell diameters. This property makes them particularly suitable for targeting localized microscopic disease, such as residual cancer cells, while minimizing the risk of damage to surrounding healthy tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> Alpha particles actually have low penetration in tissue, not deep tissue penetration, which limits their use to more localized or superficial treatments rather than targeting distant metastases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> While alpha particles have a high ionizing power, they do not cause widespread damage beyond targeted cells due to their limited penetration range. The risk of toxicity is more related to their potential to cause significant damage within a short range, which is why they need to be precisely targeted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong> Alpha particles have a much higher ionizing power compared to beta particles but a much shorter range in tissue. Beta particles can penetrate deeper into tissue, making them suitable for larger tumors, whereas alpha particles are more effective for localized treatment due to their short range.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-emitting radiopharmaceuticals are utilized in targeted radionuclide therapy for their high ionizing power, which allows for dense ionization and significant DNA damage within cancer cells. Their limited penetration depth makes them ideal for treating localized microscopic disease while minimizing collateral damage to surrounding healthy tissue.</span></span></p>",
    "correct_choice_id": 213226,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53437,
    "choices": [
      {
        "id": 213229,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It uses radioactive decay of elements like cobalt-60 to emit X-rays. </span></span></span></p>"
      },
      {
        "id": 213230,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It accelerates electrons to high speeds, which then collide with a tungsten target to produce X-rays.</span></span></span></p>"
      },
      {
        "id": 213231,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It accelerates protons in a circular path, and these protons generate X-rays when they hit a target. </span></span></span></p>"
      },
      {
        "id": 213232,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It manipulates the path of high-speed electrons using magnetic fields to produce X-rays.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman with early-stage breast cancer has undergone lumpectomy and is now consulting with her radiation oncologist about adjuvant radiation therapy. The oncologist explains that the treatment will involve using a machine called a linear accelerator. Which of the following BEST describes how a linear accelerator generates X-rays for radiation therapy?</span></span></span></p>",
    "unique_key": "Q2951586",
    "question_audio": null,
    "question_video": null,
    "map_id": 25241,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It accelerates electrons to high speeds, which then collide with a tungsten target to produce X-rays.</span></strong> &nbsp; </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linear accelerators (linacs) are the most commonly used devices for external beam radiation therapy. They work by using microwave technology to accelerate electrons to near the speed of light. These high-energy electrons then strike a heavy metal target, typically made of tungsten. The interaction of the electrons with the target&#39;s atoms generates X-rays, which are then shaped and directed to the tumor site. &nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It uses radioactive decay of elements like cobalt-60 to emit X-rays:</span></strong><span style=\"font-size:12.0pt\"> This describes the principle behind older cobalt-60 radiotherapy units, which are less commonly used today.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It accelerates protons in a circular path, and these protons generate X-rays when they hit a target:</span></strong><span style=\"font-size:12.0pt\"> This is the principle of proton therapy, a more specialized form of radiation therapy that uses protons instead of X-rays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It manipulates the path of high-speed electrons using magnetic fields to produce X-rays:</span></strong><span style=\"font-size:12.0pt\"> This describes the mechanism of a synchrotron, a type of particle accelerator used for research purposes and not typically for clinical radiation therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linear accelerators are the primary source of X-rays in modern radiation therapy for cancer treatment. They generate high-energy X-rays by accelerating electrons and colliding them with a tungsten target.</span></span></span></p>",
    "correct_choice_id": 213230,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InstrumentsBased"
    ]
  },
  {
    "id": 53438,
    "choices": [
      {
        "id": 213233,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conventional photon therapy</span></span></p>"
      },
      {
        "id": 213234,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gamma knife radiosurgery</span></span></p>"
      },
      {
        "id": 213235,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proton beam therapy</span></span></p>"
      },
      {
        "id": 213236,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intensity-modulated radiation therapy (IMRT)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient with a deep-seated brain tumor is being considered for radiation therapy. The treatment plan involves using a type of radiation that has a distinct advantage in sparing surrounding healthy tissues while delivering a high dose to the tumor. Which type of radiation therapy is being considered for this patient?</span></span></p>",
    "unique_key": "Q4546870",
    "question_audio": null,
    "question_video": null,
    "map_id": 25242,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Proton beam therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proton beam therapy is a type of radiation therapy that uses protons rather than X-rays (photons) to treat cancer. The unique physical properties of protons allow them to deposit most of their energy at a specific depth in tissue, known as the Bragg peak, beyond which there is a rapid fall-off in dose. This characteristic enables proton beam therapy to deliver a high dose of radiation to the tumor while minimizing exposure to surrounding healthy tissues, which is particularly advantageous for treating tumors in sensitive locations like the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> <strong>Conventional photon therapy:</strong> Uses X-rays to treat cancer. While effective, it may not offer the same level of precision in sparing surrounding tissues as proton therapy, especially for deep-seated tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> <strong>Gamma knife radiosurgery:</strong> Is a form of stereotactic radiosurgery that uses focused beams of gamma rays to treat small to medium-sized lesions, primarily in the brain. While it is highly precise, it may not be the best option for larger tumors or those located deep within the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Intensity-modulated radiation therapy (IMRT):</strong> Is an advanced form of photon therapy that modulates the intensity of the radiation beams to conform to the shape of the tumor. It offers improved sparing of healthy tissues compared to conventional photon therapy but still uses X-rays, which have a different dose distribution compared to protons.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proton beam therapy is particularly advantageous for treating deep-seated tumors, such as those in the brain, due to its ability to deliver a high dose of radiation to the tumor with minimal exposure to surrounding healthy tissues. This is achieved through the unique dose distribution of protons, characterized by the Bragg peak.</span></span></span></p>",
    "correct_choice_id": 213235,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53439,
    "choices": [
      {
        "id": 213237,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Compton scattering </span></span></p>"
      },
      {
        "id": 213238,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Photoelectric effect </span></span></p>"
      },
      {
        "id": 213239,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pair production </span></span></p>"
      },
      {
        "id": 213240,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bremsstrahlung radiation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A radiologist is reviewing a chest X-ray of a 50-year-old patient. They note a clear distinction between the denser, brighter areas representing the ribs and the darker areas representing the lungs. This contrast allows them to visualize the lung parenchyma and identify any potential abnormalities.&nbsp; Which of the following radiation interactions is PRIMARILY responsible for creating the contrast observed on this chest X-ray?</span></span></p>",
    "unique_key": "Q8190320",
    "question_audio": null,
    "question_video": null,
    "map_id": 25243,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Photoelectric effect</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The photoelectric effect is highly dependent on the atomic number (Z) of the material the X-ray interacts with. Tissues with higher Z (e.g., bone) will absorb more X-rays than tissues with lower Z (e.g., soft tissue), creating the contrast seen on X-ray images.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Compton scattering:</span></strong><span style=\"font-size:12.0pt\"> Contributes to image noise and reduces contrast.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pair production:</span></strong><span style=\"font-size:12.0pt\"> Occurs at very high photon energies, not typically used in diagnostic imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bremsstrahlung radiation:</span></strong><span style=\"font-size:12.0pt\"> Is the process of X-ray production, not an interaction within the patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The photoelectric effect is crucial in generating image contrast in diagnostic radiology due to its dependence on the atomic number of the tissues.</span></span></span></p>",
    "correct_choice_id": 213238,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53440,
    "choices": [
      {
        "id": 213241,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cells with a high mitotic rate and low differentiation are more radiosensitive.</span></span></p>"
      },
      {
        "id": 213242,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cells with a low mitotic rate and high differentiation are more radiosensitive.</span></span></p>"
      },
      {
        "id": 213243,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All cell types are equally sensitive to radiation.</span></span></p>"
      },
      {
        "id": 213244,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiosensitivity is independent of cell type and depends only on the radiation dose.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Law of Bergonie and Tribondeau describes the relative radiosensitivity of different cell types. Which of the following statements BEST encapsulates this law?</span></span></span></p>",
    "unique_key": "Q6295011",
    "question_audio": null,
    "question_video": null,
    "map_id": 25244,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Cells with a high mitotic rate and low differentiation are more radiosensitive.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Law of Bergonie and Tribondeau states that cells that are actively dividing (high mitotic rate) and less specialized (low differentiation) are more susceptible to the damaging effects of ionizing radiation. This is because rapidly dividing cells have less time to repair DNA damage before entering mitosis, leading to the propagation of errors and potentially cell death<strong>.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> <strong>Cells with a low mitotic rate and high differentiation are more radiosensitive:</strong> This is the opposite of the correct answer. Highly differentiated and slowly dividing cells are generally more resistant to radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> <strong>All cell types are equally sensitive to radiation:</strong> This is incorrect. Different cell types exhibit varying degrees of radiosensitivity based on their proliferative and differentiation status.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong> <strong>Radiosensitivity is independent of cell type and depends only on the radiation dose:</strong> While radiation dose is a crucial factor, the inherent radiosensitivity of different cell types also plays a major role in determining the extent of radiation damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Law of Bergonie and Tribondeau is a fundamental principle in radiation biology that explains why some tissues are more susceptible to radiation damage than others. This has important implications for radiation therapy planning and minimizing side effects.</span></span></span></p>",
    "correct_choice_id": 213241,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53441,
    "choices": [
      {
        "id": 213245,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sievert (Sv)</span></span></p>"
      },
      {
        "id": 213246,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gray (Gy)</span></span></p>"
      },
      {
        "id": 213247,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Becquerel (Bq)</span></span></p>"
      },
      {
        "id": 213248,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Roentgen (R)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A medical physicist is calculating the absorbed dose of radiation received by a patient during a radiotherapy session. Which of the following units is used to measure the absorbed dose of radiation in tissues?</span></span></span></p>",
    "unique_key": "Q5601271",
    "question_audio": null,
    "question_video": null,
    "map_id": 25245,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Gray (Gy)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Gray (Gy) is the unit used to measure the absorbed dose of radiation in tissues. One Gray is defined as the absorption of one joule of radiation energy by one kilogram of matter. It is a physical unit that quantifies the amount of ionizing radiation energy deposited in a unit mass of tissue and is used primarily in the field of radiation therapy to specify the dose of radiation a patient receives.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> <strong>Sievert (Sv)</strong>: Is a unit that measures the biological effect of the absorbed radiation, not the absorbed dose itself. It takes into account the type of radiation and its biological effectiveness, and is often used in radiation protection to quantify the risk associated with the exposure to ionizing radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> <strong>Becquerel (Bq)</strong>: Is a unit of radioactivity that measures the rate of decay or disintegration of radioactive material. It is defined as one disintegration per second and is not a measure of absorbed dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong> <strong>Roentgen (R)</strong>: Is an older unit that was used to measure the exposure or the amount of ionization produced in air by X-rays or gamma rays. It does not directly measure the absorbed dose in tissue, which is why it has largely been replaced by the Gray in medical and scientific contexts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Gray (Gy) is the unit used to measure the absorbed dose of radiation in tissues, indicating the amount of radiation energy deposited per unit mass of tissue. It is a critical measurement in radiation therapy planning to ensure that the target area receives the prescribed dose while minimizing the dose to surrounding healthy tissues.</span></span></span></p>",
    "correct_choice_id": 213246,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53442,
    "choices": [
      {
        "id": 213249,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone marrow </span></span></p>"
      },
      {
        "id": 213250,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Salivary glands </span></span></p>"
      },
      {
        "id": 213251,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid </span></span></p>"
      },
      {
        "id": 213252,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonads</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following tissues has the LOWEST tissue weighting factor, indicating it is the LEAST sensitive to radiation?</span></span></p>",
    "unique_key": "Q1168551",
    "question_audio": null,
    "question_video": null,
    "map_id": 25246,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Salivary glands</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong> <strong><span style=\"font-size:12.0pt\">B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table lists salivary glands under &quot;Low&quot; tissue sensitivity with a tissue weighting factor of 0.01, the lowest among the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bone marrow:</span></strong><span style=\"font-size:12.0pt\"> Bone marrow is highly radiosensitive due to its role in blood cell production. It has a tissue weighting factor of 0.12, indicating a relatively high risk of stochastic effects from radiation exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thyroid:</span></strong><span style=\"font-size:12.0pt\"> The thyroid gland has an intermediate tissue weighting factor of 0.04, indicating moderate radiosensitivity. It&#39;s more sensitive than salivary glands but less sensitive than bone marrow or gonads.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gonads:</span></strong><span style=\"font-size:12.0pt\"> The gonads (ovaries and testes) are also relatively radiosensitive due to their role in reproduction. They have a tissue weighting factor of 0.08.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tissues with low tissue weighting factors are less sensitive to radiation, meaning they can tolerate higher doses before experiencing significant damage.</span></span></p>",
    "correct_choice_id": 213250,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53443,
    "choices": [
      {
        "id": 213253,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphocytes circulating in the blood </span></span></p>"
      },
      {
        "id": 213254,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spermatogonia in the testes </span></span></p>"
      },
      {
        "id": 213255,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestinal epithelial cells lining the gut </span></span></p>"
      },
      {
        "id": 213256,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurons in the brain</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old man with a glioblastoma is undergoing radiation therapy to his brain. The radiation oncologist explains that while radiation therapy can be effective in treating the tumor, it&#39;s important to be aware of potential side effects due to the varying sensitivity of different cell types to radiation. Considering the principles of radiosensitivity, which of the following cell types within the radiation field is MOST likely to be the LEAST affected by the radiation therapy?</span></span></span></p>",
    "unique_key": "Q5927924",
    "question_audio": null,
    "question_video": null,
    "map_id": 25247,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Neurons in the brain</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neurons are highly differentiated and generally non-dividing cells. According to the Law of Bergonie and Tribondeau, cells that are actively dividing and less differentiated are more sensitive to radiation. Therefore, neurons, being relatively inactive and highly differentiated, are more resistant to radiation compared to the other cell types listed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lymphocytes circulating in the blood:</span></strong><span style=\"font-size:12.0pt\"> Lymphocytes are a type of white blood cell involved in the immune response. They are actively dividing and relatively undifferentiated, making them quite sensitive to radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Spermatogonia in the testes:</span></strong><span style=\"font-size:12.0pt\"> Spermatogonia are the stem cells in the testes that give rise to sperm. They are constantly dividing, making them highly radiosensitive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Intestinal epithelial cells lining the gut:</span></strong><span style=\"font-size:12.0pt\"> These cells have a high turnover rate, constantly dividing to replenish the gut lining. This rapid cell division makes them more susceptible to radiation damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The radiosensitivity of different cell types varies, and understanding these differences is important in predicting and managing the potential side effects of radiation therapy.</span></span></span></p>",
    "correct_choice_id": 213256,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53444,
    "choices": [
      {
        "id": 213257,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cataracts </span></span></p>"
      },
      {
        "id": 213258,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myelosuppression </span></span></p>"
      },
      {
        "id": 213259,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility </span></span></p>"
      },
      {
        "id": 213260,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cognitive decline</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with Hodgkin lymphoma is receiving radiation therapy. Which of the following side effects is the physician MOST likely to monitor for due to the high radiosensitivity of the affected tissue?</span></span></p>",
    "unique_key": "Q9616272",
    "question_audio": null,
    "question_video": null,
    "map_id": 25248,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Myelosuppression</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin lymphoma is often treated with radiation therapy that encompasses lymph node regions. The image shows that bone marrow is one of the most radiosensitive tissues. Bone marrow suppression leads to a decrease in blood cell production, resulting in myelosuppression.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cataracts:</span></strong><span style=\"font-size:12.0pt\"> Cataracts are a long-term complication of radiation therapy, particularly when the lens of the eye is within the radiation field. While possible, they are less likely to be a primary concern during the active treatment phase compared to myelosuppression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Infertility:</span></strong><span style=\"font-size:12.0pt\"> Infertility can occur if the gonads (testes or ovaries) are within the radiation field. In Hodgkin lymphoma treatment, the radiation field is often directed at lymph nodes in the chest, neck, or abdomen, making direct gonadal exposure less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cognitive decline:</span></strong><span style=\"font-size:12.0pt\"> Cognitive decline is a potential late complication of radiation therapy to the brain, but it&#39;s not a primary concern in the treatment of Hodgkin lymphoma, where the radiation field usually doesn&#39;t encompass the brain</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone marrow is a highly radiosensitive tissue, and myelosuppression is a common side effect of radiation therapy.</span></span></p>",
    "correct_choice_id": 213258,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53445,
    "choices": [
      {
        "id": 213261,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.5 mSv </span></span></p>"
      },
      {
        "id": 213262,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 mSv </span></span></p>"
      },
      {
        "id": 213263,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 mSv </span></span></p>"
      },
      {
        "id": 213264,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 mSv</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pregnant radiation worker is concerned about the potential effects of radiation on her fetus. What is the recommended dose limit for the entire pregnancy?</span></span></p>",
    "unique_key": "Q2541402",
    "question_audio": null,
    "question_video": null,
    "map_id": 25249,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 5 mSv</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table explicitly states that the dose limit for pregnancy is 5 mSv for the entire duration or 0.5 mSv per month.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 0.5 mSv:</span></strong><span style=\"font-size:12.0pt\"> This is the recommended <strong>monthly</strong> dose limit for a pregnant radiation worker, not the limit for the entire pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 1 mSv:</span></strong><span style=\"font-size:12.0pt\"> This is the annual dose limit for the general public, which is lower than the limit for occupational exposure during pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 20 mSv:</span></strong><span style=\"font-size:12.0pt\"> This is the annual dose limit for radiation workers, which is significantly higher than the limit for pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnant radiation workers should take precautions to limit their radiation exposure to protect the developing fetus.</span></span></p>",
    "correct_choice_id": 213263,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53446,
    "choices": [
      {
        "id": 213265,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT head</span></span></p>"
      },
      {
        "id": 213266,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Extremity X-ray</span></span></p>"
      },
      {
        "id": 213267,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chest X-ray</span></span></p>"
      },
      {
        "id": 213268,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PET-CT whole body</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which diagnostic modality typically involves the least radiation exposure?</span></span></p>",
    "unique_key": "Q1095730",
    "question_audio": null,
    "question_video": null,
    "map_id": 25250,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Extremity X-ray</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Among the options listed, an extremity X-ray typically involves the least radiation exposure. Extremity X-rays, such as those of the hand, foot, knee, or elbow, are focused on small areas and use relatively low doses of radiation to produce images of the bones and joints. The radiation dose in these procedures is minimal compared to more complex imaging modalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> A CT (Computed Tomography) head scan involves a higher dose of radiation than an extremity X-ray because it uses multiple X-ray beams and a computer to create detailed cross-sectional images of the head, including the brain. CT scans provide more detailed information but at the cost of higher radiation exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C.</strong> A chest X-ray is a common diagnostic test that uses a small amount of radiation to produce images of the chest, including the heart, lungs, airways, blood vessels, and bones of the spine and chest. While a chest X-ray involves more radiation than an extremity X-ray, it is still lower in dose compared to a CT scan.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong> A PET-CT (Positron Emission Tomography-Computed Tomography) whole-body scan combines a PET scan, which uses a radioactive tracer to show organ and tissue function, with a CT scan, which provides detailed anatomical information. This combination results in a higher radiation dose compared to the other options, making it the modality with the highest radiation exposure among those listed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Among the diagnostic modalities listed, an extremity X-ray involves the least radiation exposure due to its focus on small areas and use of relatively low doses of radiation. It is important to consider the radiation dose and the diagnostic value of imaging tests when selecting the most appropriate modality for patient evaluation</span></span></span></p>",
    "correct_choice_id": 213266,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53447,
    "choices": [
      {
        "id": 213269,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10 days</span></span></p>"
      },
      {
        "id": 213270,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">12 years</span></span></p>"
      },
      {
        "id": 213271,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8 years</span></span></p>"
      },
      {
        "id": 213272,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 year</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The radiation exposure from a whole-body PET-CT scan is approximately equivalent to how many days/ months/ years of natural background radiation?</span></span></p>",
    "unique_key": "Q6431691",
    "question_audio": null,
    "question_video": null,
    "map_id": 25251,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 8 years</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A whole-body PET-CT scan exposes a patient to a substantial amount of radiation, and it is approximately equivalent to the radiation exposure from 8 years of natural background radiation. Natural background radiation comes from a variety of sources including cosmic rays, terrestrial sources, and internal radionuclides in the human body. The exact equivalence can vary based on geographic location and other factors due to variations in natural background radiation levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A.</strong> <strong>10 days:</strong>&nbsp;Of natural background radiation exposure is significantly less than the dose received from a whole-body PET-CT scan, which utilizes both the ionizing radiation from CT imaging and the radioactive tracer used in PET scanning.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B.</strong> <strong>12 years:&nbsp;</strong>Of natural background radiation exposure is higher than the typical exposure from a whole-body PET-CT scan, although estimates can vary based on specific protocols and equipment used.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D.</strong> <strong>1 year:</strong> Of natural background radiation exposure is less than the typical dose received from a whole-body PET-CT scan. The comparison to several years of natural background radiation helps to contextualize the relative magnitude of exposure from such medical imaging procedures.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The radiation exposure from a whole-body PET-CT scan is roughly equivalent to 8 years of natural background radiation, highlighting the significant amount of radiation involved in such diagnostic procedures. This comparison underscores the importance of judicious use of high-radiation diagnostic tests, ensuring that the potential benefits outweigh the risks associated with radiation exposure.</span></span></span></p>",
    "correct_choice_id": 213271,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53782,
    "choices": [
      {
        "id": 214601,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Re-assortment </span></span></span></span></p>"
      },
      {
        "id": 214602,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Re-oxygenation </span></span></span></span></p>"
      },
      {
        "id": 214603,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Repair </span></span></span></span></p>"
      },
      {
        "id": 214604,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Repopulation</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A radiation oncologist is planning a course of radiotherapy for a patient with a large, solid tumor. The oncologist is concerned about the presence of hypoxic regions within the tumor, as these areas are known to be relatively resistant to radiation. To enhance the effectiveness of the treatment, the oncologist decides to fractionate the radiation dose, delivering it in multiple smaller doses over several weeks. Which of the following, oncologist primarily leveraging by using fractionated radiotherapy to target hypoxic tumor cells?</span></span></span></p>",
    "unique_key": "Q6599838",
    "question_audio": null,
    "question_video": null,
    "map_id": 25377,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><span style=\"color:black\"><strong>Ans.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"color:black\"><strong>B) Re-oxygenation</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hypoxic tumor cells are resistant to radiation due to the lack of oxygen, which is required for the formation of free radicals that cause DNA damage. Fractionated radiotherapy allows time between doses for some of these hypoxic cells to become re-oxygenated, increasing their sensitivity to subsequent radiation fractions and improving treatment outcomes.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">&nbsp;Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Re-assortment:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This refers to the redistribution of tumor cells into more radiosensitive phases of the cell cycle after radiation. While this can contribute to overall tumor cell killing, it&#39;s not the primary mechanism for overcoming hypoxia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Repair:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This process allows normal tissues to recover between radiation fractions, reducing toxicity. However, it&#39;s not directly related to addressing hypoxia in tumor cells.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Repopulation:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This refers to the accelerated growth of both normal and tumor cells between fractions. While it can benefit normal tissue repair, it can also lead to tumor regrowth and is not specifically aimed at hypoxic cells.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Re-oxygenation is a critical factor in the success of fractionated radiotherapy. By allowing time between doses for hypoxic tumor cells to become oxygenated, it increases their radiosensitivity and improves the overall effectiveness of the treatment.</span></span></span></span></p>",
    "correct_choice_id": 214602,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53783,
    "choices": [
      {
        "id": 214605,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1</span></span></span></p>"
      },
      {
        "id": 214606,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1.5</span></span></span></p>"
      },
      {
        "id": 214607,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2.5</span></span></span></p>"
      },
      {
        "id": 214608,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A radiation oncologist is considering the impact of oxygen on the effectiveness of radiation therapy for a tumor. The oxygen enhancement ratio (OER) is a measure of the increased effectiveness of ionizing radiation in the presence of oxygen. What is the typical value of the OER for X-rays?</span></span></p>",
    "unique_key": "Q1254216",
    "question_audio": null,
    "question_video": null,
    "map_id": 25378,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) 3</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The oxygen enhancement ratio (OER) quantifies the increased effectiveness of ionizing radiation in the presence of oxygen compared to anoxic conditions. It is calculated as the ratio of the radiation dose required to achieve a certain biological effect in an anoxic environment to the dose needed under oxygenated conditions. For X-rays, the OER is typically about 3, meaning that the presence of oxygen makes cells, including tumor cells, about three times more sensitive to the damaging effects of X-rays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\">An OER of <strong>1 </strong>would imply no difference in radiation sensitivity between oxygenated and anoxic conditions, which contradicts the known radiosensitizing effect of oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><span style=\"font-size:12.0pt\">An OER of <strong>1.5</strong> would indicate a moderate increase in radiation sensitivity due to oxygen, but this value is lower than what is typically observed for X-rays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\">An OER of <strong>2.5</strong> indicates a significant increase in radiation sensitivity with oxygen, but it&#39;s still lower than the more commonly accepted value of 3 for X-rays.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The oxygen enhancement ratio (OER) for X-rays is around 3, indicating that the presence of oxygen makes cells three times more susceptible to radiation damage compared to anoxic conditions. Understanding OER is crucial in radiation therapy, as it underscores the importance of tumor oxygenation in enhancing the therapeutic effect of radiation.</span></span></span></p>",
    "correct_choice_id": 214608,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53786,
    "choices": [
      {
        "id": 214617,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Zinc oxide (ZnO) </span></span></span></p>"
      },
      {
        "id": 214618,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pentoxifylline </span></span></span></p>"
      },
      {
        "id": 214619,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amifostine </span></span></span></p>"
      },
      {
        "id": 214620,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulocyte-macrophage colony-stimulating factor (GM-CSF)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 58-year-old man with newly diagnosed head and neck squamous cell carcinoma (HNSCC) is about to start radiation therapy. His oncologist discusses the potential side effects of radiation, including mucositis (inflammation of the mucous membranes) and xerostomia (dry mouth). The oncologist also mentions the possibility of using a radioprotector to mitigate these side effects. However, they express concerns about one specific radioprotector due to its potential to worsen mucositis and xerostomia, despite being the most extensively studied in this context. Which of the following radioprotectors is the oncologist MOST likely referring to?</span></span></span></p>",
    "unique_key": "Q3076435",
    "question_audio": null,
    "question_video": null,
    "map_id": 25381,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Amifostine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amifostine is a radioprotector that acts as a free radical scavenger, protecting normal tissues from radiation-induced damage. However, it can also cause side effects such as nausea, vomiting, hypotension, and importantly, <strong>mucositis and xerostomia</strong>, <u>especially in patients receiving head and neck radiation. This paradoxical effect limits its clinical use in HNSCC, despite being extensively studied.</u></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Zinc oxide (ZnO):</span></strong><span style=\"font-size:12.0pt\"> Zinc oxide is primarily used topically for its anti-inflammatory and wound-healing properties. It&#39;s not a systemic radioprotector and doesn&#39;t have the side effects mentioned.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pentoxifylline:</span></strong><span style=\"font-size:12.0pt\"> Pentoxifylline improves blood flow and has some radioprotective effects, but it&#39;s not associated with exacerbating mucositis or xerostomia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Granulocyte-macrophage colony-stimulating factor (GM-CSF):</span></strong><span style=\"font-size:12.0pt\"> GM-CSF stimulates white blood cell production and can help reduce the risk of infection during radiation therapy. It&#39;s not known to cause mucositis or xerostomia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While amifostine is a well-studied radioprotector, its potential to worsen mucositis and xerostomia in HNSCC patients limits its clinical use.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This highlights the importance of carefully considering the potential benefits and risks of any intervention, even those that are well-researched, in the context of specific patient populations and treatment modalities.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 214619,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53787,
    "choices": [
      {
        "id": 214621,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3D conformal radiation therapy (3D CRT) </span></span></span></p>"
      },
      {
        "id": 214622,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intensity-modulated radiation therapy (IMRT) </span></span></span></p>"
      },
      {
        "id": 214623,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Volumetric modulated arc therapy (VMAT) </span></span></span></p>"
      },
      {
        "id": 214624,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Image-guided radiation therapy (IGRT)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">50-year-old man with localized prostate cancer is undergoing external beam radiation therapy. The radiation oncologist uses a technique that involves delivering radiation from multiple angles, with varying doses to precisely target the tumor and spare surrounding normal tissues. This technique is called:</span></span></p>",
    "unique_key": "Q1334127",
    "question_audio": null,
    "question_video": null,
    "map_id": 25382,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Intensity-modulated radiation therapy (IMRT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IMRT is characterized by its ability to deliver varying doses of radiation from different angles, allowing for better dose conformity to the tumor and sparing of nearby critical structures. 3D CRT also aims for precise targeting but does not modulate the intensity within each beam. VMAT is a form of IMRT that delivers radiation in a single 360&deg; arc. IGRT uses imaging to improve treatment accuracy but is not a specific radiation delivery technique.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 3D conformal radiation therapy (3D CRT):</span></strong><span style=\"font-size:12.0pt\"> While 3D CRT uses 3D imaging to shape radiation beams to the tumor, it does not modulate the intensity of the beam within each field. IMRT, on the other hand, can vary the intensity within each beam, allowing for even more precise dose delivery and sparing of surrounding normal tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Volumetric modulated arc therapy (VMAT):</span></strong><span style=\"font-size:12.0pt\"> VMAT is an advanced form of IMRT where the radiation beam is continuously modulated as it rotates around the patient. While it offers even further precision and efficiency compared to traditional IMRT, the question stem emphasizes the use of multiple angles with varying doses, which is a core feature of IMRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Image-guided radiation therapy (IGRT):</span></strong><span style=\"font-size:12.0pt\"> IGRT involves the use of imaging during treatment to ensure accurate targeting. While it enhances precision, it&#39;s not a specific radiation delivery technique like IMRT or 3D CRT. IGRT can be used in conjunction with various delivery methods, including IMRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IMRT is a sophisticated radiotherapy technique that allows for precise dose delivery and improved sparing of normal tissues.</span></span></span></p>",
    "correct_choice_id": 214622,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53788,
    "choices": [
      {
        "id": 214625,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">45 Gy in 25 fractions over 5 weeks</span></span></span></p>"
      },
      {
        "id": 214626,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50 Gy in 25 fractions over 5 weeks, plus a boost of 10 Gy to the tumor bed</span></span></span></p>"
      },
      {
        "id": 214627,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">60 Gy in 30 fractions over 6 weeks</span></span></span></p>"
      },
      {
        "id": 214628,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">66 Gy in 33 fractions over 6.5 weeks</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 52-year-old woman undergoes a lumpectomy for a 2 cm, stage I, estrogen receptor-positive breast tumor. The patient is interested in adjuvant radiation therapy to reduce the risk of local recurrence. Which of the following radiation therapy regimens is most appropriate for this patient following breast-conserving surgery?</span></span></span></p>",
    "unique_key": "Q6013008",
    "question_audio": null,
    "question_video": null,
    "map_id": 25383,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) 50 Gy in 25 fractions over 5 weeks, plus a boost of 10 Gy to the tumor bed</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For patients undergoing breast-conserving surgery (lumpectomy) for early-stage breast cancer, the standard adjuvant radiation therapy regimen typically involves a total dose of approximately 45-50 Gy delivered to the whole breast over 5 weeks, in daily fractions (Monday through Friday). This regimen is aimed at reducing the risk of local recurrence within the breast. Additionally, a boost dose of 10 Gy to the lumpectomy bed (the area from which the tumor was removed) is commonly recommended, particularly for patients with higher risk features such as close margins, young age, or aggressive tumor biology. The boost dose further decreases the risk of tumor recurrence in the area where the tumor was originally located.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 45 Gy in 25 fractions over 5 weeks:</span></strong><span style=\"font-size:12.0pt\"> Is a standard dose for whole breast irradiation, but it does not include a boost to the tumor bed, which is typically recommended for additional risk reduction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 60 Gy in 30 fractions over 6 weeks:</span></strong><span style=\"font-size:12.0pt\"> Is a higher total dose than typically used for adjuvant breast irradiation following breast-conserving surgery and may be more appropriate for certain other cancer types or treatment settings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 66 Gy in 33 fractions over 6.5 weeks:</span></strong><span style=\"font-size:12.0pt\"> Is also a higher total dose than typically used for adjuvant breast irradiation and may increase the risk of side effects without providing additional benefit in the setting of early-stage breast cancer following lumpectomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Following breast-conserving surgery for early-stage breast cancer, the standard adjuvant radiation therapy regimen involves whole breast irradiation with a total dose of approximately 45-50 Gy delivered over 5 weeks, often with an additional boost of 10 Gy to the lumpectomy bed to further reduce the risk of local recurrence.</span></span></span></p>",
    "correct_choice_id": 214626,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53789,
    "choices": [
      {
        "id": 214629,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intensity-Modulated Radiation Therapy (IMRT)</span></span></span></p>"
      },
      {
        "id": 214630,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Volumetric Modulated Arc Therapy (VMAT)</span></span></span></p>"
      },
      {
        "id": 214631,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stereotactic Radiosurgery (SRS)</span></span></span></p>"
      },
      {
        "id": 214632,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stereotactic Body Radiation Therapy (SBRT)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A neurosurgeon is considering a non-invasive treatment option for a patient with a small, well-defined brain tumor. Which of the following radiation therapy techniques involves delivering a high dose of radiation to a precise target in the brain in a single session, minimizing exposure to surrounding healthy tissue?</span></span></p>",
    "unique_key": "Q3376103",
    "question_audio": null,
    "question_video": null,
    "map_id": 25384,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Stereotactic Radiosurgery (SRS)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stereotactic radiosurgery (SRS) is a non-invasive radiation therapy technique designed to deliver a high dose of radiation precisely to a small, well-defined target within the brain in a single session. This precision minimizes radiation exposure to the surrounding healthy brain tissue. SRS is commonly used for treating small brain tumors, arteriovenous malformations (AVMs), and other intracranial conditions. The technique relies on detailed imaging, computer-based planning, and highly focused radiation beams to ensure accuracy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intensity-Modulated Radiation Therapy (IMRT):</span></strong><span style=\"font-size:12.0pt\"> (IMRT) is an advanced form of radiation therapy that modulates the intensity of the radiation beams, allowing for the delivery of precise radiation doses to a tumor while minimizing the dose to surrounding normal tissue. IMRT is used for various cancers throughout the body, not limited to the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Volumetric Modulated Arc Therapy (VMAT): </span></strong><span style=\"font-size:12.0pt\">(VMAT) is an advanced form of IMRT that delivers radiation by rotating the radiation machine around the patient, allowing for rapid and precise treatment of the tumor from multiple angles. Like IMRT, VMAT is used for various cancers, not just in the brain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &nbsp;Stereotactic Body Radiation Therapy (SBRT):</span></strong><span style=\"font-size:12.0pt\"> &nbsp;(SBRT) is similar to SRS in its precision and delivery of high-dose radiation, but it is used for tumors outside the brain, such as those in the lung, liver, spine, and prostate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">:</span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stereotactic radiosurgery (SRS) is a precise, non-invasive radiation therapy technique used to deliver a high dose of radiation to a small, well-defined target in the brain in a single session, minimizing exposure to surrounding healthy tissue.</span></span></span></p>",
    "correct_choice_id": 214631,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 53791,
    "choices": [
      {
        "id": 214637,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Whole-brain radiation therapy (WBRT)</span></span></span></p>"
      },
      {
        "id": 214638,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Conventional external beam radiation therapy (EBRT) </span></span></span></p>"
      },
      {
        "id": 214639,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stereotactic radiosurgery (SRS) </span></span></span></p>"
      },
      {
        "id": 214640,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brachytherapy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with a history of lung cancer presents with new-onset seizures. Imaging reveals a single, 2 cm well-circumscribed lesion in the right frontal lobe, consistent with a brain metastasis. Which of the following treatment modalities is MOST appropriate for this patient?</span></span></span></p>",
    "unique_key": "Q2949113",
    "question_audio": null,
    "question_video": null,
    "map_id": 25386,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C)</strong> <strong>Stereotactic radiosurgery (SRS)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Precision:</span></strong><span style=\"font-size:12.0pt\"> SRS delivers a high dose of radiation very precisely to the tumor while minimizing damage to surrounding healthy brain tissue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Efficacy:</span></strong><span style=\"font-size:12.0pt\"> SRS has excellent local control rates for solitary brain metastases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Convenience:</span></strong><span style=\"font-size:12.0pt\"> SRS is typically delivered in a single session or a few sessions, making it more convenient for patients than other options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Whole-brain radiation therapy (WBRT):</span></strong><span style=\"font-size:12.0pt\"> WBRT treats the entire brain and is typically reserved for patients with multiple brain metastases or those who are at high risk of developing new metastases. It can cause cognitive decline and other side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Conventional external beam radiation therapy (EBRT):</span></strong><span style=\"font-size:12.0pt\"> EBRT is less precise than SRS and typically requires multiple treatment sessions. It is also associated with a higher risk of side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Brachytherapy:</span></strong><span style=\"font-size:12.0pt\"> Brachytherapy involves placing radioactive sources directly into or near the tumor. It is not typically used for brain metastases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SRS is the preferred treatment for solitary brain metastases due to its precision, efficacy, and convenience.</span></span></span></p>",
    "correct_choice_id": 214639,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 53792,
    "choices": [
      {
        "id": 214641,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Palladium-103</span></span></span></p>"
      },
      {
        "id": 214642,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Iodine-125</span></span></span></p>"
      },
      {
        "id": 214643,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cesium-131</span></span></span></p>"
      },
      {
        "id": 214644,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cesium-137</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male with localized prostate cancer is being considered for a procedure, as shown in the image. Which of the following sources is not commonly used in the above procedure?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-121235.jpg\" style=\"height:215px; width:400px\" /></span></span></p>",
    "unique_key": "Q9855610",
    "question_audio": null,
    "question_video": null,
    "map_id": 25387,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Cesium-137</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cesium-137, on the other hand, is not commonly used for prostate brachytherapy. It has a longer half-life and different energy characteristics, making it less ideal for this particular type of treatment. It&#39;s more often used in applications such as high-dose-rate brachytherapy for other types of cancer, but not typically for prostate cancer. Therefore, the answer is D) Cesium-137.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Palladium-103, Iodine-125, and Cesium-131:</span></strong><span style=\"font-size:12.0pt\"> These are all commonly used radioactive isotopes in prostate brachytherapy. They emit low-energy radiation that is effective in treating the tumor while minimizing damage to surrounding tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate brachytherapy is a precise and effective treatment for localized prostate cancer. The choice of radioactive isotope depends on various factors, including tumor characteristics and desired dose rate.</span></span></span></p>",
    "correct_choice_id": 214644,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 53795,
    "choices": [
      {
        "id": 214653,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostate</span></span></span></p>"
      },
      {
        "id": 214654,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cervical</span></span></span></p>"
      },
      {
        "id": 214655,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin</span></span></span></p>"
      },
      {
        "id": 214656,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brain</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A radiation oncologist is planning to use the following instrument shown in the image for the treatment of cancer. Which of the following cancers is most likely to be treated with the instrument?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-121514.jpg\" style=\"height:207px; width:400px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>",
    "unique_key": "Q5133008",
    "question_audio": null,
    "question_video": null,
    "map_id": 25390,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Cervical</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B:</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image appears to depict a brachytherapy applicator, which is commonly used to treat cancers by providing high-dose radiation directly to the tumor site while sparing surrounding healthy tissue. Given the options and the typical use of such applicators, the most likely cancer to be treated with this instrument is cervical cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brachytherapy is frequently used as part of the standard treatment regimen for cervical cancer. This type of applicator is inserted into the cervix and the uterus, allowing for precise delivery of radiation to the tumor. It is an integral part of cervical cancer treatment, especially in locally advanced stages where it can be combined with external beam radiation therapy (EBRT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Prostate:</span></strong><span style=\"font-size:12.0pt\"> Prostate cancer is also treated with brachytherapy, but the applicators used for prostate cancer typically involve seed implants rather than the ring applicators shown in the image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Skin:</span></strong><span style=\"font-size:12.0pt\"> Skin cancer treatments typically do not use this type of brachytherapy applicator. Instead, external beam radiation or superficial brachytherapy might be used depending on the type and stage of the skin cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Brain:</span></strong><span style=\"font-size:12.0pt\"> Brain cancers are not commonly treated with brachytherapy. Treatment for brain tumors more often involves external beam radiation therapy, including stereotactic radiosurgery or Gamma Knife surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The instrument shown in the image is a brachytherapy applicator likely used for the treatment of cervical cancer, which allows for localized radiation treatment directly to the affected area with minimal impact on surrounding healthy tissue.</span></span></span></p>",
    "correct_choice_id": 214654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InstrumentsBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 53796,
    "choices": [
      {
        "id": 214657,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Small cell lung cancer (SCLC)</span></span></span></span></p>"
      },
      {
        "id": 214658,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Acute lymphoblastic leukemia (ALL) </span></span></span></span></p>"
      },
      {
        "id": 214659,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Medulloblastoma </span></span></span></span></p>"
      },
      {
        "id": 214660,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Non-small cell lung cancer (NSCLC)</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which of the following is NOT a common indication for prophylactic whole-brain irradiation (WBI)?</span></span></span></p>",
    "unique_key": "Q1889367",
    "question_audio": null,
    "question_video": null,
    "map_id": 25391,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><span style=\"color:black\"><strong>Ans.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"color:black\"><strong>D) Non-small cell lung cancer (NSCLC)</strong> </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">NSCLC is not typically treated with prophylactic WBI. It&#39;s more common for SCLC and ALL due to their higher risk of brain metastasis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation: </span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A and option B.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Small cell lung cancer (SCLC) and acute lymphoblastic leukemia (ALL): Are common indications for prophylactic WBI.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Medulloblastoma:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Is treated with CSI, not prophylactic WBI.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Prophylactic WBI is used selectively in cancers with high risk of brain metastasis.</span></span></span></span></p>",
    "correct_choice_id": 214660,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53797,
    "choices": [
      {
        "id": 214661,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">TSEB </span></span></span></span></p>"
      },
      {
        "id": 214662,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">CSI </span></span></span></span></p>"
      },
      {
        "id": 214663,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">WBI </span></span></span></span></p>"
      },
      {
        "id": 214664,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">TBI</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 4-year-old child presents with a medulloblastoma. Which of the following radiation therapy techniques is MOST appropriate for this patient?</span></span></span></p>",
    "unique_key": "Q6494388",
    "question_audio": null,
    "question_video": null,
    "map_id": 25392,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><span style=\"color:black\"><strong>Ans.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"color:black\"><strong>B) CSI </strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Craniospinal Irradiation (CSI) is the standard radiation therapy technique for medulloblastoma, as it targets the entire brain and spinal cord where tumor cells may spread.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. TSEB:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">TSEB is used for cutaneous lymphomas.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. WBI:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Prophylactic WBI is used to prevent brain metastasis in certain cancers.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. TBI:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">TBI is used as conditioning before allogeneic stem cell transplantation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;CSI is crucial in treating medulloblastoma to address potential leptomeningeal spread.</span></span></span></p>",
    "correct_choice_id": 214662,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53798,
    "choices": [
      {
        "id": 214665,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Localized basal cell carcinoma</span></span></span></p>"
      },
      {
        "id": 214666,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute sunburn</span></span></span></p>"
      },
      {
        "id": 214667,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycosis fungoides</span></span></span></p>"
      },
      {
        "id": 214668,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriasis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is a common indication for using total skin electron beam therapy (TSEBT) as part of the treatment regimen?</span></span></span></p>",
    "unique_key": "Q2356740",
    "question_audio": null,
    "question_video": null,
    "map_id": 25393,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Mycosis fungoides</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Total skin electron beam therapy (TSEBT) is a specialized form of radiation therapy that is used to treat the entire surface of the skin. It is most commonly indicated for mycosis fungoides, which is the most common form of cutaneous T-cell lymphoma (CTCL). TSEBT is effective in treating mycosis fungoides because it allows for the delivery of a uniform dose of radiation across the entire skin surface, targeting malignant T-cells infiltrating the skin without penetrating deeply into the underlying tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Localized basal cell carcinoma:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Localized basal cell carcinoma is typically treated with more focused forms of radiation therapy or other modalities such as surgical excision, cryotherapy, or topical treatments, rather than TSEBT which treats the entire skin surface.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute sunburn:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Acute sunburn is a condition caused by excessive exposure to ultraviolet (UV) radiation from the sun, leading to skin inflammation and damage. It does not require radiation therapy as a treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Psoriasis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Psoriasis is a chronic autoimmune skin condition characterized by red, itchy, and scaly patches. Treatment options include topical treatments, phototherapy, systemic medications, and biologics, but not typically TSEBT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Total skin electron beam therapy (TSEBT) is primarily indicated for the treatment of mycosis fungoides, a type of cutaneous T-cell lymphoma, as it allows for uniform radiation delivery across the entire skin surface, effectively targeting malignant cells without significant penetration into deeper tissues.</span></span></span></p>",
    "correct_choice_id": 214667,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53799,
    "choices": [
      {
        "id": 214669,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Acute radiation syndrome (ARS)</span></span></span></span></p>"
      },
      {
        "id": 214670,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Chronic radiation syndrome </span></span></span></span></p>"
      },
      {
        "id": 214671,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation-induced cancer </span></span></span></span></p>"
      },
      {
        "id": 214672,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation-induced cataracts</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">A patient presents to the emergency department 6 hours after a radiation accident with nausea, vomiting, and headache. Which of the following is the MOST likely diagnosis?</span></span></span></span></p>",
    "unique_key": "Q3542962",
    "question_audio": null,
    "question_video": null,
    "map_id": 25394,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans.&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">A) Acute radiation syndrome (ARS)</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The symptoms of nausea, vomiting, and headache within hours of radiation exposure are classic for the prodromal phase of ARS.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B. Chronic radiation syndrome:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This develops over months or years of low-dose radiation exposure, not within hours.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Radiation-induced cancer:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cancer is a long-term effect of radiation exposure and wouldn&#39;t present with symptoms this quickly.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Radiation-induced cataracts:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cataracts develop slowly over time due to radiation exposure and wouldn&#39;t be an immediate concern in this scenario.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Early symptoms of ARS are non-specific and can easily be mistaken for other conditions.</span></span></span></span></p>",
    "correct_choice_id": 214669,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53800,
    "choices": [
      {
        "id": 214673,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Age of the individual </span></span></span></span></p>"
      },
      {
        "id": 214674,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Type of radiation exposure </span></span></span></span></p>"
      },
      {
        "id": 214675,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Dose of radiation received </span></span></span></span></p>"
      },
      {
        "id": 214676,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Time since exposure</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which of the following is the most important factor in determining the severity of acute radiation syndrome (ARS)?</span></span></span></p>",
    "unique_key": "Q9920498",
    "question_audio": null,
    "question_video": null,
    "map_id": 25395,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans.&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">C) Dose of radiation received</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The dose of radiation received is the most critical factor in determining the severity and type of ARS. Higher doses lead to more severe damage and faster onset of symptoms.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Age of the individual:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While age can influence an individual&#39;s overall health and resilience, it is not the primary determinant of ARS severity. Younger individuals may recover faster, but the dose received is the key factor in determining the initial damage.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B. Type of radiation exposure:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">The type of radiation (alpha, beta, gamma, X-ray, neutron) does influence the biological effectiveness of the radiation, but the dose is still the primary determinant of overall severity. Different radiation types have different weighting factors in terms of damage, but the absorbed dose takes this into account.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Time since exposure:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Time since exposure is important for determining the onset and progression of symptoms, but the dose ultimately determines the extent of the damage and potential for recovery. Early intervention can be crucial, but it cannot reverse the damage caused by a high dose of radiation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Radiation dose is the primary determinant of ARS severity.</span></span></span></p>",
    "correct_choice_id": 214675,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53801,
    "choices": [
      {
        "id": 214677,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">20-40 Gy; Acute skin erythema</span></span></span></p>"
      },
      {
        "id": 214678,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50-70 Gy; Stochastic tumor induction</span></span></span></p>"
      },
      {
        "id": 214679,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10-30 Gy; Hormesis</span></span></span></p>"
      },
      {
        "id": 214680,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">60-80 Gy; Radiation pneumonitis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the typical dosage range for radiotherapy in the treatment of cancer, and which of the following is a deterministic effect of local irradiation?</span></span></span></p>",
    "unique_key": "Q7965425",
    "question_audio": null,
    "question_video": null,
    "map_id": 25396,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) 20-40 Gy; Acute skin erythema</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The typical dosage range for radiotherapy in the treatment of cancer varies depending on the type of cancer, the stage of the disease, and whether the radiotherapy is being used as the primary treatment or in combination with other treatments such as surgery or chemotherapy. For many cancer types, a common total dosage range for curative treatment is approximately 20-70 Gy, administered in fractions (daily doses) over several weeks. Lower doses may be used for palliative treatments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute skin erythema is a deterministic effect that can occur with local irradiation, typically at doses within the 20-40 Gy range. Deterministic effects have a threshold dose below which they do not occur, and their severity increases with the dose above this threshold. Skin erythema is a common acute side effect of radiotherapy, manifesting as redness of the skin in the treated area.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 50-70 Gy; Stochastic tumor induction:</span></strong><span style=\"font-size:12.0pt\"> Stochastic tumor induction, or the development of a second cancer due to radiation exposure, is a stochastic effect, meaning it has a chance of occurring that increases with dose, but its severity does not depend on the dose. It typically occurs many years after radiation exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 10-30 Gy; Hormesis:</span></strong><span style=\"font-size:12.0pt\"> Hormesis is a concept that low doses of radiation may have beneficial effects. It is not typically associated with the therapeutic dose ranges used in cancer treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 60-80 Gy; Radiation pneumonitis:</span></strong><span style=\"font-size:12.0pt\"> Radiation pneumonitis is a deterministic effect that can occur following irradiation of the chest, potentially within the 20-40 Gy range but more commonly associated with higher doses, particularly when large volumes of lung tissue are irradiated. It presents as inflammation of the lung tissue and usually occurs within weeks to a few months after therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The typical dosage range for curative radiotherapy in cancer treatment varies but often falls within approximately 20-70 Gy, administered over several weeks. Acute skin erythema is a deterministic effect associated with radiotherapy and can occur within lower ranges of this dosage spectrum. Deterministic effects have a threshold and their severity increases with the dose above this threshold, unlike stochastic effects, which are probability-based and do not have a threshold.</span></span></span></p>",
    "correct_choice_id": 214677,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53802,
    "choices": [
      {
        "id": 214681,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Miscarriage </span></span></span></span></p>"
      },
      {
        "id": 214682,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Fetal malformation </span></span></span></span></p>"
      },
      {
        "id": 214683,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Low IQ/Mental Retardation </span></span></span></span></p>"
      },
      {
        "id": 214684,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">No risk</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">A 25-year-old woman in her 6th week of pregnancy is involved in a motor vehicle accident. She is hemodynamically stable but requires a CT scan of the abdomen and pelvis to rule out internal injuries. The estimated fetal dose is 80 mGy. The fetus is at GREATEST risk for which of the following?</span></span></span></span></p>",
    "unique_key": "Q3237002",
    "question_audio": null,
    "question_video": null,
    "map_id": 25397,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><span style=\"color:black\"><strong>Ans.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"color:black\"><strong>B) Fetal malformation</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The most critical period for radiation-induced malformations is during the period of organogenesis, which occurs between the 3rd and 8th weeks of gestation. The estimated fetal dose of 80 mGy is within the range associated with an increased risk of malformations.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Miscarriage:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While high doses of radiation can increase the risk of miscarriage, especially in the very early stages of pregnancy, the risk is lower at 6 weeks compared to the risk of malformations.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Low IQ/Mental Retardation:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This is a potential risk with radiation exposure between 9-15 weeks of gestation, but less likely at 6 weeks.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. No risk:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">There is no &quot;no risk&quot; level of radiation exposure during pregnancy. Although the risk from a single CT scan is low, it is not zero, and the potential for malformation is the greatest concern at this gestational age.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk of specific radiation-induced effects on the developing fetus varies depending on the gestational age at the time of exposure. The 3rd-8th weeks are the most critical period for the development of fetal malformations</span></span></span></span></p>",
    "correct_choice_id": 214682,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53803,
    "choices": [
      {
        "id": 214685,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation pneumonitis </span></span></span></span></p>"
      },
      {
        "id": 214686,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pericardial effusion </span></span></span></span></p>"
      },
      {
        "id": 214687,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Constrictive pericarditis </span></span></span></span></p>"
      },
      {
        "id": 214688,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pulmonary embolism</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 50-year-old man with a history of Hodgkin&#39;s lymphoma treated with mediastinal radiation 10 years ago presents with progressive dyspnea and orthopnea. He also reports fatigue and chest discomfort. On examination, you note elevated jugular venous pressure and muffled heart sounds. Which of the following is the most likely cause of his symptoms?</span></span></span></p>",
    "unique_key": "Q6377048",
    "question_audio": null,
    "question_video": null,
    "map_id": 25398,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C) Constrictive pericarditis</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">This is a late complication of radiation therapy to the chest, in which the pericardium becomes thickened and fibrotic, impairing cardiac filling and leading to right-sided heart failure. The elevated jugular venous pressure and muffled heart sounds are classic signs of constrictive pericarditis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation: </span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Radiation pneumonitis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While possible, radiation pneumonitis typically occurs within the first few months after radiation therapy and is less likely to present years later.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B. Pericardial effusion:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pericardial effusion can also be caused by radiation, but it usually presents with more acute symptoms and would not explain the muffled heart sounds.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Pulmonary embolism:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pulmonary embolism is unlikely given the patient&#39;s history of radiation therapy and the clinical findings.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Constrictive pericarditis is a late complication of radiation therapy to the chest that can present with dyspnea, orthopnea, and signs of right-sided heart failure.</span></span></span></span></p>",
    "correct_choice_id": 214687,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53804,
    "choices": [
      {
        "id": 214689,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute radiation necrosis</span></span></span></p>"
      },
      {
        "id": 214690,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leukoencephalopathy</span></span></span></p>"
      },
      {
        "id": 214691,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Meningioma</span></span></span></p>"
      },
      {
        "id": 214692,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiotherapy myelopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old man presents to the neurology clinic with complaints of progressive memory difficulties, difficulty concentrating, and episodes of confusion over the past six months. He has a history of medulloblastoma, for which he underwent surgical resection followed by cranial irradiation therapy 10 years ago. His neurological examination is notable for mild cognitive impairment without focal deficits. Which of the following is the most likely late effect of cranial irradiation that this patient is experiencing?</span></span></p>",
    "unique_key": "Q9712151",
    "question_audio": null,
    "question_video": null,
    "map_id": 25399,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Leukoencephalopathy</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leukoencephalopathy is a late effect of cranial irradiation characterized by white matter changes in the brain, leading to cognitive impairments such as memory difficulties, concentration issues, and confusion. This condition typically manifests years after radiation therapy, making it a plausible late effect for the patient, who underwent cranial irradiation 10 years ago.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute radiation necrosis:</span></strong><span style=\"font-size:12.0pt\"> Acute radiation necrosis is a potential acute or subacute complication of radiation therapy, usually occurring within the first few months to years after treatment. It involves the necrosis (death) of brain tissue due to radiation damage, but it is not consistent with the patient&#39;s long-term post-irradiation timeframe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Meningioma:</span></strong><span style=\"font-size:12.0pt\"> Meningioma is a type of benign brain tumor that can be a secondary effect of cranial irradiation, typically occurring many years after exposure. While it could cause cognitive symptoms depending on its location, the patient&#39;s presentation of diffuse cognitive symptoms without focal deficits or mention of a new mass lesion makes leukoencephalopathy more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Radiotherapy myelopathy:</span></strong><span style=\"font-size:12.0pt\"> Radiotherapy myelopathy is a rare late complication affecting the spinal cord after radiation therapy. It typically presents with symptoms related to spinal cord dysfunction such as weakness, sensory loss, or bowel/bladder dysfunction, not primarily cognitive impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leukoencephalopathy is a late effect of cranial irradiation that can manifest as progressive cognitive impairments, including memory difficulties, concentration issues, and confusion. It results from radiation-induced damage to the white matter of the brain and typically develops several years after treatment.</span></span></span></p>",
    "correct_choice_id": 214690,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53805,
    "choices": [
      {
        "id": 214693,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Contact dermatitis </span></span></span></span></p>"
      },
      {
        "id": 214694,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation recall syndrome </span></span></span></span></p>"
      },
      {
        "id": 214695,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cellulitis </span></span></span></span></p>"
      },
      {
        "id": 214696,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Allergic reaction</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">A 65-year-old female with a history of breast cancer treated with radiation therapy (RT) 6 months ago presents with a painful, erythematous rash on her chest within the radiation field. She recently started chemotherapy with doxorubicin and cyclophosphamide (AC). Which of the following is the most likely diagnosis?</span></span></span></span></p>",
    "unique_key": "Q9303180",
    "question_audio": null,
    "question_video": null,
    "map_id": 25400,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans.&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">B) Radiation recall syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><span style=\"color:black\"><strong>Option</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"color:black\"><strong>B:</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation recall syndrome is an inflammatory skin reaction that occurs in a previously irradiated area, typically triggered by certain chemotherapy agents like AC. The patient&#39;s history and presentation are consistent with this diagnosis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Contact dermatitis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While contact dermatitis can cause a rash, it typically occurs in areas exposed to irritants or allergens, not necessarily within a previous radiation field. The patient&#39;s history of recent chemotherapy makes radiation recall syndrome more likely.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Cellulitis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cellulitis is a bacterial skin infection characterized by warmth, redness, and swelling. However, it is less likely in this patient due to the rash occurring within the radiation field and the temporal association with chemotherapy initiation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Allergic reaction:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Although an allergic reaction to chemotherapy is possible, it is less likely to be localized to the radiation field and typically presents with other systemic symptoms like fever or hives. Radiation recall syndrome is a more specific inflammatory reaction related to previous radiation exposure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation recall syndrome is a rare but important consideration in patients receiving chemotherapy after radiation therapy.</span></span></span></span></p>",
    "correct_choice_id": 214694,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53806,
    "choices": [
      {
        "id": 214697,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk is highest during the first year after radiation and declines rapidly thereafter. </span></span></span></span></p>"
      },
      {
        "id": 214698,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk peaks around 5 years after radiation and then gradually declines. </span></span></span></span></p>"
      },
      {
        "id": 214699,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk remains constant over time, independent of the time elapsed since radiation. </span></span></span></span></p>"
      },
      {
        "id": 214700,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk increases gradually over time, with the highest risk occurring &gt;7 years after radiation.</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 45-year-old woman presents for a routine follow-up appointment 5 years after completing radiation therapy for Hodgkin lymphoma. She is currently asymptomatic and disease-free. Which of the following statements BEST reflects her risk for developing a second solid cancer related to her previous radiation therapy?</span></span></span></p>",
    "unique_key": "Q5905791",
    "question_audio": null,
    "question_video": null,
    "map_id": 25401,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. D) The risk increases gradually over time, with the highest risk occurring &gt;7 years after radiation.</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation-induced malignancies (RIMs)&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">are a known late effect of radiation therapy. The risk of developing a second solid cancer generally <strong>increases over time</strong> following radiation exposure. The <strong>latency period</strong> for the development of solid tumors is typically <strong>several years to decades</strong>. While some RIMs may occur sooner, the peak incidence is usually seen <strong>&gt;7 years </strong>after radiation exposure. The risk continues to increase over time, and it may eventually plateau or gradually decline over many years.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. The risk is highest during the first year after radiation and declines rapidly thereafter:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This is incorrect. The risk of developing a second solid cancer increases with time after radiation exposure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B. The risk peaks around 5 years after radiation and then gradually declines:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While some radiation-induced cancers may appear around 5 years, the risk for many solid tumors continues to rise beyond this point.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. The risk remains constant over time, independent of the time elapsed since radiation:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">This is incorrect. The risk of developing a second solid cancer is not constant and generally increases with time since radiation exposure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The risk of developing a second solid cancer after radiation therapy is a long-term concern for patients. The risk increases over time, with the peak incidence often occurring 7-10 years or more after exposure. Continued surveillance and monitoring are essential for the early detection and management of potential secondary malignancies.</span></span></span></span></p>",
    "correct_choice_id": 214700,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53807,
    "choices": [
      {
        "id": 214701,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The latency period is typically less than 1 year.</span></span></span></p>"
      },
      {
        "id": 214702,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The latency period is usually more than 2 years.</span></span></span></p>"
      },
      {
        "id": 214703,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The latency period is always more than 20 years.</span></span></span></p>"
      },
      {
        "id": 214704,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The latency period is variable and depends on the type of primary cancer.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements is true regarding the latency period for a second hematological cancer after radiotherapy?</span></span></span></p>",
    "unique_key": "Q5314186",
    "question_audio": null,
    "question_video": null,
    "map_id": 25402,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) The latency period is usually more than 2 years</span></strong><span style=\"font-size:12.0pt\">.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Second hematological cancers that develop after radiotherapy, such as acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), typically have a shorter latency period compared to solid tumors. However, the latency period is generally more than 2 years, often ranging from 2 to 10 years after exposure to radiotherapy. This reflects the time required for radiation-induced changes to affect hematopoietic stem cells and lead to the development of a hematological malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. The latency period is typically less than 1 year:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is generally considered too short for the latency period associated with the development of second hematological cancers after radiotherapy. These cancers usually take a few years to develop due to the time required for radiation-induced DNA damage to manifest in the hematopoietic system.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. The latency period is always more than 20 years:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This is not accurate for hematological cancers, which tend to have a shorter latency period compared to solid tumors. Hematological malignancies like AML or MDS typically manifest within a decade after radiotherapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The latency period is variable and depends on the type of primary cancer:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While the latency period can indeed vary based on several factors, including the type of primary cancer, the statement is too broad. Specifically, for second hematological cancers following radiotherapy, the latency period is more consistently within the range of 2 to 10 years.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The latency period for second hematological cancers following radiotherapy, such as acute myeloid leukemia or myelodysplastic syndromes, typically ranges from 2 to 10 years. This shorter latency period compared to solid tumors reflects the time required for radiation-induced damage to affect hematopoietic stem cells and lead to hematological malignancy</span></span></span></p>",
    "correct_choice_id": 214702,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53808,
    "choices": [
      {
        "id": 214705,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Contact dermatitis </span></span></span></span></p>"
      },
      {
        "id": 214706,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation recall syndrome </span></span></span></span></p>"
      },
      {
        "id": 214707,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cellulitis </span></span></span></span></p>"
      },
      {
        "id": 214708,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Allergic reaction</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">A 65-year-old female with a history of Right breast cancer treated with radiation therapy (RT) 6 months ago presents with a painful rash on the right side as shown in the image. She recently started chemotherapy with doxorubicin and cyclophosphamide (AC). Which of the following is the most likely diagnosis?</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-124126.jpg\" style=\"height:398px; width:400px\" /></span></span></span></span></p>",
    "unique_key": "Q9521506",
    "question_audio": null,
    "question_video": null,
    "map_id": 25403,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans.&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">B) Radiation recall syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Radiation recall syndrome is an inflammatory skin reaction that occurs in a previously irradiated area, typically triggered by certain chemotherapy agents like AC. The patient&#39;s history and presentation are consistent with this diagnosis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A. Contact dermatitis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">While contact dermatitis can cause a rash, it typically occurs in areas exposed to irritants or allergens, not necessarily within a previous radiation field. The patient&#39;s history of recent chemotherapy makes radiation recall syndrome more likely.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C. Cellulitis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cellulitis is a bacterial skin infection characterized by warmth, redness, and swelling. However, it is less likely in this patient due to the rash occurring within the radiation field and the temporal association with chemotherapy initiation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D. Allergic reaction:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Although an allergic reaction to chemotherapy is possible, it is less likely to be localized to the radiation field and typically presents with other systemic symptoms like fever or hives. Radiation recall syndrome is a more specific inflammatory reaction related to previous radiation exposure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Radiation recall syndrome is a rare but important consideration in patients receiving chemotherapy after radiation therapy.</span></span></span></p>",
    "correct_choice_id": 214706,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53448,
    "choices": [
      {
        "id": 213273,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Family history of breast cancer</span></span></span></p>"
      },
      {
        "id": 213274,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Past history of fibroadenoma</span></span></span></p>"
      },
      {
        "id": 213275,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age</span></span></span></p>"
      },
      {
        "id": 213276,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Moderate alcohol consumption</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old postmenopausal woman with a family history of breast cancer is concerned about her risk of developing the disease. Her past medical history is significant for fibroadenoma and alcohol use. Which of the following factors most significantly increases her risk for breast cancer?</span></span></p>",
    "unique_key": "Q6181089",
    "question_audio": null,
    "question_video": null,
    "map_id": 25252,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Advanced age</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age is a significant risk factor for breast cancer. The likelihood of developing breast cancer increases as a woman ages, particularly after menopause. Most breast cancers are diagnosed in women aged 50 years and older. While family history, fibroadenomas, and alcohol consumption are also risk factors for breast cancer, the risk associated with aging is more significant due to the cumulative exposure to estrogen and the increased likelihood of genetic mutations over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Family history of breast cancer: </span></strong><span style=\"font-size:12.0pt\">Although a family history of breast cancer is an important risk factor, especially if the cancer occurred in a first-degree relative or involved high-risk genes like BRCA1 or BRCA2, the overall risk increases with age regardless of family history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Past history of fibroadenoma</span></strong><span style=\"font-size:12.0pt\">: Fibroadenomas are benign breast tumors and are not considered a significant risk factor for developing breast cancer. They are common in younger women and do not significantly increase the risk of breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Moderate alcohol consumption</span></strong><span style=\"font-size:12.0pt\">: While alcohol consumption is associated with an increased risk of breast cancer, the risk level is generally lower compared to the risk associated with advancing age. The risk increases with the amount of alcohol consumed, but age remains a more significant factor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age is a significant risk factor for breast cancer, with most cases diagnosed in women aged 50 years and older. The risk increases with age due to factors such as cumulative exposure to estrogen and the increased likelihood of genetic mutations over time.</span></span></span></p>",
    "correct_choice_id": 213275,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53449,
    "choices": [
      {
        "id": 213277,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute mastitis </span></span></p>"
      },
      {
        "id": 213278,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal ectasia </span></span></p>"
      },
      {
        "id": 213279,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget disease of the breast </span></span></p>"
      },
      {
        "id": 213280,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contact dermatitis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman presents with a 6-month history of a persistent, itchy rash on her right nipple. The area is also slightly red and crusted. On examination, you note a small amount of clear discharge from the nipple. Which of the following is the MOST likely diagnosis?</span></span></p>",
    "unique_key": "Q1406169",
    "question_audio": null,
    "question_video": null,
    "map_id": 25253,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paget disease of the breast</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paget disease of the breast. This condition is characterized by eczema-like changes in the nipple, often accompanied by nipple discharge. The underlying cause is usually an underlying ductal carcinoma in situ (DCIS) or invasive ductal carcinoma (IDC) extending into the nipple epidermis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute mastitis:</span></strong><span style=\"font-size:12.0pt\"> Mastitis is a breast infection that typically presents with pain, swelling, redness, and fever. It is less likely to cause chronic eczema-like changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ductal ectasia:</span></strong><span style=\"font-size:12.0pt\"> Ductal ectasia is a benign condition characterized by dilated ducts and thick, sticky nipple discharge, usually green or black in color. It is not typically associated with eczema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Contact dermatitis:</span></strong><span style=\"font-size:12.0pt\"> Contact dermatitis is an allergic skin reaction that can cause a rash. However, it is unlikely to be limited to the nipple and present with nipple discharge.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget disease of the breast is an important differential diagnosis for patients presenting with chronic nipple eczema and discharge. A biopsy is necessary to confirm the diagnosis and determine the extent of the underlying malignancy.</span></span></p>",
    "correct_choice_id": 213279,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53450,
    "choices": [
      {
        "id": 213281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cooper&#39;s ligament</span></span></span></p>"
      },
      {
        "id": 213282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermal lymphatics</span></span></span></p>"
      },
      {
        "id": 213283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest wall</span></span></span></p>"
      },
      {
        "id": 213284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with skin changes over her left breast as shown in the image. This finding is most suggestive of the involvement of which of the following?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115533.jpg\" style=\"height:295px; width:400px\" /></span></span></p>",
    "unique_key": "Q1828528",
    "question_audio": null,
    "question_video": null,
    "map_id": 25254,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Dermal lymphatics</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peau d&#39;orange (&quot;orange peel skin&quot;) is caused by the blockage of dermal lymphatics by cancer cells.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This obstruction leads to edema and thickening of the skin, causing the characteristic dimpled appearance.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cooper&#39;s ligaments:</span></strong><span style=\"font-size:12.0pt\"> These are fibrous bands that support breast tissue, and their involvement would lead to retraction and dimpling but not the widespread skin changes seen in peau d&#39;orange.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chest wall:</span></strong><span style=\"font-size:12.0pt\"> Chest wall involvement would present with pain, fixation of the breast, and possibly ulceration, but not the specific peau d&#39;orange pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Skin:</span></strong><span style=\"font-size:12.0pt\"> While the skin is involved, the primary cause of peau d&#39;orange is the blockage of lymphatic drainage within the dermis, not a primary skin condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peau d&#39;orange is a highly suggestive sign of inflammatory breast cancer due to tumor invasion of the dermal lymphatics. It requires prompt evaluation and diagnosis.</span></span></span></p>",
    "correct_choice_id": 213282,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 53451,
    "choices": [
      {
        "id": 213285,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 1 </span></span></p>"
      },
      {
        "id": 213286,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 2 </span></span></p>"
      },
      {
        "id": 213287,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 3 </span></span></p>"
      },
      {
        "id": 213288,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 4</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman undergoes her annual screening mammogram. The radiologist identifies an abnormality which is shown below. There are no associated masses or architectural distortions. Which BI-RADS category is MOST appropriate for this finding?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115548.jpg\" style=\"height:210px; width:400px\" /></span></span></p>",
    "unique_key": "Q7231836",
    "question_audio": null,
    "question_video": null,
    "map_id": 25255,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) BI-RADS 4</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most appropriate BI-RADS category for this finding is <strong>(D) BI-RADS 4.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pleomorphic microcalcifications</span></strong><span style=\"font-size:12.0pt\"> are considered suspicious because they can be associated with malignancy, such as ductal carcinoma in situ (DCIS).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While the absence of a mass or distortion might be reassuring, the presence of these microcalcifications alone is enough to warrant further investigation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">BI-RADS 4</span></strong><span style=\"font-size:12.0pt\"> indicates a suspicious abnormality that has a 2-95% likelihood of being malignant. This category requires tissue sampling, typically with a biopsy, to make a definitive diagnosis.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BI-RADS 1:</span></strong><span style=\"font-size:12.0pt\"> Negative, normal mammogram</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. BI-RADS 2:</span></strong><span style=\"font-size:12.0pt\"> Benign finding, no further workup needed</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BI-RADS 3:</span></strong><span style=\"font-size:12.0pt\"> Probably benign, but short-term follow-up is recommended</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pleomorphic microcalcifications on a mammogram are a suspicious finding and should be investigated further with biopsy to rule out malignancy.</span></span></p>",
    "correct_choice_id": 213288,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "ImageBased"
    ]
  },
  {
    "id": 53452,
    "choices": [
      {
        "id": 213289,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enucleation</span></span></p>"
      },
      {
        "id": 213290,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wide local excision with 1 cm margin</span></span></p>"
      },
      {
        "id": 213291,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Local radiotherapy</span></span></p>"
      },
      {
        "id": 213292,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mastectomy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 29-year-old woman presents to her primary care physician with a palpable lump in her left breast that she discovered three weeks ago during a self-examination. She reports that the lump is painless and mobile. A mammography is performed, which is shown in the image. Given the clinical presentation and mammography findings, what is the appropriate treatment for this patient?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115604.jpg\" style=\"height:490px; width:400px\" /></span></span></p>",
    "unique_key": "Q2708232",
    "question_audio": null,
    "question_video": null,
    "map_id": 25256,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Enucleation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical description and mammographic findings of a round density with smooth borders and popcorn calcification are suggestive of a fibroadenoma, which is a benign breast tumor commonly found in young women. Fibroadenomas are well-circumscribed, mobile, and often painless lumps. The &quot;popcorn calcifications&quot; are characteristic of fibroadenomas and indicate a benign process. Enucleation, or surgical removal, is a treatment option that can be considered if the lump is symptomatic, shows rapid growth, or the patient desires removal for peace of mind. It is a conservative approach that spares breast tissue and is usually done with local anesthesia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Wide local excision with 1 cm margin:</span></strong><span style=\"font-size:12.0pt\"> Is typically reserved for malignant lesions where clear margins are necessary to ensure complete removal of cancerous cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Local radiotherapy</span></strong><span style=\"font-size:12.0pt\">: Is a treatment modality used in the management of breast cancer, not benign lesions like fibroadenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mastectomy:</span></strong><span style=\"font-size:12.0pt\"> Or complete removal of the breast, is a more radical treatment generally reserved for invasive breast cancer or high-risk patients and is not indicated for benign lesions such as fibroadenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenomas are benign breast tumors characterized by mammography findings of round densities with smooth borders and popcorn calcification. They can be managed conservatively with observation or enucleated if symptomatic or upon patient request.</span></span></p>",
    "correct_choice_id": 213289,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53453,
    "choices": [
      {
        "id": 213293,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma </span></span></p>"
      },
      {
        "id": 213294,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrocystic changes </span></span></p>"
      },
      {
        "id": 213295,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenoma </span></span></p>"
      },
      {
        "id": 213296,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phyllodes tumor</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-years-old woman presents with a rapidly enlarging mass in her right breast that has doubled in size over the past 2 months. The mass is now mildly tender to the touch. Ultrasound-guided core needle biopsy done and shown below. Which of the following is the MOST likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115621.jpg\" style=\"height:440px; width:400px\" /></span></span></p>",
    "unique_key": "Q5904957",
    "question_audio": null,
    "question_video": null,
    "map_id": 25257,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Phyllodes tumor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key features supporting this diagnosis:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapid growth: Phyllodes tumors are known for their rapid growth rate, often doubling in size within a few months.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mild tenderness: While not always present, mild tenderness can be a feature of phyllodes tumors.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leaf-like projections and hypercellular stromal tissue: These are characteristic histopathologic findings of phyllodes tumors. The &quot;leaf-like&quot; pattern refers to the way the tumor grows in a frond-like or finger-like pattern.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Invasive ductal carcinoma:</span></strong><span style=\"font-size:12.0pt\"> While invasive ductal carcinoma is the most common type of breast cancer, it typically does not grow as rapidly as described in this vignette.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fibrocystic changes:</span></strong><span style=\"font-size:12.0pt\"> Fibrocystic changes are benign and typically do not present with a rapidly enlarging mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fibroadenoma:</span></strong><span style=\"font-size:12.0pt\"> Fibroadenomas are benign tumors that typically grow slowly and are well-circumscribed. They are not associated with the leaf-like pattern seen in the biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phyllodes tumors are uncommon but should be considered in the differential diagnosis of rapidly growing breast masses, particularly when histopathology shows a leaf-like pattern and hypercellular stromal tissue.</span></span></span></p>",
    "correct_choice_id": 213296,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53454,
    "choices": [
      {
        "id": 213297,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemotherapy alone </span></span></p>"
      },
      {
        "id": 213298,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine therapy alone </span></span></p>"
      },
      {
        "id": 213299,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-HER2 therapy alone </span></span></p>"
      },
      {
        "id": 213300,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Combined endocrine and chemotherapy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman presents with a newly diagnosed invasive ductal carcinoma of the breast. Immunohistochemistry (IHC) reveals that the tumor is strongly positive for both estrogen (ER) and progesterone (PR) receptors, negative for human epidermal growth factor receptor 2 (HER2), and has a low Ki-67 index (&lt;14%). Which of the following treatment options is MOST appropriate for this patient?</span></span></p>",
    "unique_key": "Q2322111",
    "question_audio": null,
    "question_video": null,
    "map_id": 25258,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Endocrine therapy alone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The tumor profile described (ER+, PR+, HER2-, low Ki-67) corresponds to Luminal A subtype, which typically has a good prognosis and is best treated with endocrine therapy alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chemotherapy alone:</span></strong><span style=\"font-size:12.0pt\"> While chemotherapy can be beneficial in some breast cancers, Luminal A tumors are generally slow-growing and have a better prognosis. Endocrine therapy alone is usually sufficient to manage the disease and improve outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anti-HER2 therapy alone:</span></strong><span style=\"font-size:12.0pt\"> This patient&#39;s tumor is HER2-negative, meaning it does not overexpress the HER2 protein. Therefore, anti-HER2 therapy would not be effective in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Combined endocrine and chemotherapy:</span></strong><span style=\"font-size:12.0pt\"> While some patients with Luminal A tumors may benefit from the addition of chemotherapy, it is typically reserved for those with higher risk features (e.g., larger tumor size, lymph node involvement). In this patient&#39;s case, the low Ki-67 index suggests a low risk of proliferation, making endocrine therapy alone the most appropriate initial treatment choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Luminal A breast cancer is hormone receptor-positive and typically responds well to endocrine therapy.</span></span></span></p>",
    "correct_choice_id": 213298,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53455,
    "choices": [
      {
        "id": 213301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">DCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) </span></span></span></p>"
      },
      {
        "id": 213302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel) </span></span></span></p>"
      },
      {
        "id": 213303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TC-AC (Docetaxel, Cyclophosphamide, Doxorubicin) + Anti-PD1 (Immune Checkpoint Inhibitor) </span></span></span></p>"
      },
      {
        "id": 213304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Letrozole (aromatase inhibitor)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">58-year-old postmenopausal woman is diagnosed with locally advanced breast cancer (LABC) with involvement of the chest wall and skin. Biopsy reveals a hormone receptor (HR)-positive, HER2-negative tumor. Which of the following is the MOST appropriate neoadjuvant chemotherapy (NACT) regimen for this patient?</span></span></p>",
    "unique_key": "Q9033318",
    "question_audio": null,
    "question_video": null,
    "map_id": 25259,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has LABC, which requires NACT.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The tumor is HR-positive and HER2-negative, which is why AC-T is the preferred regimen, especially in postmenopausal women.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp; A. DCHP:</span></strong><span style=\"font-size:12.0pt\"> This regimen includes Trastuzumab and Pertuzumab, which are anti-HER2 therapies not indicated for HER2-negative tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. TC-AC + Anti-PD1:</span></strong><span style=\"font-size:12.0pt\"> This regimen includes an immune checkpoint inhibitor, which is typically reserved for triple-negative breast cancer (TNBC) and is not indicated in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Letrozole</span></strong><span style=\"font-size:12.0pt\">: This is an endocrine therapy and is not suitable for NACT in LABC. It may be used as adjuvant therapy after surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The choice of neoadjuvant chemotherapy in LABC depends on the tumor&#39;s hormone receptor and HER2 status. For HR-positive, HER2-negative LABC in postmenopausal women, AC-T is the preferred regimen.</span></span></p>",
    "correct_choice_id": 213302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53456,
    "choices": [
      {
        "id": 213305,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IIIa</span></span></p>"
      },
      {
        "id": 213306,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IV</span></span></p>"
      },
      {
        "id": 213307,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IIIc</span></span></p>"
      },
      {
        "id": 213308,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage II</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents to oncologist after being diagnosed with left breast invasive ductal carcinoma. On examination, two axillary nodes are palpable on the right side. Given the findings, what is the stage of the cancer?</span></span></p>",
    "unique_key": "Q1171389",
    "question_audio": null,
    "question_video": null,
    "map_id": 25260,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Stage IV</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of palpable cervical lymph nodes on the contralateral side (right side when the cancer is in the left breast) suggests the possibility of distant metastatic spread, which is categorized as stage IV in the TNM (Tumor, Nodes, Metastasis) staging system for breast cancer. The TNM system does not typically classify contralateral lymph node involvement as regional lymphadenopathy; instead, it is considered distant metastasis because lymphatic spread to the contralateral cervical nodes is not a typical pattern for local or regional breast cancer spread.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The stages are as follows:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage II: The cancer is in the breast and may have spread to up to three axillary lymph nodes but not to distant sites.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IIIa: The cancer has extended into multiple axillary lymph nodes or the nodes are clumped together, but there is no spread to distant organs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IIIc: The cancer is found in 10 or more axillary lymph nodes, nodes near the collarbone, or internal mammary nodes, but not to distant organs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IV: The cancer has metastasized beyond the regional lymph nodes to distant organs, which could include contralateral lymph nodes or other body areas.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In breast cancer staging, stage IV indicates distant metastasis. This can include metastatic spread to lymph nodes not typically involved in local or regional breast cancer dissemination, such as contralateral cervical lymph nodes. This stage is consistent with the most advanced form of the disease, where the cancer has spread to other parts of the body beyond the breast and regional lymph nodes.</span></span></p>",
    "correct_choice_id": 213306,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 53457,
    "choices": [
      {
        "id": 213309,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel lymph node biopsy (SLNB) </span></span></p>"
      },
      {
        "id": 213310,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph node dissection (ALND)</span></span></p>"
      },
      {
        "id": 213311,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No axillary surgery </span></span></p>"
      },
      {
        "id": 213312,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Observation with serial ultrasounds</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with a newly diagnosed T2N0 invasive ductal carcinoma of the right breast undergoes neoadjuvant chemotherapy (NACT). After NACT, she is restaged as ycT1cN1. Which of the following is the MOST appropriate surgical approach for managing the axilla in this patient?</span></span></p>",
    "unique_key": "Q5787303",
    "question_audio": null,
    "question_video": null,
    "map_id": 25261,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Sentinel lymph node biopsy (SLNB)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with LABC (locally advanced breast cancer) who has received NACT and is now clinically node-negative (cN0) or cN1, SLNB is the recommended approach. This is because the NACT may have down staged the axillary nodes, and SLNB can accurately assess the need for further axillary surgery.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ALND:</span></strong><span style=\"font-size:12.0pt\"> ALND is more extensive and associated with greater morbidity than SLNB. It would only be considered if the SLNB is positive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. No axillary surgery:</span></strong><span style=\"font-size:12.0pt\"> Even though the patient is clinically node-negative after NACT, there is still a risk of residual disease in the axilla. SLNB is necessary to assess this risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Observation with serial ultrasounds:</span></strong><span style=\"font-size:12.0pt\"> While ultrasound can be helpful in monitoring the axilla, it is not a substitute for definitive staging with SLNB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The management of the axilla in breast cancer has evolved, and SLNB is now the preferred approach for staging the axilla in many cases. The decision between SLNB and ALND depends on clinical and pathological factors.</span></span></p>",
    "correct_choice_id": 213309,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53458,
    "choices": [
      {
        "id": 213313,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abemaciclib </span></span></p>"
      },
      {
        "id": 213314,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpelisib </span></span></p>"
      },
      {
        "id": 213315,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olaparib </span></span></p>"
      },
      {
        "id": 213316,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pembrolizumab</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with HR-positive, HER2-negative breast cancer has a PIK3CA mutation detected on tumor genomic testing. Which of the following medications would be most appropriate to add to her treatment regimen?</span></span></p>",
    "unique_key": "Q2270008",
    "question_audio": null,
    "question_video": null,
    "map_id": 25262,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B. Alpelisib</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpelisib is a PI3K inhibitor specifically indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abemaciclib:</span></strong><span style=\"font-size:12.0pt\"> Abemaciclib is a CDK4/6 inhibitor, which is approved for HR-positive, HER2-negative breast cancer. However, it is not specifically targeted for PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Olaparib:</span></strong><span style=\"font-size:12.0pt\"> Olaparib is a PARP inhibitor primarily used in breast cancer patients with BRCA1/2 mutations. It is not indicated for PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pembrolizumab:</span></strong><span style=\"font-size:12.0pt\"> Pembrolizumab is an immune checkpoint inhibitor used in some types of triple-negative breast cancer (TNBC). It does not target PIK3CA mutations and is not indicated for HR-positive breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Targeted therapies like Alpelisib can be effective for specific breast cancer mutations.</span></span></span></p>",
    "correct_choice_id": 213314,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 53459,
    "choices": [
      {
        "id": 213317,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine therapy </span></span></p>"
      },
      {
        "id": 213318,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab </span></span></p>"
      },
      {
        "id": 213319,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olaparib </span></span></p>"
      },
      {
        "id": 213320,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pertuzumab</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with metastatic triple-negative breast cancer (TNBC) has a germline BRCA1 mutation. Which of the following treatments is MOST likely to be effective in this scenario?</span></span></p>",
    "unique_key": "Q5222550",
    "question_audio": null,
    "question_video": null,
    "map_id": 25263,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Olaparib</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Olaparib is a PARP inhibitor specifically indicated for patients with germline BRCA1 or BRCA2 mutations who have HER2-negative metastatic breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Endocrine therapy:</span></strong><span style=\"font-size:12.0pt\"> Triple-negative breast cancer (TNBC) lacks hormone receptors (estrogen and progesterone) and HER2 receptors, making it unresponsive to endocrine therapies that target these pathways.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Trastuzumab:</span></strong><span style=\"font-size:12.0pt\"> This is an anti-HER2 therapy specifically designed for HER2-positive breast cancer. TNBC, by definition, is HER2-negative, making Trastuzumab ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pertuzumab:</span></strong><span style=\"font-size:12.0pt\"> Similar to Trastuzumab, Pertuzumab is also an anti-HER2 therapy and is not indicated for TNBC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PARP inhibitors are a targeted therapy for BRCA-mutated breast cancers.</span></span></p>",
    "correct_choice_id": 213319,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Medical Oncology';
        const quizFilename = 'medical-oncology-164cc204.html';
        let hierarchy = ["Cerebellum", "qBank", "Medicine"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>